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Abstract 
 
Leprosy, a highly disabling and stigmatizing infectious disease, is caused by 
Mycobacterium leprae and the newly discovered agent, Mycobacterium lepromatosis. Though 
treatable with antibiotics, leprosy has still not been eradicated, and around 200,000 new cases 
are reported every year worldwide, mainly in India, Brazil, and Indonesia. Tipping the 
balance towards leprosy elimination begins with improving our understanding of the 
pathogenesis and the transmission of the disease, which remains poorly understood. Current 
research on leprosy is markedly hindered by our incapacity to cultivate the leprosy bacilli on 
artificial media, as well as by the variation of the clinical forms of the disease. The rise of 
genomics in the 2000s has helped to get around these problems by opening new ways of 
studying organisms. Tools were developed to recover enough genetic material for 
downstream genomic applications; however, none of them is yet suitable for high throughput 
purposes.  
 In this thesis, we describe an optimized DNA extraction method from skin tissue that 
allows direct whole-genome sequencing, and enabled us to obtain ~ 250 genome sequences of 
M. leprae from different geographical locations throughout the world. Firstly, this dataset 
deepened our insight into the phylogeny of M. leprae, and points to the ancestral strain 
originating in East Asia and/or Europe. In addition, analysis of more than twenty drug-
resistant strains revealed mutations in candidate genes potentially associated with new 
biological mechanisms such as drug resistance. Moreover, we analysed isolates from 
restricted geographic areas and from recurrent cases, and show that the distinction between 
relapse and reinfection with a closely related strain can be made but this remains challenging.  
The whole genome sequencing of M. lepromatosis was achieved in 2015, and the 
discovery and use of new specific molecular detection methods allowed us to identify M. 
lepromatosis in the red squirrel population in the British Isles. In parallel, M. leprae was also 
discovered in red squirrels on Brownsea Island in the south of England. Though the risk of 
transmission from animals to humans is not yet clear, the discovery of a new animal reservoir 
for leprosy bacilli in a non-endemic country raises the question about the existence of other 
such reservoirs, especially in endemic countries, which could contribute to ongoing 
transmission.  
Reliable and sensitive methods for detection of leprosy bacilli are crucial for early 
diagnosis and monitoring the disease. We show that efficient cell lysis during extraction 
increases the yield of genetic material recovered from leprosy bacilli and significantly 
improves the sensitivity of diagnosis by PCR for all leprosy forms. 
Overall, our results highlight the impact and efficiency of genomics and whole genome 
sequencing for uncovering new biological mechanisms in unculturable bacteria such as the 
leprosy bacilli. Our results generated new hypotheses that await testing, and underline the 
massive potential of omics and bioinformatics for better understanding and fighting the 
disease. 
 
Keywords: leprosy, Mycobacterium leprae, Mycobacterium lepromatosis, whole genome 
sequencing, drug resistance, animal reservoir, and transmission 
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Résumé ?
La lèpre est une maladie infectieuse progressive, invalidante et toujours stigmatisée, causée 
par Mycobacterium leprae et dans une moindre mesure par Mycobacterium lepromatosis. 
Bien qu’elle soit curable par une association d’antibiotiques, la lèpre n’est toujours pas 
éradiquée, et environ 200 000 nouveaux cas sont rapportés chaque année à l’échelle mondiale, 
touchant principalement l’Inde, le Brésil et l’Indonésie. Un des prérequis pour atteindre une 
élimination de la maladie passe par la compréhension de sa pathogenèse et de ses mécanismes 
de transmission qui demeurent aujourd’hui encore très mal décrits. La recherche 
fondamentale sur la lèpre est largement freinée par l’impossibilité de cultiver les bacilles sur 
des milieux artificiels ainsi que par l’existence d’un large panel de formes de la maladie 
suggérant des mécanismes biologiques différents. L’apparition des outils de génomique dans 
les années 2000 a permis de contourner ce problème et ouvert de nouveaux axes de recherche 
sur la lèpre. Plusieurs outils ont été développés permettant d’obtenir suffisamment de matériel 
génétique pour les tests génomiques. Cependant, aucun d’entre eux n’est adapté aux 
applications de haut débit. 
Dans ce document, nous décrivons une méthode d’extraction d’ADN directement à 
partir de tissue cutané permettant le séquençage direct du génome bactérien. A ce jour, plus 
de 250 génomes de M. leprae ont été séquencés provenant de différents pays et couvrant tous 
les continents. A partir de ces résultats, nous avons tout d’abord affiné la phylogénie de M. 
leprae avec une origine hypothétique entre l’Asie de l’Est et l’Europe. Suite à cela, l’analyse 
de plus de vingt souches résistantes aux traitements nous a permis de mettre en évidence de 
possibles nouveaux mécanismes biologiques notamment associés à la résistance aux 
antibiotiques. Enfin, nous avons également analysés des isolats cliniques provenant de la 
même région ainsi que de patients présentant une récurrence de la maladie et démontré que la 
distinction entre rechute et réinfection avec une souche proche est difficile à déterminer.  
Le séquençage du génome de M. lepromatosis a été achevé en 2015 et grâce à de 
nouveaux marqueurs spécifiques de la bactérie, nous avons pu identifier M. lepromatosis dans 
la population d’écureuils roux dans des îles britanniques. En parallèle, M. leprae a également 
été découvert dans le même réservoir sur l’île de Brownsea dans le sud de l’Angleterre. Bien 
que le risque de transmission de la maladie de l’animal à l’homme n’ai pas pu être établi avec 
les données disponibles, la découverte d’un nouveau réservoir pour la lèpre dans un pays non 
endémique soulève la question de l’existence d’autres réservoir, notamment dans les pays 
endémiques, contribuant à la transmission active de la maladie et notre incapacité à l’éliminer. 
 Enfin, le développement de méthodes de détection fiable et sensibles des bacilles de 
lèpre est crucial pour un diagnostic précoce de la maladie. Dans notre dernière étude, nous 
montrons que la réalisation d’une lyse efficace durant l’extraction augmente la quantité de 
matériel génétique de la bactérie disponible et améliore significativement la sensibilité de 
détection par PCR pour toutes les formes de lèpre.  
En conclusion, nos résultats soulignent l’utilité et l’efficacité de la génomique et du 
séquençage haut débit pour identifier de nouveaux mécanismes biologiques chez des bactéries 
non cultivables pour lequel l’étude systématique est difficile comme les bacilles de la lèpre. 
Nos résultats offrent de nouvelles hypothèses biologiques et soulignes le potentiel des outils 
de omiques et de bioinformatiques pour l’amélioration des connaissances sur cette maladie et 
vers son élimination.  ?????? ???????? lèpre, Mycobacterium leprae, Mycobacterium lepromatosis, séquençage haut 
débit, résistance aux antibiotiques, réservoir animal, et transmission?
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bones, leading to severe deformities. 
Osteoporosis can also occur, albeit more 
slowly and mainly in the limbs (39). 
Peripheral neuropathy indirectly results in 
sensory loss leading to ulcerations and 
secondary infections. Nerve injuries are also 
responsible for motor neuropathy with muscle 
atrophy and eyes involvement (39). Therefore, 
early diagnosis of leprosy is essential to stop 
disease progression, avoid irreversible lesions 
and reduce transmission. 
Infection mechanism and host response  
 
Characteristics of M. leprae 
 
M. leprae was discovered in a human skin 
biopsy by Armauer Hansen during in 1873, 
and was the first microorganism associated 
with an infectious disease (3). Like other 
mycobacteria, M. leprae is a gram-positive 
bacterium composed of a thick cell wall with 
a layer of peptidoglycan linked to mycolic 
acid by arabinan and galactan chains. The cell 
wall is surrounded by a lipid layer mainly 
composed of phenolic-glycolipids (PGLs) 
(40). PGL-1 is the dominant lipid in the 
membrane conferring the immunological 
specificity. Altogether, these layers contribute 
to the resistance to acido-alcoholo treatments. 
M. leprae is an obligate intracellular pathogen 
and among the slowest growing bacteria with 
a doubling time of 10-12 days (twelve times 
longer than M. tuberculosis, the causative 
agent of tuberculosis) (15,42). M. leprae can 
grow between 10 to 32°C, which may explain 
its tropism for cooler parts of the human body 
(42). Despite many attempts, M. leprae is one 
of the few known pathogenic bacteria that 
cannot be successfully cultured in an artificial 
medium, significantly impairing the study of 
pathogenesis (1,43).  
While M. leprae can be maintained in 
axenic culture for a limited period of time, 
large quantities of bacilli can only be obtained 
from in vivo models. Many important 
discoveries in the leprosy field were achieved 
using the mouse footpad assay (MFP) and the 
nine-banded armadillo (44–47). However, 
experiments relying on these methods require 
9-18 months due to the slow-growing nature 
of the bacterium, and considerable resources. 
Widely used to test the efficiency of drugs, 
the usefulness of the MFP assay is limited in 
physiopathological studies because the model 
does not mimic leprosy symptoms and the 
infection remains localized in the footpad 
(40). On the other hand, the nine-banded 
armadillo displays the specific granulomatous 
response and the whole spectrum of leprosy 
forms, so it is extensively used for this 
purpose (48). Also, armadillos can 
successfully be challenged and immunized 
with heat-inactivated M. leprae bacilli or 
BCG vaccine (40). However, only one facility 
worldwide is working with this model at the 
moment, and the time required for such 
experiments is a major obstacle for using 
armadillos for vaccine development. 
Nevertheless, in contrast to the MFP model, 
infection of the peripheral nerve is widely 
described in armadillos, which is a unique 
model for nerve involvement in human (40).  
Finally, the leprosy bacillus has a tropism 
for cells of the reticuloendothelial system, and 
a unique property to infect Schwann cells of 
the peripheral nervous system (15). Known 
mechanisms and the host response are 
presented in the next paragraph.  
 
Host response and genetic markers 
 
When entering the human body (probably 
through the nose or the skin); M. leprae is 
recognized by phagocytic cells such as 
macrophages and dendritic cells through the 
interaction between the pathogen-associated 
molecular patterns and the pattern recognition 
receptor. Once inside the host cell, the 
mechanism by which the host will develop a 
cytotoxic-like or antibody-like response is 
unknown, but it seems to depend on the 
immune response’s cytokine secretion, the 
type of cells at the site of recognition, and the 
host genetic profile (discussed below) (49–
51). From here, the bacterial growth depends 
on a cascade of cytokines that will activate the 
naïve T-cell CD4, either through the Th1 
cytotoxic response leading to BT/TT lesions, 
or the Th2 helper response leading to the 
humoral response resulting in BL/LL lesions 
(40,51). Thus, depending on the host, the 
severity of infection might range from no 
infection to an extreme case of leprosy. In the 
cell-mediated immune response case, the 
disease might progress to spontaneous 
healing. However, it might also lead to sub-
clinical and undetectable infections, where 
multiplication of bacilli is confined within 
localized granulomas, and the chronic 
inflammatory response can lead to long-term 
? ? ??
?? ???
disabilities (40). On the other side of the 
spectrum, in lepromatous lesions, the disease 
is not contained, and the number of bacilli is 
high. Inside the host cell, the bacilli stimulate 
host cell lipid metabolism leading to 
intracellular survival. Cells form foamy 
macrophages called Virchow’s cells (49). In 
the last ten years, additional key players were 
identified in the pathogenesis mechanism of 
leprosy, such as Th17, Th22, and regulatory 
lymphocytes, opening a new area for research 
and improving our understanding of the 
disease (50,52).  
Several host genetic markers have been 
associated with an increased protection or 
susceptibility to leprosy. The most convincing 
marker was discovered in a study including 
more than 1000 individuals from Vietnam and 
Brazil (53). A total of nine polymorphic 
alleles in the regulatory regions of PARK2, 
coding for an E3-ubiquitin ligase designated 
Parkin, and the co-regulated gene PACRG 
might increase susceptibility to leprosy in 
both populations (53). Mutations in TLR 
genes are also associated with susceptibility to 
different infectious diseases (54). In leprosy, 
specific mutations in the TLR1 in human and 
armadillo was associated with protective 
phenotypes whereas a specific mutation in 
TLR2 is linked to increased susceptibility to 
reversal reactions (40,51,55). Other SNPs in 
HLA, vitamin D receptor, TNF-?, IL-10, 
NRAMP1, and IFN-? also defined genetic 
markers for the disease or reactions 
(51,52,56). While specific genetic host 
markers were associated with particular 
leprosy forms or level of protection against 
the disease, no association of specific M. 
leprae strains with clinical forms of the 
disease has been identified yet (57).  
M. leprae has a tropism for infecting 
Schwann cells, which are glial cells 
conferring protection to peripheral nerves. It 
has been proposed that M. leprae binds to the 
?2-laminin of the Schwann cells through 
PGL-1, and with lesser affinity to ML-LBP21, 
a 21-kDa surface protein in M. leprae. Once 
internalized in Schwann cells, M. leprae 
would persist and multiply, and in response, 
the Schwann cells would express HLA-class 
II and activated CD4 T-cells which would 
initiate a chronic inflammatory reaction (40).  
However, this hypothesis was challenged 
several times by the observations that the M. 
leprae bacillary load is low in peripheral 
nerves in paucibacillary patients despite nerve 
injuries being of the same intensity as in MB 
patients (58). Recently, a macrophage-induced 
mechanism was proposed by Madigan et al. as 
an alternative to explain nerve damage in 
leprosy, with PGL-1 as the main virulence 
factor (59). Briefly, using a zebrafish infection 
model, they observed that after phagocytosis 
of M. leprae by resident macrophages, M. 
leprae’s PGL-1 triggered the secretion of 
CCL2 by the resident macrophages, probably 
through the STING pathway, which lead to 
recruitment of permissive monocytes and 
enabled the transfer of the bacteria from the 
macrophages to the monocytes (59–61). At 
this point, infected monocytes are 
disseminated through skin lesions or blood 
and might reach peripheral nerves (59). Once 
in the proximity of peripheral nerves, PGL-1 
induced progression toward a neurotoxic 
macrophage population through the secretion 
of inducible-nitric oxide synthase (iNOS), 
causing mitochondrial swelling and myelin 
loss in axons (59). Although not yet validated, 
it is possible that in MB cases, the abundance 
of M. leprae leads to death of macrophages, 
and bacteria become free to infect Schwann 
cells. 
Further studies are needed to fully 
elucidate the exact mechanism by which the 
bacilli reach the Schwann cells (40), 
especially the differences between the PB and 
MB responses. Understanding of this 
mechanism could help to identify new drug 
targets. 
 
LEPROSY BACILLI AND GENOMICS 
 
Because of our inability to cultivate M. 
leprae in vitro, and the delays required for in 
vivo growth, working with the leprosy bacilli 
is prohibitively challenging, and this is where 
genomics has revolutionized leprosy research. 
The rise of molecular biology in the 80's has 
helped to develop new tools to study 
physiology (62–67) and to detect M. leprae 
directly from animal and human tissues such 
as skin, nasal swab or blood (68–72).  
 
The whole genome era 
 
In 2001, the first M. leprae genome was 
sequenced from the TN strain, isolated from a 
patient from Tamil Nadu in India and 
passaged in mice (73). With a genome size of 
? ? ??
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3,268,210 bp and an average GC content of 
57.8%, M. leprae is the smallest and the AT-
richest genome of any known mycobacteria 
(74). Surprisingly, only half of the genome is 
occupied by coding genes (1614), including 
165 without a counterpart in M. tuberculosis, 
which could be good biomarker candidates for 
the development of specific diagnostic tools 
(74). The leprosy bacillus shows the highest 
pseudogene content of all sequenced 
genomes, with a total number of 1293 
pseudogenes making up nearly half the total 
genome (75). The analysis of the original 
functional categories of pseudogenes revealed 
a massive loss of genes from the catabolism 
machinery, such as lipid uptake or energy 
metabolism, which might explain M. leprae’s 
slow growth and our inability to grow it in 
vitro (73). By comparing non-synonymous 
substitutions in the pseudogenes with 
functional orthologs from closely related 
genomes, it was estimated that M. leprae and 
M. tuberculosis diverged 66 million years ago, 
with a single pseudogenization event 
occurring 20 million years ago (75). This 
extreme genome decay is explained by a 
probable modification of the lifestyle of the 
bacteria, with adaptation to a new host or a 
strict intracellular niche (73–75). The exact 
genomic trigger of M. leprae’s reductive 
evolution is unknown, but the loss of sigma 
factors, the two-component systems and the 
DnaQ-mediated proofreading activity of DNA 
polymerase III probably contributed to the 
accumulation of pseudogenes (74). In addition 
to pseudogenes, 2% of the genome is 
occupied by 26 insertion elements and four 
families of dispersed repeats, with RLEP 
being the most abundant and accounting for 
37 copies (76). Former transposable elements 
also participated in chromosomal 
rearrangements and genome downsizing 
(74,76).  
In 2015, the whole-genome sequence of 
the pathogenic species M. haemophilum 
revealed a genetic closeness with M. leprae 
(77) (Fig. 3). This aspect is further discussed 
in the conclusion of this work. 
 
Genotyping methods: VNTRs, SNP-typing 
or whole-genome typing? 
 
In the absence of a bacterial phenotype, 
genetic markers can help to understand the 
transmission and epidemiology of leprosy. 
Molecular typing systems for leprosy 
epidemiological studies are based on different 
genetic markers within the genome of M. 
leprae. 
Variable-number tandem repeats (VNTR) 
are widely used in epidemiological studies. 
They have been found to vary in copy number 
between strains of M. leprae. A total of 44 
loci were described based on genome 
mapping, but only nine were reported stable 
and to be gave reproducible results (78). 
Besides, studies in India and Benin have 
shown variation in VNTR copy number in 
samples from the same patient, questioning 
the reliability of such markers (79,80). On the 
other hand, other studies have shown that 
groups of different VNTRs can be used for 
strain differentiation in a specific 
geographical area (81–83).  
Comparative genomics of four different 
strains from India, Brazil, Thailand and the 
United States revealed remarkable genome 
conservation with 99.995% identity 
uncovered in only 215 polymorphic sites, 
mainly single nucleotide polymorphisms 
(SNPs) (84,85). Mapping these 
polymorphisms in more than 400 strains from 
28 countries defined 84 informative markers 
(78 SNPs and six InDels in homopolymeric 
tracts) used for the classification in 16 SNP-
subtypes of M. leprae (85), 1A-D, 2E-H, 3I-M 
and 4N-P (Fig. 4). SNP typing is a robust 
method, and the SNP subtypes were 
Figure 3: Maximum likelihood tree of M. leprae and 
selected mycobacterial species. The tree was created
using MEGA7 from concatenated amino acid
sequences of 11 proteins (DnaN, RpII, GrpE, MetG,
RplY, PheT, FtsQ, HolA, MiaA, FtsY and, FtsX)
[78,79] 
? ? ??
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associated with geographical localization (85). 
This is of high interest for global 
dissemination studies, but the resolution for 
short-range transmission, such as family 
cases, is limited. One solution could be to 
combine both VNTR and SNP typing (74).  
Recently, whole-genome sequencing was 
successfully applied on M. leprae DNA 
extracted from ancient human remains (teeth 
and bones) and skin biopsies from patients 
from different countries (86). The principal 
challenge to deeply sequence M. leprae 
genomes is to recover enough bacterial DNA 
from the patient’s sample and to remove 
enough host DNA, especially for samples 
with a low number of bacilli. To do so, 
Schuenemann et al. have developed an 
enrichment method based on DNA arrays 
coated with probes spanning the entire 
genome of M. leprae to capture DNA prior to 
sequencing (86). Thanks to this method, it is 
now possible to sequence genomes directly 
from human skin samples even if the amount 
of bacilli is low in the biopsy. Due to its high 
resolution, whole-genome sequencing is the 
ultimate tool that can be used to study the 
transmission of strains in a small geographical 
area, or to compare samples from different 
countries and to perform species-level 
phylogeny. However, the main drawbacks of 
this method are the cost, the time required 
from DNA extraction to sequencing, and the 
bioinformatics expertise. This is why such 
methods are not widely used in the leprosy 
field yet.  
 
CHALLENGES OF LEPROSY 
 
Stigma and leprosy: the unfortunate old 
partners 
 
Leprosy stigma is still present in several 
parts of the world. Stigma arose most 
probably from the fear and revulsion certain 
individuals displayed toward persons affected 
by leprosy, notably the intensity of symptoms 
and body deformations associated with the 
disease (87).  
The discrimination against people affected 
by leprosy was already described during the 
Middle Ages from where records of massive 
execution of people infected with leprosy 
were reported (88). At this time, leprosy was 
associated with God’s punishment of the 
sinful and patients with the disease were 
quarantined in houses called leprosarium or 
lazar houses, often isolated from the general 
community i.e. islands (2,89). These “houses” 
were highly stigmatized, and most of the time, 
run by a religious community. Leprosy was 
considered for a long time hereditary until the 
discovery of the pathogen by Gerhard Hansen 
(90). Leprosaria slowly disappeared in Europe 
after the end of the Middle Ages and today, 
only one hospital is still active, in Fontilles in 
Spain where 60 patients were under treatment 
in 2005 (91). In other countries such as 
Vietnam, Laos, or India, villages of people 
suffering from leprosy still exist but are often 
taboo. 
Nowadays, this discrimination has remains 
and has a major impact on the patient life at 
different levels: physically, psychologically, 
socially and economically. More worrisome, 
studies have shown a negative effect of stigma 
on disease management and especially for 
early diagnosis because patients prefer to 
conceal their illness to avoid discrimination 
(88,92). Unfortunately, such discrimination is 
rooted in the community as exemplified by 
the “Leper act” from 1893 applied in India. 
By this law, leprosy can be a cause for 
divorce, it can bar leprosy sufferers from 
voting, increase social charges, forbid public 
transport and driving, and even discriminate 
against those who resort to begging for 
support. Other studies have shown that 
discrimination does not only alter patients’ 
llives impacts, but also the patients’ family 
and other members of the community who 
support them, such as caregivers (93). 
Figure 4: SNP typing system for the 16 SNP-subtype 
based on 16 markers (SNPs and indels) from Monot et 
al. (85) 
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Leprosy stigma affects women even more. 
Time to diagnose leprosy in women can be 
twice as long compared to men (94–96).  
Most of the current stigma is associated 
with a lack of information about the disease. 
Thus, several organizations are working on 
decreasing this stigma using various 
approaches such as information campaigns or 
interventions with the governments (92).  
Altogether intervention to decrease the 
stigma attached to leprosy is part of the 
challenge to halt leprosy transmission by 
promoting early detection and improvement 
of life for all patients.  
 
Leprosy treatment 
 
The monotherapy era 
 
Sulfones were the first effective drugs used 
against leprosy in the 1940s Promin was soon 
replaced by its derivative Dapsone, a 
bacteriostatic compound, which was widely 
used in monotherapy due to its high activity 
and fewer side effects compared to other 
drugs (97). Dapsone acts at the first step of the 
folate pathway (98). Other inhibitors of the 
folate pathway such as trimethoprim or para-
aminosalicylate (PAS), acting later in the 
folate cycle, proved to be ineffective against 
M. leprae (99). In parallel, clofazimine 
(B663), another bacteriostatic drug, was 
successfully tested in leprosy patients in a 
shortened treatment compared to dapsone 
alone, even if resistance to the therapy 
appeared after one year of monotherapy (97).  
The development of new anti-leprosy 
drugs has always been impaired due to the 
uncultivability of the leprosy bacilli. The test 
of new drugs was drastically improved by the 
development of the in vivo mouse footpad 
model (MFP) by Shepard in 1960 (44,45). 
Since that time, all major anti-leprosy drugs 
were first tested using Shepard’s method. 
Several anti-tuberculosis drugs were tested 
against M. leprae, some of which were 
inefficient, such as isoniazid, pyrazinamide or 
ethambutol, whereas ethionamide 
(protionamide), rifampicin and streptomycin 
were highly efficient (97,100,101). 
Ethionamide was soon abandoned due to the 
rapid emergence of drug resistance from 
monotherapy (97). Rifampicin is the most 
effective anti-leprosy drug due to its strong 
bactericidal activity (102). The drug binds to 
the ß subunit of the RNA polymerase and 
prevents transcription in the bacteria.  
 
Multidrug therapy  
 
Soon after the implementation of dapsone 
monotherapy, resistance arose in relapse cases 
but also in primary leprosy cases by 1980’s 
followed by rifampicin resistance as well 
Figure 5: Multidrug therapy regimen for multi-and paucibacillary patients and in case of drug resistance. First-line 
drugs are in red, second-line drugs are in blue. d = daily, m = monthly. 
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(9,103). MDT was implemented by WHO in 
1981 to prevent and treat drug-resistant strains 
as well as shorten the leprosy treatment (103). 
For practical treatment purpose, the WHO has 
established a simplified classification of 
leprosy patients. Paucibacillary (PB) cases, 
showing less than five skin lesions, are treated 
for six months with a combination of 
rifampicin and dapsone (Fig. 5), while 
multibacillary (MB) cases, harbouring five or 
more skin lesions, are treated for a minimum 
of 12 months with a combination of 
rifampicin, dapsone and clofazimine (Fig. 5). 
MDT is highly efficient and free of charge for 
all patients (104). Several clinical trials using 
the same drugs, but with shortened treatments, 
or with different therapeutical schemes have 
been tested, but the efficiency was never 
higher than the current MDT (105).  
 
Second line drugs and other treatments 
 
Emergence of drug resistance is 
unavoidable even with an efficient MDT. 
Rifampicin is the cornerstone drug of the 
leprosy treatment due to its rapid bactericidal 
activity (40), so efficiency of MDT will be 
severely compromised in cases of rifampicin 
resistance This led to the implementation of 
second-line antibiotics such as ofloxacin, 
minocycline, and clarithromycin (Fig. 5). 
These are highly effective drugs, but their 
high cost restricts their use as first-line drugs 
(106). Besides antibiotics, leprosy neuritis is 
treated with corticosteroids such as 
prednisone while thalidomide, prednisone or 
clofazimine can be used for ENL. 
Administrated at the early stage of the 
disease, MDT can prevent severe deformities 
and disabilities. However, in an advanced 
stage of the disease, lesions are irreversible 
and can only be treated with surgery. Such 
intervention does not usually help to recover 
sensory loss, but have a substantial impact on 
social rehabilitation, especially when lesions 
are located on the face (107).  
Since the implementation of MDT, a 
limited number of trials was undertaken to test 
new and less toxic drugs for leprosy 
treatment. One of the main apparent reasons is 
the fastidious experiment required for the in 
vivo efficiency studies. However, the rapid 
increase of drug-resistant M. tuberculosis 
strains has forced the community to develop 
new effective antibiotics, which could in turn 
be tested for leprosy. Thanks to the available 
genome sequence, it is now possible to predict 
the efficiency of new drugs in silico. For 
example, bedaquiline and PBTZ169, currently 
being evaluated for tuberculosis, are 
potentially effective drugs against M. leprae 
because the genes encoding for both targets, 
atpE, and dprE1, are functional in M. leprae. 
Also, bedaquiline was already tested in vivo 
and showed a high bactericidal activity 
against M. leprae in the MFP model (9). Q203 
should work as well against M. leprae as the 
target is present (QcrB) and the alternative 
cytochrome oxydase (CydBC) has been 
deleted during the genome downsizing 
(108,109). 
On the other hand, the prodrugs 
pyrazinamide and delamanid are probably 
inefficient, because their corresponding 
activators are not produced in M. leprae (110–
114). Also, the resistance to PA-824, a 
nitroimidazole, was confirmed by MFP assay 
and it is probably due to the absence of the 
nitroreductase enzyme Ddn in M. leprae 
(115).  
 
Molecular mechanisms of drug resistance 
 
Since antibiotics are the only weapons against 
leprosy, surveillance of emergence of drug 
resistance is crucial. The gold standard 
method for antimicrobial resistance testing is 
the MFP assay. However, this method is time-
consuming (6 to 9 months), laborious, and it 
requires highly trained technicians (116). For 
these reasons, the method is not suitable for 
routine use in a surveillance program. 
Following whole-genome sequencing and 
relying on studies conducted on M. 
tuberculosis and other bacteria, mechanisms 
of resistance to three antileprosy drugs were 
identified, namely rifampicin, dapsone, and 
ofloxacin (64,117,118). Specific mutations in 
the drug resistance-determining region 
(DRDR) of the DNA-dependent RNA 
polymerase subunit-ß (rpoB) decrease affinity 
for rifampicin and lead to resistance (Table1). 
Dapsone is an analog of para-aminobenzoic 
acid (PABA) and inhibits the dihydropteroate 
synthetase (folP1), the first step of the folate 
pathway (98). Two residues of FolP1 are 
involved in the resistance to dapsone (Table 
1). Resistance to ofloxacin occurs in genes 
encoding DNA gyrase, principally in the 
DRDR of gyrA and, less frequently, in the 
? ? ??
?????
DRDR of gyrB (119) (Table 1). M. leprae 
clinical isolates harbouring mutation in gyrB 
have never been identified while in vitro 
models showed that mutation in the DRDR of 
gyrB should confer resistance. Clofazimine 
has both anti-inflammatory and antimicrobial 
activity, but the exact mechanism of action is 
not fully elucidated. Clofazimine tends to 
accumulate in body tissues, probably due to 
its highly lipophilic characteristics. With its 
long half-life, and depending on the 
administration frequency, clofazimine can 
remain in the body for months after treatment 
(120). There are different hypotheses to 
clofazimine’s mode of action, the two most 
accepted involve a modulation of the bacterial 
potassium level, or the formation of reactive 
oxygen species after activation of the drug 
(121,122).  
 
Table 1: Known mutations within the DRDR of rpoB, 
folP1, gyrA and gyrB that confer resistance to 
Mycobacterium leprae – most frequent mutations are in 
bold  
Gene 
Amino acid 
substitution 
References 
rpoB 
Gln438Val 
(123,124) 
Asp441Tyr 
Asp441Asn 
His451Asp 
His451Tyr 
Ser456Leu 
Ser456Met 
Ser456Phe 
Ser456Trp 
Leu458Val 
Leu458Pro 
folP1 
Thr53Ala 
(98,117,123,125) 
Thr53Arg 
Thr53Ile 
Pro55Arg 
Pro55Leu 
Pro55Ser 
gyrA 
Gly89Cys 
(123,124) 
Ala91Val 
gyrB 
Asp464Asn 
(126) Asn502Asp 
Glu504Val 
 
Clarithromycin and minocycline are part of 
the macrolide and tetracycline families, 
respectively. Their mechanism of action has 
not been elucidated in M. leprae infections 
(40).  
PCR-sequencing of amplified DRDR is the 
screening tool recommended by the WHO. 
The main drawback of this method is the need 
for Sanger sequencing, a service that is not 
easily available, or affordable, in many 
endemic countries. As an alternative, the 
GenoType LepraeDR® from Hain 
LifeScience, a qualitative DNA strip assay 
based on classic PCR and reverse 
hybridization (127), allows identification of 
M. leprae DNA as well as simultaneous 
detection of antibiotic resistance in the three 
known targets (rpoB, folP1, and gyrA) without 
Sanger sequencing. The absence of some rare 
mutations and the DRDR of gyrB is the only 
drawback of this test. But overall, these 
methods do not offer enough resolution for 
identification of new resistance mutations or 
resistance mechanisms.  
The global surveillance of drug resistance 
network was launched in 2008 and included 
18 countries for sample collection and 18 
reference centres for the analysis (128). 
Thanks to molecular techniques such as PCR-
sequencing, the results of drug resistance 
screens can be obtained within hours. First 
used only in the assessment of relapse cases, 
antimicrobial resistance surveillance is now 
applied for all new leprosy cases because of 
the concerns from the increasing emergence 
and transmission of strains resistant to 
rifampicin, dapsone and ofloxacin (129). In 
the last WHO report, a total of 1600 strains 
were analysed between 2006 and 2013, of 
which 4% harboured mutations conferring 
resistance to rifampicin, 4% to dapsone and 
1.5% to ofloxacin (129). While these numbers 
do not pose a direct threat for the global 
control of leprosy (128), of a bigger concern 
are the mounting reports of multidrug 
resistance (MDR) and primary cases of 
resistant strain transmission in M. leprae from 
different parts of the world (118,124,130–
135). MDR is particularly problematic 
because the number of antibiotics available is 
low and three out of the six anti-leprosy drugs 
have an unknown mechanism of action, 
impeding a genomic-based survey of the 
resistance Therefore, monitoring the 
emergence and transmission of drug and 
multidrug resistance is an essential aspect of 
the global control of leprosy.  
 
Vaccines 
 
There is currently no effective vaccine for 
leprosy. The gap in our understanding of the 
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full pathogenesis of the bacteria and the host 
response at the different stages of infection 
including sub-clinical infections is holding up 
any prospects of efficiently developing one 
(40).  
Several studies reported different ranges of 
protection by the M. bovis bacille Calmette et 
Guérin (BCG) vaccine, ranging from 30-50% 
(136). Another approach was to combine 
BCG vaccine with heat-inactivated M. leprae 
bacteria, however no significant benefit 
compared to BCG alone was observed. Also, 
the mass implementation of this vaciine would 
have been challenging since bacteria can be 
obtained only from armadillo lesions 
(136,137). Analysing the M. leprae genome 
revealed several candidate genes, and 
recombinant antigens were tested. The 
primary objective was to choose an antigen, or 
combination of antigens, that induce a strong 
INF? response against the bacteria (138,139). 
One promising candidate is the 73f, a 
chimeric fusion protein composed of 
ML2028, ML2346 and ML2044 formulated 
with a TLR4L-adguvant. This protein is 
recognized by MB patient (IgG) and 
stimulated INF? production in PB patients. 
This candidate vaccine entered into clinical 
trial in 2017 and early results should be 
available in 2018 (136,139).  
M. indicus pranii (MIP), was tried as 
alternative leprosy vaccine. The formulation 
contained heat-killed MIP and was developed 
in the 90’s. The vaccine protection was shown 
to be highest in children and protected 60% of 
contacts for six to seven years (136). Also, 
several studies reported the beneficial 
association of standard MDT with the vaccine 
leading to significant and faster recovery 
(140). In May 2017, a large trial was launched 
in India to evaluate the immune-therapeutic 
effect of single dose of rifampicin with the 
vaccine in patients and contacts. Data are not 
available yet.  
 
Origin and spread of the leprosy bacillus 
 
The dynamics of leprosy transmission 
throughout human history is not fully 
resolved, and characterization of the most 
ancestral strains is crucial for deciphering the 
nature of leprosy's origin. In this part, we will 
describe the current knowledge about the 
origin and evolution of M. leprae strains.  
M. leprae is a clonal organism, and is 
genetically very conserved. The geographical 
distribution of M. leprae genotypes has helped 
retrace evolution and dissemination of 
leprosy. Earlier phylogeographical data 
showed a correlation of M. leprae genotypes 
with large human migrations, and support the 
hypothesis that leprosy originated either in 
East Africa (SNP type 2) or in India (SNP 
type 1), from where it spread to Europe and 
Asia via trade routes (84). In a newer study, 
Monot et al. suggested that the M. leprae 
ancestor was probably an intermediate 
between the SNP type 2 and SNP type 3 (85). 
Based on current genotyping studies, SNP 
type 2 is mainly found in Turkey (2F), Iran 
(2F), Ethiopia (2H), India (2E, 2H), Nepal 
(2G) and Europe (2F) (85,141,142).  
Figure 6: Phylogeny of medieval and modern M. leprae strain as described by Schueneman et al. [87] (A) Maximum
parsimony tree of M. leprae genomes, rooted with M. avium. Geographic origin and SNP-subtype are given at each branch. 
Bootstrap (500) node support is shown in grey, and nucleotide substitution in bold. (B) Bayesian phylogenetic tree
calculated with BEAST 1.7.1 inferred from 516 genome-wide variable positions. Posterior probabilities are in grey. B.C.E:
before the Common Era; C.E: Common Era 
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Palaeoepidemiology is an emerging field 
that can provide clues to solve and understand 
the nature of infectious diseases and give a 
more comprehensive picture of the 
emergence, evolution, and spread of bacterial 
pathogens throughout history (86,142–147). 
However, studies on ancient DNA are 
technically complex, mainly because of the 
low amounts and poor quality of the DNA, 
and because the technique relies on cutting-
edge protocols and requires specialized 
laboratories. 
In 2013, using the array-based enrichment 
method, the first ancient M. leprae whole 
genomes were sequenced from Northern 
European cases. These strains correspond to 
SNP type 2F and 3I in the UK and Denmark 
(86,148) revealing a link between European 
strains and those currently reported from the 
Middle East (SNP type 2) and USA (SNP 
subtype 3I). Unfortunately, at that time no 
modern SNP type 2 genome was available. In 
the study of Schuenemann et al., comparison 
of modern and ancient genomes also revealed 
that the 3K sub-type forms a distinct branch in 
the M. leprae phylogeny, called branch 0 (86), 
which was estimated to have diverged from 
the most common ancestor around the first 
millennium B.C. (Fig. 6). The 3K genotype 
has mainly been found in modern samples 
from China, Japan, and the Middle East 
(85,149) as well as in ancient isolates from 
Europe (142). It is noteworthy that the SNP 
subtypes 3M and 3J have not been sequenced 
yet, so their ancestral relationship with the 
other branches is not known (85). The only 
reported occurrences of these genotypes were 
in the French West Indies, and they are scarce 
in modern isolates while the genotype 3M was 
also identified in medieval European strains 
by PCR-sequencing (142).  
The spread of leprosy throughout the world 
seems to be linked with human migrations, as 
several lines of evidence suggest (85). The 
most evident case is the introduction of 
leprosy into the Americas. The prevalence of 
SNP type 3I in contemporary South America, 
including the armadillo population currently 
spreading north, most likely derives from 
European settlers, as 3I was common in 
Medieval Europe. The abundance of SNP type 
4 on the other hand is probably linked with 
the slave trade between South America and 
West Africa, where this genotype 
predominates (86) . 
Human migrations and the contacts 
between different societies were dynamic 
during the last millennia, which blurs the 
genetic footprint of ancient leprosy 
transmissions. A global analysis of a large 
number of genomes might help to retrace the 
history of this disease. 
 
Other leprosy-causing bacilli 
 
The mysterious Mycobacterium lepromatosis: 
a new species or an M. leprae strain? 
 
Leprosy had always been exclusively 
associated with M. leprae until 2008 when 
Han et al. discovered M. lepromatosis (150), 
in a liver sample from a Mexican leprosy 
patient. Despite several attempts, M. 
lepromatosis remains uncultivable in vitro 
(150). 
Sequencing of more than 20 genes, including 
rrs (16S rRNA), rpoB, groEL, and rpoT, 
revealed that the overall level of nucleotide 
identity between M. lepromatosis and M. 
leprae is 90.9%, which is different enough to 
classify it as a new species (150,151). M. 
lepromatosis is the closest species to M. 
leprae known to date.. Strikingly, the 
bacterium has been reported mainly in Mexico 
and the Caribbean region, and it seems to be 
associated with the DLL form and especially 
with Lucio's phenomenon (152,153), but 
given the small sample size, the extent of this 
association or the possibility that M. 
lepromatosis causes other forms of leprosy 
remain unclear. (153).  
Later, Han and colleagues identified M. 
lepromatosis in Singapore and Canada using a 
PCR-based screening, but most of the cases 
were still recorded in Mexico [116–118].  
Whole-genome sequencing of M. 
lepromatosis was achieved in 2015. The 
description of the genome and the 
development of new tools to study the spread 
of the leprosy-causing bacteria is presented in 
Chapter II.  
 
M. lepraemurium: leprosy or non-leprosy 
bacillus?  
 
M. lepraemurium was described in 1903 
and was associated with leprosy-like lesions 
in wild rats and mice in Russia, Germany, 
Japan and Puerto Rico (157). For a long time, 
M. lepraemurium was referred to as a “leprosy 
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bacillus” because of the clinical similarities 
between the human and rat symptoms and the 
difficulty to grow it in vitro (158,159). 
Moreover, several similarities were observed 
by electron microscopy between both 
pathogens. M. lepraemurium was successfully 
cultivated in rats and mice before the MFP 
method was developed for M. leprae by 
Shepard (159). Thus, M. lepraemurium 
infected mice was the only in vivo model of 
leprosy available at that time. Recently, M. 
lepraemurium were also associated with feline 
leprosy (158). Whole-genome sequencing of 
M. lepraemurium was achieved in 2017. The 
description of the genome and the 
relationships with M. leprae and other 
mycobacteria is presented in Chapter II.  
 
Transmission  
 
The mystery and challenges around the 
disease transmission  
 
The exact mode of transmission of leprosy 
is unknown, but it seems that close contact 
with infected individuals in the family or the 
same community is a high-risk factor of 
transmission (160). Nasal mucosae or skin 
might serve as an entry route into the human 
host because leprosy bacilli were found in the 
nasal secretion and the skin of seemingly 
healthy individuals in endemic areas. (38). 
Generally, leprosy is considered to be poorly 
contagious and patients with a low bacillary 
index are usually less contagious compared to 
patients with a high bacillary load (161).  
Most leprosy transmission studies focused 
on general clinical or societal markers to 
establish transmission patterns between 
patients, while some studies used genetic 
markers such as genotyping methods in an 
effort to increase specificity and resolution 
(38). However, monitoring the transmission of 
an M. leprae strain in a small geographic area 
and over a short period of time is challenging 
because of the scarcity of mutations that could 
distinguish between different isolates. SNP 
typing methods (not enough resolution) and 
VNTRs (variable mutation rates between loci 
and frequent reversal mutations) are not apt 
for this challenge. Whole genome-based 
approaches have the potential to reveal the 
full dynamic range of transmission of closely 
related strains. 
An important area where such resolution is 
needed is the differentiation between relapse 
and reinfection cases. Relapse rate is an 
indicator of treatment efficiency directly link 
to drug-resistant or persistent strains, while re-
infection is an indicator of active transmission 
in the area (81). Leprosy re-occurrence most 
often happens in cases with a high bacillary 
index and is mostly attributed to relapse, 
possibly due to the dogma about protection 
gained to the disease after the first infection 
(162) (communication Leprosy Mailing List – 
July 17, 2017). For example, a study 
conducted in India found three recurrent cases 
among 163 followed-up cases after two, four, 
and eleven years post MDT. All three 
recurrent cases were attributed as relapse 
without any molecular confirmation (163). 
Recently, using a combination of VNTRs and 
SNP-typing, Da Silva Rocha and colleagues 
identified two cases of reinfection that 
occurred nine and fifteen years post primary 
infection (81). Such findings are of particular 
importance for endemic areas where 
convalescents continue to be exposed to M. 
leprae (164). Leprosy recurrence is commonly 
observed in some parts of the world, but no 
study has systematically assessed the rate of 
relapse compared to reinfection in these areas 
(162). More information about leprosy 
recurrence is needed in order to improve 
treatment management, and to better assess 
the effectiveness of new short-course 
treatment regimens (165). 
 
The natural non-human source of leprosy 
bacilli 
 
Humans were thought to be the only 
source of leprosy infection (166) until non-
human natural hosts of M. leprae were 
identified in the 1970’s [75]. M. leprae is well 
established in the wild nine-banded armadillo 
(Dasypus novemcinctus) and to a lesser extent 
in some primates, mainly in Africa (47,169–
171). Prevalence in the wild armadillo is 
around 20% but it depends on the 
geographical area (172). The territory covered 
by nine-banded armadillos includes Brazil, 
Central America and the Southern United 
States. Using genomics approaches, it was 
shown that leprosy in the USA can be a 
zoonotic infection between nine-banded 
armadillos and human (173). Leprosy was 
likely transmitted to the nine-banded 
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armadillo by European settlers. Leprosy 
disappeared from the USA during the modern 
period, but it re-emerged in the South about a 
century ago, which roughly corresponds with 
the time of introduction (?1850) and 
expansion of the nine-banded armadillo 
population from Mexico into the Southern 
USA (172,174,175). As for humans, the 
mechanism of transmission of leprosy 
between nine-banded armadillos and humans 
is not known, but it is assumed that close 
contact with infected animals and 
contaminated flesh and blood is a high risk 
factor (172,173,176). The burden of leprosy in 
nine-banded armadillos in Brazil, a highly 
endemic country for human leprosy, and its 
possible impact to the human population, have 
not been studied yet. 
 Recently, the newly discovered leprosy 
agent M. lepromatosis has been identified in 
red squirrels in Scotland, presenting with 
leprosy like lesions (177,178). This is the first 
report of a non-human reservoir of M. 
lepromatosis. It is surprising to find M. 
lepromatosis in Scotland, a non-endemic 
country for leprosy. Additional work is 
needed to define the role of the red squirrel as 
a new source of leprosy bacilli and 
transmission.  
 
Other potential natural reservoirs 
 
The existence of animal reservoirs and 
newly detected human cases with no tangible 
direct source of infection known from leprosy 
patient has led to the idea that additional 
reservoirs of M. leprae might exist (179,180). 
Several studies have shown the presence of M. 
leprae in soil or water (38). In a survey 
conducted in India, the authors found the 
presence of M. leprae 16S rRNA in 35% of 
the soil samples and concluded that viable M. 
leprae were present in the soil at the time of 
collection (181,182).  
In the environment, free-living amoebae 
can feed on bacteria. Encystment is a survival 
stage in amoebae, also known as a resting 
form. Several bacteria can survive within free-
living amoebae, including some mycobacteria. 
Encysted amoebae provide protection to the 
internalized bacteria (183) and contribute to 
their spread in the environment. Interestingly, 
Lahiri et al. have shown that M. leprae can 
survive in a free-living amoebae such as 
Acanthamoeba castellani for a few days and 
can grow when re-inoculated in MFP (184). 
Following this study, Wheat et al. reported 
that M. leprae could survive up to eight 
months in encysted amoebae without loss of 
virulence (185), but so far, no M. leprae has 
been found in amoebae in the environment. 
Overall, it is evident that the natural 
reservoir of M. leprae is broader than 
previously anticipated, and studying non-
human sources more deeply might provide a 
leap for leprosy control.  
 
Diagnosis of leprosy 
 
Diagnosis of leprosy at its early stages is 
essential to prevent disabilities. Nowadays, 
leprosy diagnosis still relies on the 
identification of three cardinal signs, namely 
skin lesions, thickness or enlargement of 
peripheral nerves, and the detection of acid-
fast bacilli in active lesions or slit skin smears 
(SSS). Accurate diagnosis of leprosy can only 
be done by trained physicians because the 
symptoms overlap with those of a number of 
other medical conditions. This emphasizes the 
importance to maintain leprosy expertise in 
endemic and non-endemic countries as well as 
to reinforce training for all health care 
workers . Another critical component of early 
diagnosis is informing and training patients, 
their contacts and the general population 
about the disease to decrease the associated 
stigma that often results in leprosy sufferers 
hiding their disease, as this will facilitate the 
identification of early symptoms and prompt 
intervention of medical staff (15,186,187).  
 
Table 2: The bacteriological index scale used for 
expression of the bacterial load – the result is 
expressed in logarithmic scale of the number of bacilli 
observed in a x100 objective field (188) 
BI Observations 
6+ Many clumps of bacilli in an average 
field (over 1000) 
5+ 100-1000 bacilli in an average field 
4+ 10-100 bacilli in an average field 
3+ 1-10 bacilli in an average field 
2+ 1-10 bacilli in 10 field 
1+ 1-10 bacilli in 100 field 
0+ No bacilli in 100 fields 
 
? ? ??
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The amount of acid-fast bacilli in active 
lesions or SSS determines the bacterial load, 
also named bacillary or bacteriological index 
(BI) (Table 2). The BI system is more 
effective with high bacillary loads, but a BI of 
zero is not an indication of the absence of 
leprosy.  
Since M. leprae and M. lepromatosis 
cannot be cultivated in vitro, their presence 
must be assessed directly in different types of 
tissues, or body fluids such as skin, nerves, 
urine, or blood. However, and especially in 
leprosy with a low BI, bacteria are commonly 
not detectable in SSS, urine or in blood (189–
191). Also, nerve sampling is usually 
undertaken only for diagnosis of pure neural 
leprosy since the procedure is highly invasive. 
Skin biopsy is the most common type of 
sample used for diagnosis. From such 
samples, histology with hematoxylin and 
eosin staining is performed to establish the 
disease classification. Then, the presence of 
leprosy bacilli is verified using microscopy or 
genomic methods (Table 3).  
 
Table 3: Non exhaustive list of methods used on SSS 
and skin biopsies for the detection of leprosy bacilli 
in skin tissues 
 Aim References* 
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 Identification of acid-
fast organisms – 
mycobacteria are 
colored in red 
(192,193) 
H
a
e
m
a
to
x
y
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n
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n
d
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o
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n
 s
ta
in
 Coloration of cells in a 
histology section 
(nucleic and anucleic 
cells) – Classification 
of the leprosy 
spectrum form 
(16,192) 
A
u
r
a
m
in
e
 
O
 
st
a
in
 
Identification of acid-
fast organisms – 
mycobacteria are 
fluorescent 
(192–194) 
P
C
R
/q
P
C
R
 Identification of a 
species based on 
detection of specific 
genomic parts. 
(194–197) 
 
Ziehl Neelsen (ZN) and Fite Faraco (FF) 
staining and light microscopy are commonly 
used in countries with limited resources. 
These low-cost methods are specific, but lack 
sensitivity, especially for samples with low BI 
and require trained and specialized 
microscopists. In this regard, genomic 
methods are superior to microscopy. First, 
conventional polymerase chain reaction 
(PCR) and real-time fluorescence-based 
quantitative PCR (qPCR) methods are known 
to be extremely sensitive with low detection 
limits (198). For example, Truman and 
colleagues reported a limit of detection of 
only three bacilli using a qPCR method (195). 
Also, since the pieces of tissue used for DNA 
extraction are much larger than those used for 
microscopy, there is more chance to encounter 
bacilli. For example, PCR methods detected 
M. leprae DNA extracted from skin biopsy 
more efficiently than SSS, because there are 
fewer bacilli in SSS (196). Among the 
different targets suitable for amplification, 
such as the manganese-dependent superoxide 
dismutase gene (sodA), the mRNA of antigen 
85B (Ag85B), and the 16S rRNA gene; 
RLEP, an M. leprae specific dispersed repeat, 
is the most sensitive marker and a promising 
candidate for PCR-based diagnosis (197,199). 
The sensitivity of detection for RLEP varies 
from 70 to 100% depending on the method 
and type of sample (200). For example, qPCR 
is more sensitive than conventional PCR and 
easier to perform but requires more 
sophisticated equipment (200). The sensitivity 
of PCR-based methods is up to 100% for MB 
cases, and around 70-80% in PB cases (200). 
Most importantly, it is possible to detect the 
presence of M. leprae by PCR even in cases 
where the result of microscopic methods is 
negative (196). 
While working with one of the most 
sensitive methods available, one could ask 
why molecular methods do not give a higher 
sensitive result for PB patients? Obviously, 
the number of bacilli present in the skin is one 
of the main reasons but another critical step, 
which is often not taken into consideration, is 
the DNA extraction method used since the 
quality and the amount of DNA recovered can 
be widely affected by the chosen method. 
Also, accurate definition of the gold standard 
differed depending on the publication, and it 
is an important point to compare the different 
results (200). Both parameters are further 
discussed in the last chapter and the 
conclusion.  
The GenoType LepraeDR® from Hain 
LifeScience is the only commercially 
available and standardized molecular test for 
leprosy diagnosis. The test shows a specificity 
of 100% and sensitivity of 100% in the cohort 
? ? ??
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tested (127). However, the cohort consisted 
exclusively of smear-positive patients (BI >0), 
avoiding the most difficult cases to be tested.  
Immunodiagnostic tools are also 
available for diagnosis of leprosy. The first 
one developed was the lepromin test, similar 
to the tuberculin test available for 
tuberculosis. Briefly, heat inactivated M. 
leprae, or synthesized M. leprae antigens, are 
intradermally injected, and the reaction is 
observed after two days (Fernandez reaction) 
and four weeks (Mitsuda reaction). Although 
the Fernandez reaction appears in both LL and 
TT cases, the Mitsuda reaction is usually 
observed in TT patients and reflects the 
cellular immunity. The sensitivity of this test 
is low, which is why it is now mainly used for 
classification purposes (201). Nevertheless, 
the Mitsuda test is still performed in several 
countries.  
PGL-I antigen from M. leprae triggers the 
formation of IgM class antibodies. These anti-
PGL-1 antibodies are found in high quantity 
in the sera of MB patients (>95% positivity) 
due to the increased humoral response, while 
they are often absent in PB patients (20-40% 
positivity) (202). The test was available 
commercially as a lateral flow test but the 
production was stopped before 2010 due to 
low demand and poor take-up by leprosy 
control programs (203). Similar to IgM, the 
IgG antibody response directed against M. 
leprae-specific recombinant proteins such as 
ML0405 and ML2331 (leprosy IDRI 
diagnostic-1 or LID-1) correlates with the 
bacterial load. Thus, like for anti-PGL-I, MB 
patients are the easiest to detect compared to 
PB patients using the IgG test. Recently, both 
tests were combined to enhance detection of 
MB cases in the so-called LID-ND-O antigen 
from the Infectious Disease Research Center 
(204). Nevertheless, IgM and IgG responses 
are weak or absent in PB patients, which 
present high cellular immunity. However, 
recently, Serrano-Coll and colleagues 
suggested in their study conducted on 80 
patients that LID-ND-O positivity is a good 
risk marker of developing neuritis and leprosy 
reactions (204).  
For PB side of the spectrum, the pro-
inflammatory mediators IFN-? and IP-10 
were tested. For tuberculosis, the commercial 
Quantiferon-TB gold diagnosis test is based 
on the interferon gamma release assay (IGRA) 
where IFN-? secretion is detected in whole 
blood after exposure to the specific 6KDa 
secreted antigenic target (ESAT-6) and 10kD 
culture filtrate protein (CFP-10) (205–207). 
This test is sensitive and specific for the 
detection of M. tuberculosis complex 
infection but does not differentiate active 
disease from latent tuberculosis (208). Studies 
have shown cross-reaction between M. leprae 
and the M. tuberculosis CFP-10 and ESAT-6 
antigen [192–194]. The IGRA test does not 
detect MB cases as expected, and only a small 
part of PB patients. But only a few studies 
have been conducted with the Quantiferon so 
far, and none of them used CFP-10 and 
ESAT-6 purified from M. leprae, which could 
increase the sensitivity (208,209). However, 
one limitation, raised by Geluk and 
colleagues, is the strong cross-reactivity 
between ESAT-6 of M. lerpae and M. 
tuberculosis, which can increase the 
complexity of diagnosis (205). Prospects for 
other IFN? specific M. leprae antigen 
stimulators were conducted to differentiate 
between PB and MB patients and PB and 
healthy endemic control. So far, no such 
antigen was described (52). Thus, current 
research is focused on the detection of one or 
several cytokines/chemokines specific for one 
or several forms of the leprosy spectrum such 
as the monocyte chemotactic protein-1 (MCP-
1) and the interleukin 1ß (IL-1ß). The primary 
aim is to provide a precise diagnosis between 
healthy controls and leprosy patients at the 
same time that an accurate classification of 
the disease (52). Recently, von Hooij et al., 
combined the detection of a set of 
cytokines/chemokines (IL-10, IP-10, and 
CCL4) and anti-PGL-I in whole blood from 
leprosy patients from Bangladesh (210). The 
selection of the markers was driven by the aim 
to distinguish between different clinical 
leprosy types. ML2478 induces high IFN-? 
and consequently IP-10 concentrations, and is 
associated with M. leprae exposure and risk of 
infection (210). The chemokine (C-C motif) 
ligand 4 (CCL4) secretion is increased in 
patients, and partly in household contacts, but 
not in endemic controls. IL-10 is involved in 
the suppression of Th1 cells in MB leprosy 
patients. Finally, anti-PGL-1 was included in 
the final set because it is specific to MB 
patients. Hence, the test can simultaneously 
perform multiple analyses in one sample and 
can distinguish different clinical leprosy 
types. Using a combination of these markers, 
? ? ??
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it is possible to identify an ongoing infection, 
and classify the disease (210). Although 
encouraging, these tests need to be validated 
in several endemic areas to assess the 
robustness of the method.  
Interruption of leprosy transmission and 
diminution of leprosy burden is impaired by 
the absence of an efficient, reliable and global 
diagnosis tool for all clinical forms but also 
for household contacts. Currently, diagnosis is 
nearly impossible before the onset of clinical 
signs, and this is particularly challenging for 
the forms with a low number of subtle 
symptoms such as pure neural leprosy, 
unusual forms (in children for example) or 
sub-clinical infections (13,15,18). An efficient 
diagnosis tool allowing detection of the 
disease prior to the onset of symptoms is one 
of the main aim and wish objectives in the 
leprosy field (12) 
Other approaches to detect leprosy include 
the “omic” techniques, such as metabolomics 
or transcriptomics. While these methods could 
help to identify global diagnostic or 
prognostic markers, they could also uncover 
pathogenic mechanisms and participate in a 
better understanding of leprosy pathogenesis.  
Metabolomics was already applied for 
various infectious diseases to identify a 
specific metabolic signature for the diagnosis 
and prognosis (211). In leprosy, investigation 
of specific metabolomic signature has been 
investigated in the serum and the urine 
(212,213). Recently, Mayboroda and 
colleagues identified a set of metabolites in 
urine that was able to discriminate between 
endemic controls and leprosy patients. Also, 
they reported a modification of the 
metabolome during type 1 reaction (213). 
Although these results are encouraging, they 
need to be validated in a more demanding 
cohort and tested in another disease to 
demonstrate the specificity to leprosy.  
An important breakthrough was recently 
made using transcriptomics to understand the 
immune response and pathogenesis of several 
infectious diseases (214,215). Genome-wide 
transcriptional profiling of individuals with 
active tuberculosis led to the identification of 
a specific 86-gene signature that can 
distinguish tuberculosis from other infectious 
or inflammatory diseases, and determine the 
severity of the disease from type I interferons 
IFN-?ß levels (216). In leprosy, a similar 
approach was used to identify transcriptional 
changes of the immune reactions (217). 
Dupnik et al. showed immunity-related 
pathways to be up regulated in the 
transcriptional profiles of leprosy patients 
with reversal reaction or ENL, with 
complement pathway deposition being part of 
the immune response to both reactions. When 
the pathology is mediated by complement and 
other components of innate immunity, they 
hypothesized that such reactions result from 
abnormal antigen recognition. This 
observation helped explaining the 
pathogenesis of reactions. Such an approach 
would also be helpful to identify global 
biomarkers of leprosy, in blood for example.  
 
Prevention in household contacts 
 
Current studies showed that leprosy 
contacts and people living in endemic areas 
have more chance to contract and develop the 
disease (200). Exposure to M. leprae can be 
evaluated by serology and qPCR on DNA 
extracted from nasal swabs. Presence of 
bacteria in the nose is not a sign of disease, 
but individuals with nasal carriage have a 
higher risk to develop leprosy (200). 
However, the fraction of nasal carriers of M. 
leprae in the population varies from 1 to 70%, 
depending on the geographical region and the 
group considered (contacts or all healthy 
individuals for example) (200). More 
interestingly, Romero-Montaya and 
colleagues confirmed the familial 
transmission between contacts and index 
cases using a set of VNTR and SNP markers 
(218). However, SNP genotyping could be 
done only for one index case, probably 
because of the low amount of bacterial DNA 
in other cases. Contacts with positive PGL-1 
also have a higher risk of developing the 
disease and especially if the index case has a 
high BI (190,200). Thus, Martinez et al., 
suggested that combining conventional PCR 
or qPCR detection methods with anti-PGL-I 
serology could help identify individuals 
exposed to M. leprae and at high risk to 
develop the disease (200). This combination 
was applied in the study from Romero-
Montaya et al., but no follow up of the tested 
individuals was done to evaluate the 
sensitivity of this association (218). Another 
study is currently ongoing using both methods 
described above and preliminary results 
showed more than 65% positivity in 
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household contacts in a high endemic area in 
Parà, Brazil (13). 
Another approach would be to try to 
identify a host biomarker based on 
comparative transcriptomics. Such an 
approach was successfully applied in 
tuberculosis. Zak and colleagues compared 
the transcriptome of individuals infected by 
M. tuberculosis (positive with the IGRA or 
tuberculin tests) who developed symptoms 
after two years with positive individuals who 
did not develop symptoms after two years 
(219). Using RNA sequencing in whole blood, 
they identified 48-biomarkers that predicted 
the risk of tuberculosis progression from 
latent to active with a sensitivity of 66% and a 
specificity of 80% (219,220). For leprosy, 
such an approach is more challenging since it 
would first require a well-established gold 
standard test to define “positive” individuals, 
such as the PGL-1 serology and PCR on DNA 
extracted from nasal samples described above. 
Moreover, since the incubation time of the 
disease be up to 20 years, the study would 
require an large number of individuals to be 
followed up during several years.  
 
Monitoring therapy efficiency 
 
The assessment of therapy efficiency is an 
important parameter that can be used to 
identify lack of observance, appearance of 
drug resistance, or potential emergence of 
persistent strains, as exemplified in M. 
tuberculosis (111,221,222). Currently, the 
primary tool to measure the viability of bacilli 
is through the assessment of RNA expression 
though RT-PCR (182). However, like for 
DNA, this approach is challenging in samples 
with low bacillary loads. In tuberculosis, 
Thompson and colleagues identified a five-
gene host signature that allows assessing the 
risk of treatment failure (223). For leprosy, 
such a signature would also help to monitor 
treatment efficiency in all leprosy forms 
despite the bacterial load and to provide an 
efficient biomarker for future clinical trials. 
 
 
OVERVIEW OF THE THESIS 
 
In the absence of tools to study the 
phenotype of leprosy bacilli, genomics 
approaches and especially whole-genome 
sequencing can provide valuable information 
to understand the biology, genetics and the 
evolution of the leprosy bacilli at different 
time scales. Whole-genome analysis provides 
deeper resolution than standard molecular 
typing methods such as SNP-typing or 
VNTRs. However, high throughput 
sequencing methods are expensive and 
challenging with DNA extracts from leprosy 
skin biopsies, especially those with low BI. 
Efficient DNA extraction methods for the 
leprosy bacillus, tailored for various types of 
samples, are therefore primordial for routine 
whole-genome sequencing applications. Thus, 
during the first years of my doctorate 
programme, I was mainly working on the 
development of an efficient and less 
expensive method to recover enough M. 
lerpae DNA directly from skin biopsies. This 
method was published in 2016 (Chapter IV 
and Chapter V). Later, other methods have 
been optimized for different types of starting 
materials such as formalin fixed samples 
(Chapter V) or pure bacterial suspensions 
(Chapter II).  
Thanks to the new extraction methods, the 
whole genomes of M. lepromatosis and M. 
lepraemurium were sequenced, providing 
more insight into the evolution and biology of 
these species. Results are presented in 
Chapter II.  
In 2013, only 15 M. leprae genomes were 
available; scarcely covering different parts of 
the world. During my thesis, I concentrated 
efforts on sequencing additional strains from 
medieval Europe in order to identify ancestral 
lineages of M. leprae (Chapter III) and a 
modern samples from Japan, Ethiopia, West 
Africa and Brazil (Chapter IV) for 
phylogenetic and transmission studies as 
exemplified by the work in Guinea-Conakry.  
In addition, I focused on the sequencing of 
known drug and multi-drug resistant strains in 
order to identify new mechanisms involved in 
drug resistance (Chapter IV). Moreover, 
recurrent cases were studied to understand the 
aetiology and to obtain information about 
strain variation within the host and within a 
limited endemic area (Chapter IV). 
Animal reservoirs of the leprosy bacillus 
were investigated in the red squirrel 
population from the British Isles using 
different approaches such as histology, 
serology and genomics (Chapter IV). 
Finally, the host depletion method for 
DNA extraction was proven to be highly 
? ? ??
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effective for high BI but it is still limited for 
BI 0 to 2. Thus, for diagnosis purposes, the 
DNA extraction method was modified to 
maximize the yield of M. leprae DNA 
recovered in the low BI samples. Combined 
with PCR, the sensitivity of the method was 
compared with other leprosy diagnostic 
methods in Chapter V. 
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Abstract 
Mycobacterium lepromatosis is an 
uncultured human pathogen associated with 
diffuse lepromatous leprosy and a reactional 
state known as Lucio’s phenomenon. By using 
deep sequencing with and without DNA 
enrichment, we obtained the near-complete 
genome sequence of M. lepromatosis present 
in a skin biopsy from a Mexican patient, and 
compared it with that of Mycobacterium 
leprae, which has undergone extensive 
reductive evolution. The genomes display 
extensive synteny and are similar in size 
(?3.27 Mb). Protein-coding genes share 93% 
nucleotide sequence identity, whereas 
pseudogenes are only 82% identical. The 
events that led to pseudogenization of 50% of 
the genome likely occurred before divergence 
from their most recent common ancestor 
(MRCA), and both M. lepromatosis and M. 
leprae have since accumulated new 
pseudogenes or acquired specific deletions. 
Functional comparisons suggest that M. 
lepromatosis has lost several enzymes 
required for amino acid synthesis whereas M. 
leprae has a defective heme pathway. M. 
lepromatosis has retained all functions 
required to infect the Schwann cells of the 
peripheral nervous system and therefore may 
also be neuropathogenic. A phylogeographic 
survey of 227 leprosy biopsies by differential 
PCR revealed that 221 contained M. leprae 
whereas only six, all from Mexico, harbored 
M. lepromatosis. Phylogenetic comparisons 
indicate that M. lepromatosis is closer than M. 
leprae to the MRCA, and a Bayesian dating 
analysis suggests that they diverged from their 
MRCA approximately 13.9 Mya. Thus, 
despite their ancient separation, the two 
leprosy bacilli are remarkably conserved and 
still cause similar pathologic conditions.  
 
Significance 
Leprosy was thought to be exclusively 
caused by infection of humans by 
Mycobacterium leprae. In 2008, Han et al. 
proposed that Mycobacterium lepromatosis, 
a separate unculturable species, might be 
responsible for a rare yet severe form of the 
disease called diffuse lepromatous leprosy. 
Here, by using comparative genomics, we 
show that the two species are very closely 
related and derived from a common 
ancestor that underwent genome downsizing 
and gene decay. Since their separation 13.9 
Mya, the two species have continued to lose 
genes, but from different regions of the 
genome, and M. leprae appears to be more 
recent. In a recent phylogeographic survey, 
by using differential PCR, we found that M. 
lepromatosis was scarce and restricted to 
patients from Mexico. 
 
Introduction 
Nearly a quarter million new case of 
leprosy (Hansen’s disease) are still recorded 
annually worldwide despite a remarkable 
decrease in prevalence in the past decade 
(1). Leprosy primarily affects the skin, 
peripheral nerves, and eyes, and manifests 
as a spectrum of diverse clinical forms 
varying in bacillary load and often 
accompanied by painful immunological 
reactions (2–4). A severe form of leprosy 
known as diffuse lepromatous leprosy 
(DLL) that is common in western Mexico 
and the Caribbean region, first described 
by Lucio and Alvarado in 1852 (5), is 
referred to as Lucio’s leprosy. Such cases 
account for a sizable proportion (more 
than 20%) of all leprosy cases in western 
Mexico (5–8), Cuba (9), and Costa Rica 
(10) but are rarely reported elsewhere. In 
1948, Latapi and Zamora noted that DLL 
cases had no dermal nodules and were 
characterized by a generalized and diffuse 
infiltration of the skin by histiocytes and 
acid-fast bacilli causing an appearance of 
swollen or “spotted” skin, which they 
termed “pure and primitive diffuse 
lepromatosis.” In addition, they reported 
that some patients developed acute necrotic 
skin reactions, “erythema necroticans,” and 
differentiated this condition as Lucio’s 
phenomenon (6).  
The most notable clinical feature of DLL 
and Lucio’s phenomenon is the diffuse 
mycobacterial invasion of endothelial cells 
surrounding small vessels, often leading to 
vascular occlusion (8). The initial cyanotic 
lesions, caused by poor blood supply and 
ischemia, gradually evolve into black necrotic 
lesions (11, 12). Hence, these cases are often 
associated with long-term morbidity (8) as 
well as a higher number of fatalities if not 
managed adequately (5, 13). Lucio’s 
phenomenon is usually observed among 
untreated or inadequately treated 
nonnodular DLL cases 1–3 y after the 
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appearance of their symptoms. Although 
rare, Lucio’s phenomenon has also been 
reported among other forms of lepromatous 
leprosy (6). Multidrug therapy (MDT) is 
currently the treatment recommended by the 
World Health Organization for all forms of 
leprosy, including DLL and Lucio’s 
phenomenon (14, 15). Until recently,
Mycobacterium leprae was considered the 
sole causative agent of all forms of 
leprosy, including Lucio’s phenomenon, 
which is often referred to as a “form of 
leprosy reaction” (13, 16). The genome of 
M. leprae has undergone reductive 
evolution, with approximately half occupied 
by pseudogenes (17), and also displays 
remarkably low levels of genetic diversity 
(18–20).  
In 2008, a new mycobacterial species 
named Mycobacterium lepromatosis was 
identified in a liver autopsy specimen from 
a homeless Mexican who died with DLL in 
Arizona (21). Since then, this species has 
been identified by PCR-based sequencing in 
several Mexican patients (22) as well as in 
individual cases from Singapore (23) and 
Canada (24). In addition, clinical 
presentations resembling Lucio’s 
phenomenon have been reported elsewhere, 
i.e., Brazil (25, 26), India (27–29), Iran (30), 
and Malaysia (31); however, molecular 
confirmation of the mycobacterial agent was 
not carried out. In addition, several cases of 
mixed infection have been reported whereby 
both M. lepromatosis and M. leprae were 
detected (22), which undermines confidence 
in M. lepromatosis being the causative 
agent of DLL. Knowledge about the biology 
and pathogenesis of M. lepromatosis is 
limited because this species remains 
uncultivated (21).  
To date, the DNA sequences of 22.8 kb 
of selected PCR fragments from M. 
lepromatosis are known, and these were 
sufficient to reveal striking sequence 
similarity to M. leprae and a close 
phylogenetic relationship, but this 
preliminary analysis provided little 
biological insight. Thus, at this stage,
genome sequencing is the most efficient 
approach to investigate M. lepromatosis. 
After the first description of M. 
lepromatosis by Han et al. in 2008 (21), we 
reported independent confirmation of this 
species in a biopsy specimen from a DLL 
case (Mx1-22A) from Monterrey, Mexico 
(32). Here, we combined various DNA 
enrichment approaches and deep sequencing 
to unveil the genome of M. lepromatosis 
directly from the archived biopsy specimen 
from this patient. Genome-wide comparison 
of M. lepromatosis and M. leprae provides 
deeper insight into the biology of M. 
lepromatosis and discloses the evolutionary 
history of these two closely related but 
clearly distinct species. 
 
Results and Discussion 
Genome Sequencing, Assembly, and Analysis. 
Because M. lepromatosis cannot be 
cultured in vitro and an animal model is not 
yet available, the only source of its DNA is 
infected human tissue. Biopsy specimen Mx1-
22A was used for DNA extraction and 
Illumina library preparation as described 
previously (20). To overcome the problem of 
host DNA, we used two methods to enrich 
M. lepromatosis DNA: whole-genome array 
capture using the M. leprae genome as bait 
(20) and removal of human DNA by 
Figure 1:
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hybridization with a human genomic DNA 
bait library (Materials and Methods). 
Illumina sequencing of the enriched as well 
as the original libraries provided 55-fold 
coverage, which was more than sufficient for 
the de novo whole-genome assembly (Table 
S1). The genome assembly was obtained by 
relaxing the assembler program’s 
parameters (Materials and Methods) to 
account for the extremely biased read 
coverage from the array capture library. 
Contigs were considerably longer compared 
with those obtained with default assembly 
parameters, but at the cost of a higher 
chance of misassemblies. To avoid assembly 
errors, we split those contigs showing 
disrupted synteny with M. leprae so that, 
from the initial 110 contigs of the de novo 
assembly, we obtained a final set of 126 
contigs. Most inconsistencies in the contigs 
were observed around areas of repetitive 
DNA, with some exceptions. One such 
exception was confirmed by PCR 
sequencing (as detailed later), proving that 
there is at least one instance of genome 
rearrangement between M. leprae and M. 
lepromatosis. However, we consider that the 
overall level of rearrangement is low, given 
that only a few contigs showed breaks in 
synteny with the reference genome and the 
GC skew of the “syntenic” version of the M. 
lepromatosis genome is virtually identical 
to that of M. leprae (Fig. S1). A total of 
3,206,741 bases of the M. lepromatosis 
Mx1-22A genome were represented in the 
126 contigs, and, with one exception, these all 
aligned to the 3.27-Mb circular genome 
sequence of the Tamil Nadu (TN) reference 
strain of M. leprae (17). The exception was a 
2.3-kb contig bearing five mycobacterial 
pseudogenes. A graphical comparison 
revealing genome-wide synteny and key 
features of the two genomes is presented in 
Fig. 1. In brief, the genome of M. 
lepromatosis appears to harbor at least 
1,477 genes encoding proteins [i.e., coding 
DNA sequence (CDS)] and 1,334 
pseudogenes. 
Repetitive DNA.  
Dispersed repeats were the major cause 
of breaks in our de novo assembly. 
Interestingly, in most cases, the locations of 
these repeats correspond to those of the four 
main families of repetitive DNA in M. 
leprae: RLEP (37 copies), REPLEP (15 
copies), LEPREP (8 copies), and LEPRPT 
(5 copies) (33). These shared 75–90% 
sequence identity, in segments as much as 
350 nt in length, with the most conserved 
corresponding to LEPREP and LEPRPT 
repeats and the lowest homology found for 
the REPLEP repeats. From this analysis, it 
is evident that the four repeat families were 
present in the most recent common ancestor 
(MRCA) of M. leprae and M. lepromatosis 
and that the levels of conservation between 
the repeats in the two species are 
proportional to their copy number. No 
additional repetitive DNA was detected in 
M. lepromatosis. 
A second draft genome.  
Using the M. lepromatosis genome 
sequence, we designed specific PCR 
primers and used them to screen ?260 
biopsies from our collection, thereby 
identifying a second case of M. lepromatosis 
in another Mexican patient (Mx177) who 
presented with Lucio’s phenomenon. This 
sample, which contained no M. leprae DNA, 
was shotgun-sequenced, without any 
enrichment, and the resultant sequences were 
mapped against the Mx1-22A genome 
assembly. Despite shallow coverage of the 
Mx177 sample (80% of the genome at an 
average coverage of 5× after excluding 
duplicate reads), we found only 12 SNPs in a 
2-Mb alignment where SNP calling was 
feasible. This very low SNP frequency (1 in 
167 kb) is reminiscent of the similarly low 
genetic diversity of M. leprae strains from the 
same geographical area (34) and in a set of 
worldwide M. leprae genomes in general 
(20). 
Synteny and conservation of the M. 
lepromatosis and M. leprae Genomes.  
Ninety-four percent of the M. lepromatosis 
genome assembly could be aligned to the M. 
leprae TN genome, and there appears to be 
near-perfect collinearity and synteny, with 
92% of the genes and pseudogenes shared 
(Fig. 1). Details of (pseudo)genes that have 
been deleted are provided in Dataset S1. In 
M. leprae, there are tandemly arranged 
asparagine permease genes (ML1304c 
ML1305c; ansP1 ansP2), but only one of 
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these is present in M. lepromatosis 
(MLPM_1304). Likewise, a duplicated cluster 
of four genes in M. leprae (ML1053-ML1056; 
ML1180c-ML1183c) is present as a single 
copy in M. lepromatosis 
(MLPM_1053MLPM_1056). This cluster 
encodes a member of the PEand PPEprotein 
families and the ESAT-6 proteins, EsxL and 
EsxK. M. lepromatosis has intact orthologs 
for 95% of the CDS present in M. leprae, 
but a further 132 CDS appear to have been 
pseudogenized in M. lepromatosis (Table 
S2). It is noteworthy that four of them (ilvX, 
proA, cysE, cysK) once encoded enzymes 
required for amino acid biosynthesis. 
Twenty-six M. leprae pseudogenes appear 
to have functional counterparts in M. 
lepromatosis (Table S3). Levels of 
nucleotide sequence conservation for 
orthologous CDS and pseudogenes from M. 
lepromatosis and M. leprae varied between 
the functional categories, as may be seen 
from the violin plot (Fig. 2). The most 
conserved genes code for the rRNA and 
tRNA (sequence identity >95%), whereas 
the least conserved were those for the 
PE/PPE proteins, as these display the 
hallmarks of selective pressure (as detailed 
later). On average, CDS shared 93% 
nucleotide sequence identity between the 
two species, but this value was only 82% for 
the pseudogenes. A wide distribution of 
sequence conservation was seen among 
pseudogenes (Fig. 2), and this may reflect 
their respective dates of pseudogenization, 
as older pseudogenes will have had longer 
to diverge. 
Species-specific sequences in M. 
lepromatosis and M. leprae.  
We identified 84 genomic regions of M. 
lepromatosis larger than 500 nt that have no 
counterparts in M. leprae, accounting for a 
total of 166 kb, or ?5% of the genome. These 
regions (range, 0.5–9.6 kb in size) consist 
essentially of pseudogenes (n = 163) except 
for three intact coding sequences: a 
hypothetical gene (MLPM_5094), a putative 
lipoprotein gene (MLPM_5098), and 
coproporphyrinogen III oxidase (hemN) 
(discussed later). Truncated remnants of 57 
of these 163 pseudogenes remain in M. 
leprae, revealing that some of the reductive 
evolution in this leprosy bacillus stemmed 
from deletions within, or encompassing, 
pseudogenes since divergence from the 
MRCA 
Horizontally acquired genes.  
Several M. leprae genes have no 
orthologs in other mycobacteria and appear 
to have been acquired by horizontal gene 
transfer. Among those with predicted 
functions are proS, encoding a eukaryotic-
like prolyl tRNA synthetase, and ML2177, 
coding for a uridine phosphorylase that 
shows similarity to insect enzymes. Both 
these genes are conserved in sequence and 
location in M. lepromatosis, indicating that 
they were present in the MRCA. Likewise, 
there are two pseudogenes (MLPM_5100 and 
MLPM_5101 encoding a ?-lactamase and 
LysR family transcriptional regulator) in a 
genomic island restricted to M. lepromatosis 
that appears to have been horizontally 
acquired by the MRCA and then lost by M. 
leprae. 
Insight into pathogenesis.  
The higher morbidity and mortality 
reported to be associated with infection by 
M. lepromatosis and the resulting DLL 
suggest the presence of new virulence 
functions possibly borne by plasmids. For 
example, the pathogenesis of 
Mycobacterium ulcerans has been attributed 
to the horizontally acquired virulence 
plasmid encoding the mycolactone toxin 
(35, 36). However, despite intensive 
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investigation of Illumina sequence reads with 
no matches in M. leprae and database 
searches, we found no evidence for plasmid 
or bacteriophage sequences. To cope with 
iron limitation, intracellular pathogens often 
scavenge heme from host tissue or produce 
and release siderophores, such as 
mycobactin, to capture iron (37, 38). Both 
leprosy bacilli have retained the ESX-3 
gene cluster that is involved in iron and zinc 
uptake in M. tuberculosis. The mycobactin 
(mbt) gene cluster is essential for the in vivo 
growth and virulence of M. tuberculosis 
(39, 40), but this cluster is missing from M. 
lepromatosis and M. leprae. In M. 
tuberculosis, hemN is located downstream of 
the mbt cluster, and, with the 
hemABCDEKLYZ genes, is required for 
heme biosynthesis. Interestingly, the hemN 
gene is present in M. lepromatosis but not in 
M. leprae (Fig. 3), indicating its loss 
occurred after separation from the MRCA 
and suggesting that M. leprae may be 
limited for heme production. 
Inspection of the genes least conserved 
between M. lepromatosis and M. leprae 
(Fig. 2) revealed that these correspond 
mainly to members of the PE and PPE 
protein families, characteristic of 
pathogenic mycobacteria, and to the ESX 
(type 7) protein secretion systems. 
Compared with M. tuberculosis and 
Mycobacterium marinum, there are very 
few PE and PPE proteins in leprosy bacilli. 
In M. leprae, ML0411 encodes a PPE 
protein that acts as an immunodominant 
serine-rich antigen, whereas the 
neighboring gene, ML0410, codes for a PE 
family protein. Both genes are present in M. 
lepromatosis but have di verged extensively: 
there is only 68% nucleotide sequence identity 
between MLPM_0411 and ML0411 (note that 
only half the genes could be aligned) and 73% 
between MLPM_0410 and ML0410. 
Interestingly, sequence comparison of ML0411 
in a range of isolates of M. leprae of different 
geographical origin revealed this to be the 
most polymorphic gene in the genome, with 
the highest number of nonsynonymous 
substitutions (20, 41). It appears that the 
marked divergence in this locus is the 
consequence of selective pressure imparted 
by the host’s immune system (20).  
 
The ability to invade the endothelium 
distinguishes M. lepromatosis from M. 
leprae. Because we found no evidence for 
the presence of a novel virulence gene that 
could account for this phenotype, we 
examined the gene clusters required to 
produce the five type 7 ESX secretion 
systems (T7Ss) for unusual features. 
Although not essential for growth in vitro, 
the ESX-1 system is the major virulence 
determinant in M. tuberculosis and M. 
marinum. ESX-1 mediates escape of the 
bacilli from the phagosome, thus allowing 
further replication, cytolysis, necrosis, and 
intercellular spread (42). The EsxA protein, 
a major substrate of ESX-1, ruptures the 
phagosomal membrane, thus acting as a 
principal virulence factor. Despite 
extensive conservation of the ESX-1 
system among other mycobacterial 
pathogens, several of its genes encoding 
ESX-1 secreted proteins (Esp, Esx) are 
missing or nonfunctional in M. leprae and 
M. lepromatosis. These include espE, espB, 
Figure 3:
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espF, espG1, espH, espJ, espK, and pe35 in 
both, and, additionally, ppe68 in M. 
lepromatosis. Of the remaining genes in this 
locus, esxB, esxA, and espH are the least 
conserved (69–73% protein identity) 
between M. leprae and M. lepromatosis, 
and a similar trend was observed for the 
unlinked espACD operon (espA, 78%; espC, 
77%; and espD, 86% protein identity) that 
regulates the expression and secretion of 
EsxA in a mutually dependent manner in M. 
tuberculosis (43–45). Of the four other 
T7Ss, ESX-2 and ESX-4 are predicted to be 
nonfunctional in M. leprae and M. 
lepromatosis, whereas the ESX-5 locus is 
highly conserved. However, compared with 
M. tuberculosis, only the ESX-5 core genes 
(eccABCDE5 and mycP5) remain intact in 
both leprosy bacilli, there are no esx genes, 
and the PE protein gene 
(ML2534c/MLPM_2534) is nonfunctional. 
On the contrary, ESX-3 is the most 
conserved T7S system in mycobacteria and 
seems to fulfill an essential function in metal 
homeostasis, although its role in virulence is 
less clear (45). 
 
Neuropathogenesis.  
The ability to invade the Schwann cells of 
the peripheral nervous system is a hallmark 
of M. leprae, and this leads to the 
neuropathy and nerve damage associated 
with leprosy. Adherence to Schwann cells 
(46) has been proposed to be mediated by 
two cell wall components: the laminin-
binding protein (ML1683c) and the terminal 
trisaccharide moiety of phenolic glycolipid 
1 (PGL-1). To produce the trisaccharide, 
several enzymes are required, namely a 
rhamnosyl transferase (ML0128), a 
glucosyltransferase (ML2348), and four 
methyltransferases (ML0126, ML0127, 
ML23246c, and ML2347) (47). The genes 
encoding both these adhesin systems are 
highly conserved in M. lepromatosis, so 
invasion of Schwann cells is to be expected. 
Given the paucity of well-defined cases of 
infection with M. lepromatosis, studies of 
nerve involvement have not yet been 
conducted, but this will be facilitated by the 
tools arising from our investigation of the 
M. lepromatosis genome. 
Disease management and new 
interventions.  
Until very recently, recognition of M. 
lepromatosis as a separate species was 
questioned. Currently, M. lepromatosis can 
be identified by a nested PCR technique that 
targets the 16S rDNA (22). Given the 98% 
identity of the M. lepromatosis and M. leprae 
16S rDNA sequences, a possible source of 
confusion, it may be advisable to establish 
a new method of identification that exploits 
sequences confined to M. lepromatosis such 
as the species-specific PCR templates and 
primers described here (Table 1 and Table 
S4). Immunodiagnostic approaches for 
leprosy are being pursued by using the 
highly specific trisaccharide from PGL-1 
and LID1 (48), a fusion protein that includes 
sequences from genes ML0405 (espA) and 
ML2331. PGL-1-based tests should also 
detect M. lepromatosis, but tests involving 
LID-1 may be less sensitive because of the 
extensive variation in EspA reported earlier. 
DLL cases resulting from infection with 
M. lepromatosis have responded favorably 
to the standard MDT (49), and, on 
examination of the drug resistance 
determining regions in the genes coding for 
the targets of rifampin, dapsone, and 
fluoroquinolones, only drug-susceptible 
sequences were found. New drugs 
developed to treat tuberculosis may also find 
application in leprosy. Inspection of the M. 
lepromatosis and M. leprae gene sequences 
for the targets of the experimental drugs 
bedaquiline, benzothiazinones, and Q203 
suggest that these should be active, whereas 
the nitroimidazole prodrugs PA-824, 
TBA354, and delamanid will not be 
effective because the ddn gene, coding for 
the nitroreductase required for their 
activation, is missing. 
 
Geographical survey for M. lepromatosis.  
To gain more insight into the global 
distribution of M. lepromatosis, a differential 
PCR test was implemented by using species-
specific primers targeting hemN and RLEP (SI 
Materials and Methods). A total of 227 
specimens from patients with leprosy were 
chosen (Table 1), including some with a 
history or suspicion of DLL or Lucio’s 
reaction (n = 6). The largest patient groups 
were from Venezuela (n = 77), Mexico (n = 
64), Mali (n = 48), and Brazil (n = 33); a 
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small number of samples suspected of 
presenting with Lucio’s reaction were 
obtained from elsewhere (Table 1). This 
analysis revealed the presence of M. leprae 
DNA in 221 cases and M. lepromatosis in 
only six, with no evidence for mixed 
infections. All six M. lepromatosis cases 
were of Mexican origin.  
 
Table 1: Geographical survey of leprosy bacilli by 
differential PCR analysis 
Country of 
origin 
Sample size 
(suspicion of 
DLL 
/Lucio’s) 
M. lepromatosis M. 
leprae 
Venezuela 77 0 77 
Mexico 64 (4) 6 58 
Mali 48 0 48 
Brazil 33 0 33 
Others 5 (2) 0 5 
PCR was performed using primers specific 
for each species: LPM244F and LPM44R for 
M. lepromatosis; RLEP-7 and RLEP-8 for M. 
leprae. Full details are provided in SI 
Materials and Method. Among the samples 
from DLL or Lucio’s reaction cases, two 
were positive for M. lepromatosis and four 
for M. leprae  
 
On the origin and evolution of M. 
lepromatosis.  
The results from the genome-wide 
comparison of M. leprae and M. 
lepromatosis indicate that pseudogenization 
took place in their ancestral forms and that 
the MRCA itself likely had a genome of 
reduced size compared with all other known 
mycobacteria. Based on the rate of 
nonsynonymous substitution in pseudogenes, 
it was estimated that a single massive 
pseudogenization event took place 
approximately 20 Mya (50). Since their 
separation from the MRCA, deletions and 
more pseudogenes have appeared in both 
species. M. lepromatosis shares the same 
repeat families with M. leprae, including 
their genomic locations, but these have 
diverged extensively in sequence. In M. 
leprae, genome reduction and gene 
truncation have been attributed to 
recombinational events between different 
repeat copies, but these events likely 
occurred in the MRCA (17, 33). 
To estimate the divergence times of M. 
lepromatosis and the currently available M. 
leprae strains, substitution rates were 
calculated in a Bayesian framework by 
using the software package BEAST 
(Bayesian Evolutionary Analysis Sampling 
Trees). For phylogenetic and divergence 
time analysis, the M. lepromatosis genome 
was aligned with 18 modern and ancient M. 
leprae genomes. On average, there were 90 
nucleotide substitutions between two M. 
leprae strains and 275,518 substitutions 
between M. leprae and M. lepromatosis. A 
substitution rate of 7.67?9 substitutions per site 
per year was estimated (Fig. S2A), similar to 
previous estimates using M. leprae genomes 
only (20). The resulting divergence time from 
the MRCA (TMRCA) for all M. leprae strains 
was calculated as 3,607 y ago [2,204–5,525 y 
ago 95% highest probability density (HPD)], 
comparable to previous results (20) (Fig. 
S2B). The TMRCA for M. leprae and M. 
lepromatosis was estimated to be 13.9 Mya 
(8.2–21.4 Mya 95% HPD; Fig. S2C). In this 
respect, the two leprosy bacilli differ quite 
markedly from the species comprising the M. 
tuberculosis complex (MTBC), as, from a 
recent paleomicrobiogical investigation that 
used two independent dating approaches, it 
Figure 4: 
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was concluded that the maximal TMRCA 
was <6,000 y for the MTBC (51).  
A phylogenetic comparison by maximum 
parsimony of M. lepromatosis with various 
M. leprae strains of different geographic 
origins and SNP subtypes is shown in Fig. 4 
and by neighbor joining in Fig. S3. To gain 
further insight into the phylogenetic 
placement of M. lepromatosis among other 
mycobacterial species, additional 
phylogenetic trees were generated based on 
the concatenated amino acid alignments of 
GyrB, RpoB, and RpoC (Fig. S4), as well as 
the alignments of the 16S genes (Fig. S5). 
In all four phylogenetic trees, M. 
lepromatosis is positioned between the 
mycobacteria used as outgroups and M. leprae. 
The M. lepromatosis branch is closest to the 
M. leprae SNPtype 3K strains, consistent with 
the very recent report of the 3K strains (branch 
0) being the most ancestral lineage of M. 
leprae known to date (20). The geographic 
distribution of type 3K strains is diverse, but 
sampling is insufficiently broad to predict a 
tentative origin. On the contrary, the 
predominance of reported DLL and confirmed 
cases of infection with M. lepromatosis in 
Mexico suggest that this pathogen may have 
evolved in Central America. More extensive 
investigation is required to explore this 
possibility and to retrace its origin. 
 
Environmental Sources.  
M. leprae has long been considered an 
obligate human pathogen with its primary 
route of transmission being interhuman. In 
the past 30 y, the nine-banded armadillo has 
been identified as a natural reservoir of M. 
leprae in the southern United States, and 
evidence for zoonotic transmission to humans 
is accumulating (34). The existence of 
nonhuman hosts or natural reservoirs of M. 
lepromatosis has not yet been investigated, 
but, recently, an apparent outbreak of M. 
lepromatosis infection in red squirrels 
(Sciurus vulgaris) was reported in the United 
Kingdom (52). Examination of infected 
squirrel tissue using the PCR-based 
sequencing procedures for the hemN gene 
outlined here has confirmed this finding and 
thus provides evidence for a nonhuman 
reservoir or intermediate host for M. 
lepromatosis.  
To date, the most convincing human cases 
of M. lepromatosis infection, particularly 
those with DLL, came from Mexico. One of 
the regional culinary traditions in rural 
Mexico is consumption of field rats (Rattus 
rattus) (53). Because M. lepromatosis seems 
to naturally infect rodents, such as squirrels, 
it is conceivable that field rats are a host and 
may serve as a disease reservoir. When a 
retrospective survey of confirmed cases of M. 
lepromatosis was conducted, two of the six 
Mexican subjects admitted having 
consumed meat from field rats. Availability 
of the M. lepromatosis genome sequence 
will enable us to search systematically for 
its presence in other potential animal 
reservoirs as well as in extant cases of 
leprosy. As a result, deeper understanding 
will be obtained of the incidence, etiology, 
epidemiology, clinical features, and 
pathogenesis of leprosy caused by M. 
lepromatosis. 
 
Materials and Methods 
DNA Extraction and Sequencing.  
DNA was extracted from the biopsy 
specimen Mx1-22A (32), and the Illumina 
library was prepared as described elsewhere 
(20). To overcome the problem of the high 
level of host DNA in the library, we used 
two methods for enrichment of M. 
lepromatosis DNA: (i) wholegenome 
array capture using an M. leprae tiling 
array (20) and (ii) removal of human DNA 
by hybridization with a human genomic 
DNA bait library. 
 
Genome Assembly and Annotation.  
Reads mapping to the human genome were 
discarded and duplicate reads were removed 
before the assembly. De novo genome 
assembly was done in MIRA version 4.0rc4 
(54). Contigs were anchored to the M. 
leprae TN genome, and those contigs that 
did not match were screened for 
contaminants and the presence of 
mycobacterial genes. Genome sequence 
synteny between M. lepromatosis and M. 
leprae was visualized in ACT (Artemis 
Comparison Tool) (55) (Fig. 1). 
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PCR Procedures.  
To confirm the presence of the hemN 
gene and its flanking sequence, including a 
genomic rearrangement, we designed PCR 
primers (Table S4) to amplify overlapping 
genomic targets. Details of the procedures 
used for the geographical survey are 
provided in SI Materials and Methods. 
 
SNP Calling and Phylogeny. Genome 
sequences of Mycobacterium avium K10 
M. lepromatosis, and the published M. 
leprae strains were aligned against the M. 
leprae TN genome. SNP alignments were 
analyzed in MEGA6 (Molecular 
Evolutionary Genetics Analysis version 6.0) 
(56). Further details of bioinformatics 
procedures, Bayesian dating analysis, and 
phylogeny are provided in SI Materials and 
Methods. 
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Supplementary materials and methods 
Clinical Specimens  
The original skin biopsy specimen from an 
86-yold Mexican woman diagnosed with 
DLL (Mx1-22A) was shipped to Ecole 
Polytechnique Fédérale de Lausanne 
(Switzerland) in 70% (vol/vol) ethanol for 
DNA extraction and sequencing. A detailed 
case report for this sample was published 
previously (1). All other biopsies were from 
our collections. 
DNA Extraction and Sequencing 
 DNA was extracted from the biopsy 
specimen Mx1-22A (1) and the Illumina 
library (labeled mmL1) was prepared as 
described elsewhere (2). Aliquots of the 
mmL1 library were used for two additional 
enrichment procedures: whole-genome 
capture array and removal of human DNA 
by hybridization. Because the 
Mycobacterium lepromatosis genome 
sequence exhibits high homology with that 
of Mycobacterium leprae, we used a 
custom-synthesized oligonucleotide array 
(Agilent) spanning the entire M. leprae 
genome (2) to capture homologous 
sequences in M. lepromatosis. This array-
enriched library was labeled mmL1-p 
(positive selection). However, as this 
strategy would miss those genomic regions 
of M. lepromatosis that have weak or no 
homology with M. leprae, we also used an 
enrichment strategy to deplete human 
DNA. This involved preparing a bait library 
with human genomic DNA by using the 
Illumina TruSeq kit followed by 
amplification with the following 
biotinylated primers.  
 
Primer Sequence 5'-3' Purpose 
P5 AATGATACGGCG
ACCACCGA 
Amplification 
of target 
library  
Bio-P5 5' Biotin-
AATGATACGGCG
ACCACCGA 
Amplification 
of human-bait 
library 
P7 CAAGCAGAAGAC
GGCATACGA 
Amplification 
of human-bait 
and target 
library 
The resultant biotinylated baits were 
denatured and coated on streptavidin 
magnetic beads to prepare “bead baits,” 
which were used for the hybridization-
capturing of human DNA from the mmL1 
library. After removing the bead-bound 
human DNA, the unbound fraction of the 
library was amplified and size selected on a 
2% (wt/vol) agarose gel. Fragments of 300 
bp (library mmL21) and 400 bp (library 
mmL25) were extracted from the gel and 
sequenced by using single-end reads on a 
HiSEq 2000 instrument. The number and 
the properties of the reads obtained from 
each of the four libraries are shown in 
Table S1. Sequence reads were deposited in 
the National Center for Biotechnology 
Information (NCBI) Sequence Read 
Archive database under accession number 
SRP047206. 
 
Genome Assembly and Annotation 
Reads were adapter-trimmed with 
Flexbar (3). Paired-end reads deriving 
from MiSeq were merged using SeqPrep 
(https://github.com/jstjohn/SeqPrep). 
Reads mapping to the human genome (hg19, 
GRCh37, using Bowtie2 v2.2.2 with “–very-
fast-local” parameter), PhiX 
(NC_001422.1, using Bowtie2 v2.2.2 with 
“–local” parameter) and Escherichia coli 
(NC_010473, using Bowtie2 v2.2.2 with “–
local” parameter) were discarded (4). The 
remaining reads were first mapped to the M. 
leprae TN genome sequence to assess the M. 
lepromatosis genome coverage and read 
quality. We noticed a high level of 
duplicate reads (reads with identical 
sequence and start-end coordinates), 
especially in the mmL1-p library (Table 
S1), which worsened the quality of our 
preliminary de novo assembly. We 
removed all duplicate reads by using 
PRINSEQ (Preprocessing and Information 
of Sequences) (5) and performed a de novo 
assembly by using MIRA version 4.0rc4 (6) 
with the “EST” mode. Contigs were anchored 
to the M. leprae TN genome using BLAST 
(7), and those with inconsistent synteny with 
M. leprae were split. Contigs that did not align 
to M. leprae were screened for contaminating 
DNA (human, phiX, and E. coli). Contigs 
consisting entirely of low-complexity sequence 
were removed. The remaining contigs were 
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queried with BLAST against mycobacterial 
proteins from NCBI to detect any putative M. 
lepromatosis contigs that did not anchor to the 
M. leprae genome (one 2.3-kb-long contig was 
detected). Annotation was carried out by using 
RATT (Rapid Annotation Transfer Tool) (8) 
followed by manual curation. M. leprae 
annotation was taken from the MycoBrowser 
portal (9), release 7. M. lepromatosis-specific 
genomic regions were queried with BLAST 
against nonredundant proteins at NCBI and 
manually annotated. Annotated contigs were 
deposited at DNA Data Bank of 
Japan/European Molecular Biology 
Laboratory/GenBank under accession number 
JRPY00000000. 
 
PCR and Sanger sequencing 
To confirm the presence of the hemN 
gene and its flanking sequence, including a 
genomic rearrangement in M. lepromatosis, 
we designed PCR primers (Table S4) to 
amplify overlapping genomic targets. PCR 
products were purified with the Illustra 
ExoProStar 1-Step cleanup kit (GE 
Healthcare) and sequenced on an ABI 
PRISM 3130xl Genomic Analyzer (Applied 
Biosystems). For the geographic survey of 
leprosy bacilli, PCR amplification was 
performed by using the following primers. 
 
Primer name Primer sequence (5’-3’) 
LPM244-F GTTCCTCCACCGACAAACAC 
LPM244-R TTCGTGAGGTACCGGTGAAA 
RLEP-7 TGAGGCTTCGTGTGCTTTGC 
RLEP-8 ATCTGCGCTAGAAGGTTGCC 
 
LPM244 primers amplify a 244-bp 
fragment from the hemN gene of M. 
lepromatosis that has been lost by M. 
leprae, whereas RLEP 7 and 8 (10) amplify 
the RLEP repetitive sequences in M. leprae. 
PCR amplifications were performed in a 50-
?L reaction volume containing 25 ?L of 
AccuStart II SuperMix (Quanta BioSciences) 
or BIO-X-ACT Short Mix (Bioline), 5 ?L of 
each primer at 2 ?M, and 2 ?L of DNA 
extracts or sterile distilled water for clinical 
specimens, positive controls (Mx1-22 and 
Thai-53 strains), and negative controls. The 
amplification started with an initial 
denaturation step at 95 °C followed by 40 
cycles of 30 s denaturation at 95 °C, 40 s 
primer annealing at 58 °C, and 30 s extension 
at 72 °C, followed by a 10-min final 
extension at 72 °C. The amplicons obtained 
were then analyzed by electrophoresis on a 
1% agarose gel in 1× Tris/acetate/EDTA 
buffer at 100 V during 35 min. The DNA 
was stained using GelRed (Chemie 
Brunschwig) and visualized by using a UV 
transilluminator. After enzymatic treatment 
with Illustra ExoProStar 1-Step (GE 
Healthcare Life Sciences), PCR products 
were submitted to BigDye Terminator 
version 3.1 cycle sequencing and analyzed 
by using an ABI3130 XL DNA 
sequencer (Applied Biosystems). 
Sequences were aligned against 
corresponding references using 
CodonCode aligner software (version 
5.0.1; CodonCode). 
 
SNP calling.  
M. lepromatosis contigs, Mycobacterium 
avium K10 (a.n. NC_002944), M. tuberculosis 
H37Rv (NC_ 000962.3), and Mycobacterium 
ulcerans Agy99 (NC_ 008611.1), and the 
published genomes of M. leprae (10, 11) 
were aligned against M. leprae TN 
(accession no. AL450380.1) with LAST (12) 
using the gammacentroid mode for M. 
lepromatosis, M. avium, M. tuberculosis, 
and M. ulcerans and default parameters for 
M. leprae strains. For each alignment, an 
mpileup file was generated with SAMtools 
version 0.1.19 (13) and processed with 
VarScan version 2.3.7 (14). For M. 
lepromatosis, sites with >1× coverage 
(repetitive areas) were removed, whereas, for 
M. avium, M. tuberculosis, and M. ulcerans, 
sites with >1× coverage (gene duplications) 
were kept except for heterozygous sites. 
Illumina reads from the M. leprae strains 
published in the work of Schuenemann et al. 
were aligned as described there (2), and the 
Illumina reads from Airaku-3 (15) were 
aligned against TN with Bowtie2 version 
2.2.2 (4). Mpileup files were generated and 
processed with VarScan (14). Minimum 
coverage was set to 3, and minimum SNP 
frequency was set to 80%. Indels were 
filtered out, as were the SNPs with 
frequencies 20–80%. Positions covered in 
the negative control SK12 (2) were 
removed. 
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Estimation of substitution rates and 
divergence times.  
To estimate the divergence times of the 
M. lepromatosis and M. leprae strains, 
substitution rates were calculated in a 
Bayesian framework by using the software 
package BEAST 1.7.5 (16). A multiple 
sequence alignment of variable positions 
between the reconstructed M. lepromatosis 
genome (LPM) as well as previously 
published ancient M. leprae genomes that 
were directly radiocarbon-dated 
(Jorgen_625, Refshale_16, 3077, SK8, SK2) 
and available modern samples (Kyoto2, 
Airaku3, TN, Br4923, Thai53, NHDP63, S2, 
S9, S10, S11, S13, S14), was made as 
described earier. The total alignment length 
was 719,495 variable positions. As described 
previously, the M. leprae genome S15 was 
excluded from the dating analysis because of 
the rather long branch observed for that 
strain, which might be a result of selection 
pressure caused by antileprosy treatment as 
reflected by the occurrence of a dapsone-
resistance mutation (17). Based on the 
previous analysis, a strict clock model with 
constant population size was chosen for the 
Bayesian framework analysis. The 
previously published calibrated radiocarbon 
dates for the five ancient genomes, as well 
as the isolation years for the modern 
genomes, were used as priors (2). Three 
Markov chain Monte Carlo (MCMC) runs 
were carried out with 50,000,000 iterations 
each, sampling every 10,000 steps. The first 
5,000,000 iterations were discarded as burn-
in. All independent runs were combined, 
resulting in 135,000,000 iterations.  
We estimate a substitution rate of 7.67?9 
substitutions per site per year (1.11 ×10?8 to 
4.2 × 10?9 95% HPD; Fig. S2A), which is 
very similar to a previous estimate using M. 
leprae genomes only (2). The resulting 
divergence times for the TMRCA for all M. 
leprae strains is 3,607 y ago (2,204–5,525 y 
ago 95% HPD; Fig. S2B), and the TMRCA 
for M. leprae and M. lepromatosis is 13.9 
Mya (8.2–21.4 Mya 95% HPD; Fig. S2C). 
Phylogeny  
A multiple-sequence alignment of 
variable positions between the 
reconstructed M. lepromatosis genome, 
previously published M. leprae genomes, 
M. tuberculosis, M. avium, and M. ulcerans 
had a total of 1,033,823 sites. All trees (Fig. 
4 and Figs. S3–S5) were generated in 
MEGA6 (18) using 500 bootstrap replicates. 
For the maximum parsimony (MP) tree in 
Fig. 4, sites with missing data were partially 
deleted (90% coverage cutoff), resulting in 
899,085 variable sites used for the tree 
calculation. Subtree-pruning-regrafting was 
used as the MP search method. For the 
neighbor joining tree (Fig. S3), sites with 
missing data were completely removed, 
resulting in 511,280 variable sites. The 
number of nucleotide differences was used 
as model, with uniform rates among sites. 
As expected, both trees strongly resemble 
each other. 
To gain further insight into the 
phylogenetic placement of M. lepromatosis 
among other mycobacterial species, 
additional phylogenetic trees were 
generated based on the concatenated amino 
acid alignments of GyrB, RpoB, and RpoC 
(Fig. S4), as well as the alignments of the 
16S rRNA genes (Fig. S5). Protein 
sequences were downloaded from the 
HOGENOM database (19) and aligned with 
Clustal Omega (20). To reduce the size of 
the tree, only representative species that 
branched around M. lepromatosis were 
selected for the generation of the final tree, 
with Rhodococcus equi as outgroup. The 
maximum-likelihood tree was generated 
using the LG model with frequencies (21) 
with rates among sites as “Gamma 
distributed with Invariant sites” (G+I), as 
this model had the lowest Bayesian 
information criterion score for this dataset 
as calculated by MEGA6, and missing data 
were partially deleted (90% coverage 
cutoff). 16S rRNA sequences were 
downloaded from the Greengenes database 
(22) and aligned with CRWalign 
(www.rna.icmb.utexas. edu) (23). For the 
MP tree (Fig. S5), positions with missing 
data (i.e., gaps) were completely deleted. 
To reduce the size of the tree, only 
? ? ??
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representative species that branched around 
M. lepromatosis were selected for the 
generation of the final tree, with 
Mycobacterium smegmatis as outgroup. 
Results from our phylogenetic analysis were 
consistent with previous studies (24–26). 
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Table S1. Sequencing libraries of M. lepromatosis Mx1-22A. 
Library 
name 
Method used for 
library preparation 
and enrichment  
Platform
* 
M reads Mappe
d onto 
M. lpm 
Dupli-
cation 
rate 
Fold 
coverage 
of M. lpm 
assembly
** 
mmL1 Library mmL1, from 
biopsy after silica 
extraction, no 
enrichment. 
HiSeq 
PE+SE  
372 + 
89 
0.12% 8% 14.2 
mmL1-p Capture of the library 
mmL1 on M. leprae 
array. 
HiSeq SE 
MiSeq PE 
239 
15 
3.0% 
3.0% 
89% 
43% 
21.6 
9.6 
mmL21 Removal of human 
DNA from the library 
mmL1 using 
biotinylated Human 
DNA baits and size 
selection of ~300 bp 
fragments. 
HiSeq SE  274  0.39% 29% 14.7 
mmL25 Removal of human 
DNA from the library 
mmL1 using 
biotinylated Human 
DNA baits and size 
selection of ~400 bp 
fragments. 
HiSeq SE 253 0.34% 22% 13.8 
All   1,242 0.82% 79%*** 54.5*** 
Legend: M = Million; PE = Paired-end reads, SE = single-end reads; M. lpm = M. lepromatosis.  
*Read length was 100 nt for HiSeq and 150 for MiSeq. 
**Excluding duplicate reads. 
***Duplicate reads removed after merging the original datasets. 
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Table S2: M. leprae protein-coding genes with disrupted ORFs in M. lepromatosis 
 
M. leprae
1 Function 
ML0008c* hypothetical protein 
ML0023c* hypothetical protein 
ML0024* hypothetical protein 
ML0029c hypothetical protein 
ML0051c PPE family protein 
ML0064c transcriptional regulator 
ML0188* hypothetical protein 
ML0218c hypothetical protein 
ML0283* cation-efflux transporter component 
ML0293c* hypothetical protein 
ML0308* hypothetical protein 
ML0316 TetR/AcrR family transcriptional regulator 
ML0354 acetohydroxyacid synthase IlvX (acetolactate synthase) 
ML0363 ESAT-6 like protein EsxT 
ML0369c hypothetical protein 
ML0376 hypothetical protein 
ML0382c transcriptional regulator 
ML0394c 3-oxoacyl-ACP synthase 
ML0398c D-ribose-binding protein 
ML0418 oxidoreductase 
ML0447* hypothetical protein 
ML0448* hypothetical protein 
ML0464* hypothetical protein 
ML0470c* hypothetical protein 
ML0508 hypothetical protein 
ML0527c hypothetical protein 
ML0580c OpcA 
ML0588* hypothetical protein 
ML0603 hypothetical protein 
ML0605 hypothetical protein 
ML0606 hypothetical protein 
ML0607 hypothetical protein 
? ? ??
 ???
ML0638 hypothetical protein 
ML0639 transcriptional regulator 
ML0664 hypothetical protein 
ML0676c hypothetical protein 
ML0678c* hypothetical protein 
ML0717c TetR family transcriptional regulator 
ML0728c thiosulfate sulfurtransferase 
ML0729c Maf-like protein 
ML0761c hypothetical protein 
ML0777* hypothetical protein 
ML0799c hypothetical protein 
ML0837 hypothetical protein 
ML0838c serine acetyltransferase, CysE 
ML0839c cysteine synthase, CysK 
ML0844 nitrite extrusion protein 
ML0845c hypothetical protein 
ML0863 hypothetical protein 
ML0923 hypothetical protein 
ML0926c* hypothetical protein 
ML0928 hypothetical protein 
ML0946 hypothetical protein 
ML0953* hypothetical protein 
ML0955c pyruvate phosphate dikinase 
ML0958* hypothetical protein 
ML1006 hypothetical protein 
ML1011c* hypothetical protein 
ML1023c* polyphosphate glucokinase 
ML1057 hypothetical protein 
ML1067 hypothetical protein 
ML1092A hypothetical protein 
ML1103c oxidoreductase subunit 
ML1188c* hypothetical protein 
ML1193 hypothetical protein 
ML1294c hypothetical protein 
? ? ??
????
ML1344c* hypothetical protein 
ML1399 hypothetical protein 
ML1420 hypothetical protein 
ML1458c gamma-glutamyl phosphate reductase, ProA 
ML1508c hypothetical protein 
ML1525c hypothetical protein 
ML1572* hypothetical protein 
ML1575c* hypothetical protein 
ML1601c* hypothetical protein 
ML1602c hypothetical protein 
ML1603c* hypothetical protein 
ML1632c exported protease 
ML1660c hypothetical protein 
ML1682 hypothetical protein 
ML1761c* hypothetical protein 
ML1783c transcriptional regulator 
ML1788c hypothetical protein 
ML1796* hypothetical protein 
ML1818c thioredoxin 
ML1821A* hypothetical protein 
ML1821c* hypothetical protein 
ML1915* hypothetical protein 
ML1937 hypothetical protein 
ML1949c* hypothetical protein 
ML1972c* hypothetical protein 
ML1976c* hypothetical protein 
ML1979c* hypothetical protein 
ML1982 hypothetical protein 
ML1989c* hypothetical protein 
ML1990c* hypothetical protein 
ML1997c hypothetical protein 
ML2041c hydrogen peroxide-inducible gene activator OxyR 
ML2048* hypothetical protein 
ML2121c* hypothetical protein 
? ? ??
 ???
ML2156 hypothetical protein 
ML2178c hypothetical protein 
ML2201c* hypothetical protein 
ML2213c aminopeptidase 
ML2242c hypothetical protein 
ML2249c* hypothetical protein 
ML2252c* hypothetical protein 
ML2264c hypothetical protein 
ML2283* hypothetical protein 
ML2284* hypothetical protein 
ML2288c* hypothetical protein 
ML2307c hypothetical protein 
ML2312 hypothetical protein 
ML2366c thiol:disulfide interchange protein 
ML2369B* hypothetical protein 
ML2379c hypothetical protein 
ML2388 hypothetical protein 
ML2468c* hypothetical protein 
ML2497* hypothetical protein 
ML2564c acetyl-CoA acetyltransferase 
ML2567 hypothetical protein 
ML2609 hypothetical protein 
ML2621c hypothetical protein 
ML2629c hypothetical protein 
ML2630c hypothetical protein 
ML2661c acyl-CoA synthetase 
ML2666c* hypothetical protein 
ML2679A* hypothetical protein 
ML2679B* hypothetical protein 
ML2696 MarR family transcriptional regulator 
ML2703* thioredoxin 
ML2709c hypothetical protein 
1 Annotation taken from the Mycobrowser database (http://mycobrowser.epfl.ch/leprosy.html). Prefix 
for M. lepromatosis is "MLPM_". 
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Table S3: M. leprae pseudogenes with intact ORFs in M. lepromatosis 
 
Pseudogene 1 Function 
ML0062A* Hypothetical protein 
ML0209c Hypothetical protein 
ML0212 Conserved hypothetical protein 
ML0302* Possible conserved membrane protein 
ML0358* Probable ferredoxin FdxD 
ML0954c Conserved hypothetical protein 
ML0970A* Hypothetical protein 
ML0976c Conserved hypothetical protein 
ML0981 Conserved 35 kDa ala-rich protein 
ML1208 Conserved hypothetical protein 
ML1254A* Hypothetical protein 
ML1341 Conserved hypothetical protein 
ML1451D* Hypothetical protein 
ML1527c* Dihydrodipicolinate reductase DapB 
ML1531c Possible transcriptional regulatory protein (Lrp/AsnC family) 
ML1636A Hypothetical protein 
ML1643 Probable low molecular weightprotein-tyrosine-phosphatase PtpA 
ML1686 Probable transcriptional regulatory protein (IclR family) 
ML1721c Probable conserved secreted protein TB22.2 homolog 
ML1725c Conserved hypothetical protein 
ML1745c Probable acyl-CoA dehydrogenase FadE22 
ML2019 Conserved hypothetical protein 
ML2119 Putative acetyl-CoA carboxylase carboxyltransferase (beta subunit) AccD3 
ML2253A* Hypothetical protein 
ML2476c Conserved hypothetical protein 
ML2633A* Hypothetical protein 
? ? ??
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Table S4. Primers used for PCR-sequencing genomic region around hemN in M. lepromatosis 
Forward 
primer Sequence 
Reverse 
primer Sequence 
hemN_F1 GGAGGAACCCCAGAGAATGC hemN_R1 CATCCGGGGGTTTTCCTTCA 
hemN_F11 CGGTGCTATGTGGAACAACG hemN_R11 CTACTGGAACGGCGGTCAAT 
hemN_F12 GTTGTGCCGACGTAACTGTG hemN_R12 TCGGGGTGTATGTGCATGTC 
hemN_F13 TATGTGATCGACACCGGCTT hemN_R13 CCACCTGGCCGGAATTTTTC 
hemN_F2 TTGAGTGGCCAACACCGTTA hemN_R2 TTGATCGCACGCAACACTTG 
hemN_F21 AATCTGCGTCGCCAAAACAC hemN_R21 CCAGTGATTCATCGGCCAGT 
hemN_F22 ACGGCAGCTGGACTAATGAC hemN_R22 CCGGAGTCACGAAACAGTGA 
hemN_F23 GGTGATCTGTCGACCAACCC hemN_R23 GTTCCGCGAAGCCTCTGATA 
hemN_F24 TCTCGAAACCGGGTACCTCA hemN_R24 TCTCGACGTGTTCCTTGGTG 
hemN_F25 CTACCCCGATTGGCACACTG hemN_R25 CCACTGCTCGATCGGATTGT 
hemN_F31 TCCGGCACAAGGGTGTAAAA hemN_R31 GCCGATTGCAGGTCGTTTAG 
hemN_F32 GCCACTCCTGCTGTTCTTCT hemN_R32 CTGGAAAGCCAGGACCAAGA 
hemN_F33 TAAGTCAGGCTACACCACGC hemN_R33 GTTGTTCCACATAGCACCGC 
hemN_F34 GTCGCAGGAAACTGTCCTCA hemN_F34 CTGCTGGGATAACCCGACG 
hemN_F41 GGCCAGGTGGATTCAGGATT hemN_R41 CGAGAATCCGCTGAGAAGCA 
hemN_F42 CCGGTACCTCACGAACAGTC hemN_R42 GTGTGAGCTTTTGCCAGACG 
hemN_F43 CTCCTGTCACTGACCCAACC hemN_R43 CGTCTAGCTTCCGCGAGATT 
hemN_F44 AACGGGTTATGCAGAAGGGG hemN_R44 TTCCCGGGCTTCTTGAGTTC
hemN_F45 ATGTCGCCAACCAGGTATCG hemN_R42 See above 
 
 
  
Fig. S1. GC skews of M. leprae and M. lepromatosis genomes. When M. lepromatosis 
contigs were anchored to the M. leprae genome and concatenated, the resulting GC skew 
was virtually identical to that of M. leprae. 
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Fig. S2. Bayesian dating analysis of M. lepromatosis. (A) Substitution rate calculated by tip 
calibration of radiocarbon dated M. leprae genomes using BEAST, a Bayesian framework 
analysis package. The substitution rate is based on the total alignment of 719,495 variable 
positions. (B) Posterior distribution for the TMRCA for all M. leprae strains. (C ) Posterior 
distribution for the TMRCA for M. leprae strains and M. lepromatosis 
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Figure S3: Phylogeny of M. lepromatosis and M. leprae strains. Phylogenetic relationship 
of M. lepromatosis genome using a neighbor-joining tree, including M. tuberculosis, M. avium, 
and M. ulcerans as outgroups. SNP type is given at branch tips. Bootstrap support is indicated for 
each node. The long branch of S15 was split to reduce space 
 
 
 
 
Figure S4: Phylogeny of selected mycobacterial species in a maximum likelihood tree based on 
the concatenated amino acid sequence alignments of GyrB, RpoB, and RpoC. Bootstrap 
support is indicated for each node 
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Figure S5: Phylogeny of selected mycobacterial species in a maximum parsimony tree based 
on 16S rRNA sequence alignments. Greengene number and accession number are given for 
each label. Bootstrap support is indicated for each node 
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ABSTRACT Mycobacterium lepraemurium is the causative agent of murine leprosy, a 
chronic, granulomatous disease similar to human leprosy. Due to the similar clinical 
manifestations of human and murine leprosy and the difculty of growing both bacilli 
axenically, Mycobacterium leprae and M. lepraemurium were once thought to be closely 
related, although it was later suggested that M. lepraemurium might be related to 
Mycobacterium avium. In this study, the complete genome of M. lepraemurium was 
sequenced using a combination of PacBio and Illumina sequencing. Phylogenomic 
analyses conrmed that M. lepraemurium is a distinct species within the M. avium 
complex (MAC). The M. lepraemurium genome is 4.05 Mb in length, which is 
considerably smaller than other MAC genomes, and it comprises 2,682 functional genes 
and 1,139 pseudogenes, which indicates that M. lepraemurium has undergone genome 
reduction. An error-prone repair homologue of the DNA polymerase III a-subunit was 
found to be nonfunctional in M. lepraemurium, which might contribute to pseudogene 
formation due to the accumulation of mutations in nonessential genes. M. lepraemurium 
has retained the functionality of several genes thought to inuence virulence among 
members of the MAC. 
 
IMPORTANCE Mycobacterium lepraemurium seems to be evolving toward a 
minimal set of genes required for an obligatory intracellular lifestyle within its host, a 
niche seldom adopted by most mycobacteria, as they are free-living. M. lepraemurium 
could be used as a model to elucidate functions of genes shared with other members of 
the MAC. Its reduced gene set can be exploited for studying the essentiality of genes in 
related pathogenic species, which might lead to discovery of common virulence factors 
or clarify host-pathogen interactions. M. lepraemurium can be cultivated in vitro only 
under specic conditions and even then with difculty. Elucidating the metabolic 
(in)capabilities of M. lepraemurium will help develop suitable axenic media and 
facilitate genetic studies.
 
KEYWORDS Mycobacterium lepraemurium, comparative genomics, genome 
sequencing, murine leprosy 
 
 
urine leprosy is a chronic, granulomatous disease caused by Mycobacterium 
lepraemurium. Murine leprosy mainly affects the skin, mucosa of the upper respiratory 
tract, and eyes; however, unlike human leprosy, the viscera are commonly affected, 
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whereas the peripheral nerves are not (1). Murine leprosy was rst reported in the early 
20th century in rats in Ukraine (2), after which similar cases were reported from other 
countries (3, 4). M. lepraemurium is one of the causative agents of leprosy in cats and 
causes granulomatous skin lesions that often involve ulceration (5).  
In humans, leprosy is primarily caused by Mycobacterium leprae and Mycobacterium 
lepromatosis. Numerous similarities exist between human and murine leprosy, including 
disease transmission through abrasions in the skin and the mucosal respiratory surfaces, a 
similar spectrum of disease progression, suppression of cell-mediated immunity, and 
strong humoral immunity (1). 
 
 
 
FIG 1 The genome of Mycobacterium lepraemurium strain Hawaii. (A) Graphical 
representation of the genome and its features. The origin of replication is at 12 o’clock, 
and the genome sequence runs clockwise. Ticks around the outermost circle mark million 
bases. Looking inwards, the outermost track or the rst track (blue) shows functional 
genes. The second track (green) shows pseudogenes. The third track shows insertion 
sequences (all dysfunctional) colored to distinguish families (orange, red, black, and blue) 
and exaggerated in size for visibility. The fourth track shows the GC skew, calculated for 
a 20-kb window sliding every 1 kb, represented as a histogram with positive values 
pointing outward (red bars) and negative values pointing inward (blue bars). (B) 
Maximum parsimony tree of M. lepraemurium and selected mycobacterial species. The 
tree was created using MEGA7 from concatenated amino acid sequences (3,936 positions) 
of 11 proteins (DnaN, RplI, GrpE, MetG, RplY, PheT, FtsQ, HolA, MiaA, FtsY, and 
FtsX). Branches corresponding to the Mycobacterium avium complex are in blue. 
Bootstrap support, estimated from 500 replicates, is given below each branch. An 
expanded version of this tree, including additional genomes, is in Fig. S1 in the 
supplemental material. 
This led to the hypothesis that these species were closely related, and hence, it was 
thought that murine leprosy might serve as a model for human leprosy (6–8). DNA 
hybridization studies and analysis of the 16S rRNA gene sequences suggested that M. 
lepraemurium might actually be more related to the Mycobacterium avium complex 
(MAC) (9, 10). However, to date, no phylogenomic study of M. lepraemurium has been 
conducted, and the lack of a genome sequence has restricted our understanding of its 
biology and evolution. 
Here, we describe the complete genome of M. lepraemurium, which was sequenced 
using single-molecule real-time (SMRT; Pacic Biosciences) and Illumina technologies. 
The M. lepraemurium genome was found to be circular, with a total GC content of 
68.99%, and 4,050,523 bp in length. No plasmids were found. The genome comprises 
3,821 “protein-coding” genes, of which 2,682 are functional genes and 1,139 are 
pseudogenes (Fig. 1A). M. lepraemurium belongs to the MAC and is more closely related 
to the M. avium clade than to the M. intracellulare clade (Fig. 1B and see Fig. S1 and S2 in 
the supplemental material). 
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Genome downsizing and pseudogene formation. At 4.05 Mb, the M. lepraemurium 
genome is the smallest within the MAC and one of the smallest among mycobacteria (9th 
out of the 350 sequenced mycobacterial species). More strikingly, within the 
mycobacteria, only the M. leprae and M. lepromatosis genomes contain fewer functional 
protein-coding genes than the M. lepraemurium genome. The presence of 1,139 
pseudogenes indicates that M. lepraemurium underwent reductive evolution, which is 
characteristic for strictly host-associated organisms. Analyses of pseudogene families 
within a diverse set of prokaryotes have shown that pseudogenes are most likely to occur 
in ABC transporter, short-chain dehydrogenase/reductase, sugar transporter, cytochrome 
P450, and proline-glutamate (PE)/proline-proline-glutamate (PPE) gene families (11). The 
M. lepraemurium genome was found to contain pseudogenes in all these families. 
M. lepraemurium is the third mycobacterial species known to have undergone reductive 
evolution. The other species include the common ancestor of M. leprae and the closely 
related M. lepromatosis, which underwent genome reduction before the two species 
diverged, as well as Mycobacterium ulcerans, which is in a state of intermediate reductive 
genome evolution (12–14). Genome size among M. avium subspecies varies considerably 
(around 4.8 to 5.5 Mb), but no extensive pseudogenization was observed in these 
organisms. Curiously, M. lepraemurium seems to be evolving convergently toward a 
minimal gene set such as the one retained by M. leprae (Fig. 2). This may be due to both 
species having adapted to a similar niche, consequently resulting in similar pathological 
manifestations. 
Loss of the DnaQ-mediated proofreading mechanism of DNA polymerase III a-subunit 
has been hypothesized as the cause of pseudogene formation in M. leprae (12), and a 
similar pattern has been observed in other obligate pathogens and symbionts (15, 16). In 
M. lepraemurium, a homologue of the error-prone repair DNA polymerase III a-subunit 
(MLM_3495) is nonfunctional, which might contribute to a higher error rate leading to 
pseudogene formation in this species. 
The AT content of the pathogen/symbiont genome seems to correlate with the age of the 
strict association with the host (16). As expected, the genome of M. leprae has the highest 
AT content of all mycobacteria (42.2%), especially in pseudogenes (43.5%). On the other 
hand, the genome of M. lepraemurium is as AT-poor as that of its closest relative, M. 
avium (31%), and shows only a small difference in the AT content of functional genes and 
pseudogenes (30.46% and 31.05%, respectively). This suggests that M. lepraemurium 
adopted the “strictly intracellular” niche relatively recently, as evidenced by its 
phylogenetic relatedness to the free-living M. avium (Fig. S1). Genomic data for other M. 
lepraemurium strains would allow us to determine whether the pseudogene content varies 
between strains, which would indicate ongoing reductive evolution. 
 
Repetitive sequences and mobile elements. Repeats and mobile elements are the major 
vehicles leading to genomic rearrangements and large deletions, and hence, they are 
thought to play an important role in genome downsizing. Yet, there seems to be a negative 
correlation between the stage of reductive evolution and repeat content (17). This is likely 
because deletions and pseudogenization impact tness as more genes become 
nonfunctional, and the remaining genes become indispensable. Therefore, it has been 
suggested that repeats might be involved in the early phase of reductive evolution and that 
a different mechanism is responsible for the gradual deletion of pseudogenes (17). M. 
lepraemurium has only a few repeats (Table S1), which mostly derive from three families 
of dysfunctional insertion sequences (IS), each consisting of up to six copies. 
Curiously, one IS family consisting of six copies (MLM_1414, MLM_1873, 
MLM_2691, MLM_2913, MLM_3078, and MLM_3876) shows 84% nucleotide identity 
with the ISMsm2 mobile element from Mycobacterium smegmatis (NCBI accession 
number WP_ 003887303). A BLAST search showed that this IS family resides in only a 
few other unrelated mycobacteria and not in the MAC, with the exception of a more 
diverged copy (with 78% identity) present in the plasmid of M. avium subsp. hominissuis 
strain 88Br (GenBank accession number KR997898.1) and a truncated copy (with 81% 
identity) in the genome of M. avium subsp. hominissuis strain H87 (GenBank accession 
number CP018363.1). 
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FIG 2 Heatmap of the gene orthology between M. avium subsp. paratuberculosis K-10, M. 
lepraemurium, M. leprae, and M. ulcerans. Genes are shown in black, and the absence of 
genes is shown in white. The raw height corresponds to the number of genes. 
 
Strikingly, when we analyzed the genomic synteny between M. lepraemurium, M. 
intracellulare, and M. avium subsp. hominissuis, all the synteny breaks in M. 
lepraemurium occurred at the locations of this particular IS (Fig. S3A and B). The 
synteny plot between M. lepraemurium and M. avium subsp. paratuberculosis looked 
different from the aforementioned genomes, which is probably due to genomic 
rearrangements in M. avium subsp. paratuberculosis (Fig. S3C). 
The presence of identical copies of dysfunctional transposable elements indicates that 
M. lepraemurium lost functional transposases relatively recently. As mentioned above, at 
least one IS family was responsible for large genomic rearrangements in M. 
lepraemurium, and a deeper analysis of the genome sequence might shed light on the 
driving force that caused major deletions in this genome. 
 
M. lepraemurium-specic sequences. Comparison of M. lepraemurium with other 
members of the MAC revealed a total of 32.2 kb of genomic sequence that was not found 
in any publicly available genome sequence. These regions contain 35 genes, of which only 
12 are functional (Table S2). One of these genes, MLM_3300, codes for a Fic family 
protein. Fic proteins have been associated with pathogenicity in bacteria, often acting as 
toxins that interfere with the host cell in different ways (18). 
 
Interaction with macrophages. After entering the macrophage, members of the MAC 
reside within phagosomes (19). There they inhibit phagosome maturation by preventing 
acidication to a pH below 6.4, and thus, prevent fusion with the extremely acidic 
lysosome. In M. avium, mutations in the PPE gene MAV_2928 and the PE gene MAV_1346 
inhibit maturation and acidication of phagosomes, resulting in decreased virulence (20, 
21). In M. lepraemurium, gene MLM_2357 (homologous to MAV_2928) and MLM_1265 
(homologous to MAV_1346) are functional, suggesting that they may help its survival in 
macrophages. Additionally, the gene MLM_2012 encodes the lipoprotein, LppM, which is 
an important virulence factor in M. tuberculosis and interferes with phagosomal 
maturation in macrophages (22). 
Reactive oxygen species (ROS) are produced by the macrophage as a bactericidal 
? ? ??
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mechanism in response to infection. The ability of pathogens to produce enzymes such as 
catalase-peroxidase, epoxide hydrolase, and superoxide dismutase (SOD), which remove 
ROS, enable their survival within macrophages. While it has been suggested that M. 
lepraemurium abolishes the production of ROS upon entering the macrophage (29), 
probably as a survival mechanism, it remains unclear whether small quantities of ROS are 
produced upon infection and handled by the bacterium. M. lepraemurium has retained four 
functional epoxide hydrolases (MLM_0642, MLM_0684, MLM_1194, and MLM_1485) 
and one catalase-peroxidase (MLM_2092), which explains its observed catalase-peroxidase 
activity (23). Moreover, M. lepraemurium is able to produce two superoxide dismutases, 
SodA and SodC (MLM_0123 and MLM_2650). 
 
Glycopeptidolipid synthesis. Glycopeptidolipids (GPLs) are synthesized by several 
nontuberculosis mycobacteria, including members of the MAC. GPLs are present on the 
outermost layer of the cell wall, and therefore, they play an important role in sliding 
motility, biolm formation, and pathogenesis (24). This is even more relevant within the 
MAC, whose members can produce a number of serovar-specic variations of GPLs. The 
M. lepraemurium cell wall contains glycolipids and amino acids (25, 26); however, 
production of GPLs in M. lepraemurium has not been studied. Most of the genes known to 
be involved in the biosynthesis of non-serovar-specic GPLs are intact in M. 
lepraemurium, albeit with a few exceptions (Table S3). Although it is difcult at this 
moment to predict the effects of these mutations, it appears that M. lepraemurium should 
be able to produce GPLs, as all of the core genes are present. 
Virulence. While the ESX-1 system is the main determinant of virulence in M. 
tuberculosis and M. leprae (27), it is absent in the MAC. However, ESX-5, which is also 
associated with virulence in pathogenic mycobacteria, is mostly intact in M. 
lepraemurium, except for the cytochrome P450 hydroxylase (MLM_2361), which is also 
nonfunctional in M. leprae. The duplicated four-gene region, ESX-5a, encoding EsxI, 
EsxJ, a PPE, and a PE protein may serve as an accessory system for transport of a subset 
of ESX-5 proteins (28) and is still functional in M. lepraemurium. In M. lepraemurium, the 
PPE and PE genes are merged into a single open reading frame, as in M. avium subsp. 
paratuberculosis but not in other members of the MAC. An interesting observation is that 
in MAC, esxI and esxJ are 100% identical to esxN and esxM from the main ESX-5 locus 
(unlike in M. tuberculosis), which indicates a novel and recent duplication event and 
suggests that a crucial function might lie behind redundancy of the ESX-5 components. 
The pks12 gene is involved in the biosynthesis of mannosyl-13-1-phosphomycoketides 
(MPM) and is found only in the slow-growing mycobacteria. In different pathogenic 
mycobacteria, including M. avium (20), pks12 was shown to be necessary for the 
virulence, and this gene is functional in M. lepraemurium (MLM_2156). 
Experimental procedures. M. lepraemurium strain Hawaii was grown in BALB/c 
mice. The DNA was sequenced using Illumina and PacBio technologies, followed by 
sequence assembly and annotation. More details are given in Text S1 in the supplemental 
material. 
Accession number(s). The annotated genome was submitted to GenBank under 
GenBank accession number CP021238. 
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SUPPLEMENTAL MATERIAL 
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Bacilli culture and purification. M. lepraemurium Hawaii was grown using serial 
infections in BALB/c mice injected by the intraperitoneal route. At four to six months post-
infection, the infected spleen and liver were harvested. Bacteria were purified by following 
the protocol in (1), followed by the Percoll step (2) and then by using previously established 
protocols (3, 4). Briefly, 4 g of tissue was suspended in 20 ml of 0.2 M sucrose and ground 
in a glass Potter–Elvehjem homogenizer. The resulting suspension was centrifuged for 20 
min at 150 xg to separate cell debris (Sorvall RC5B, rotor HB4, Sorvall Instruments, 
Wilmington, Delaware, USA). Then, 9 ml of the isolated supernatant was overlaid onto 12 
ml of 0.3 M sucrose and the tubes were centrifuged at 3,500 xg for 10 min at 4–10°C 
(Sorvall RC5B, rotor SS34). The resulting bacilli-rich pellet was resuspended in 20 ml of 
0.2 M sucrose and overlaid, in 9-ml aliquots, onto 12 ml of 1.5 M KCl. The tube was then 
centrifuged at 4°C for 10 min at 3,500 xg. The bacilli were collected, washed 3 times with 
phosphate-buffered-saline (PBS) at pH 7.4 (PBS is 0.01 M Na/K phosphate, 0.15 M NaCl), 
and suspended in 40 ml of a solution containing a mixture of Percoll (3 parts) and 0.1% 
Tween 80 (7 parts). The suspension was centrifuged at 23,000 xg (Sorvall RC5B, rotor 
SS34) for 60 min at 40°C. Then the bacillary layer was resuspended in 20 ml of Percoll-
Tween and centrifuged as before. The final bacillary pellet was collected and washed 5 
times with PBS pH 7.4 or until the Percoll was completely eliminated. The purity of the 
bacillary preparation was verified by Ziehl–Neelsen staining. The purified bacillary 
suspension was prepared in synthetic 7H9 Middlebrook broth-OADC medium (DIFCO, 
Detroit, MI, USA), and quantified via a nephelometric reference curve prepared with known 
quantities of bacteria. The bacillary suspension was aliquoted and frozen at -20°C until 
ready for use.  
For DNA extraction, several aliquots were combined, centrifuged at 3,500 xg for 10 min, 
the supernatant was eliminated and the pellet was frozen (-20°C) without any further 
treatment.  
 
DNA extraction. DNA extraction was carried out using a custom-designed protocol for 
mycobacterial DNA. The bacterial cell pellet was washed with 500 µL of phosphate buffer 
saline (PBS) prior to centrifugation at 5000 g for 10 min. The supernatant was discarded 
and the pellet was re-suspended in 1 mL of bacterial lysis buffer B1 (50 mM Tris-HCl pH 
8.0; 50 mM EDTA pH 8.0; 0.5% Tween 20; 0.5% Triton-X100) containing 45 µL of 
proteinase K (20 mg/mL) and 20 µL of lysozyme (100 mg/mL). The mixture was then 
transferred into bead-beating tubes containing 500 ?L of silica beads (0.1 mm zirconia 
beads) prior to physical disruption using the Precellys24 homogenizer at 6.5 m/s for 25 sec. 
After incubating at 56°C for 1 h, the mixture was centrifuged and the supernatant was 
transferred to a new tube. An additional incubation with 20 µL proteinase K (20 mg/mL) 
was conducted at 56°C for 30 min. The mixture was then incubated at 4°C for 15 min. 
RNAse A (Sigma) was added and the sample was incubated 30 min at 37°C, followed by 
the addition of 350 µL of bacterial lysis buffer B2 (3M guanidine hydrochloride, 20% 
Tween 20), and incubated for 30 min at 50°C. DNA was purified using the Qiagen 
Genomic-Tip/20G according to the manufacturer’s instructions, and eluted in 2 mL elution 
buffer. The DNA was precipitated using 0.7x volume of isopropanol and centrifuged at 4°C 
for 15 min. The pellet was washed twice with 200 µL 70% ethanol, air-dried, and suspended 
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overnight in 200 µL Tris HCl buffer (pH 8.0) at room temperature under continuous 
shaking. The DNA was then purified using AMPure beads (Thermofisher) at a ratio of 0.45. 
The quality of the DNA extract was checked using the Fragment Analyzer (Advanced 
Analytical Technologies) and quantified using the Qubit 2.0 (Life Technologies).  
 
Illumina sequencing. DNA (50 ?L) was sheared using the Covaris S220 Focused-
ultrasonicator (Covaris) to obtain 400 bp-long DNA fragments, and purified using AMPure 
beads (1.8x) and the manufacturer’s protocol. The sheared DNA was quantified using the 
dsDNA High Sensitivity assay and the Qubit 2.0 flurometer (Life Technologies). Up to 1 ?g 
of DNA in 50 ?L was used for library preparation using the Kapa Hyper prep kit (Roche) 
and PentAdapters (Pentabase) for indexing. The library was quantified using the dsDNA 
Broad Range assay and the Qubit 2.0 fluorometer. The library was sequenced on an 
Illumina HiSeq 2500 (1 x 101 bp run). 
 
PacBio sequencing. DNA (5.1 µg) was sheared using a Covaris g-TUBE (Covaris S220) to 
obtain 10 kb fragments and the size distribution was checked using the Fragment Analyzer 
(Advanced Analytical Technologies). Sheared DNA (4 µg) was used to prepare a SMRTbell 
library with the PacBio SMRTbell Template Prep Kit 1 (Pacific Biosciences) according to 
the manufacturer's recommendations. The resulting library was size-selected using a 
BluePippin system (Sage Science, Inc.) for molecules larger than 8 kb. The recovered 
library was sequenced using a SMRT cell with P6/C4 chemistry and MagBeads on a PacBio 
RSII system (Pacific Biosciences) at 240 min movie length.  
 
Genome assembly. PacBio reads were processed using the HGAP2 and HGAP3 pipelines 
(5). The resulting contigs were compared to the nucleotide database at NCBI using BLAST 
(6). The two largest contigs produced by HGAP3 v2.3.0 (which were 2.3 and 1.7 Mb in 
length, respectively) matched to M. avium sequences. These two contigs corresponded to 
the three largest contigs produced by HGAP2 v2.3.0 (which were 1.7, 1.6, and 0.6 Mb in 
length) and two shorter contigs (61 and 21 kb in length). The two HGAP3 contigs could be 
joined by the overlapping HGAP2 contigs, resulting in a single consensus sequence with 
overlapping ends, indicative of a circular genome. To correct for possible sequence errors, 
Illumina reads were mapped onto the draft genome sequence using Bowtie2 (7) resulting in 
35-fold coverage of non-duplicate reads. Variants were called using SAMtools mpileup (Li 
et al., 2009) and VarScan2 (9), resulting in only five single nucleotide polymorphisms 
(SNPs) and two short insertion-deletions (InDels). 
Illumina reads (4%) that did not map to the final genome sequence were assembled using 
MIRA (https://sourceforge.net/projects/mira-assembler/). The resulting 34 contigs (of which 
the largest was 1.9 kbp long) were compared to the nucleotide and protein databases at 
NCBI using BLAST. The contigs matched to Mus musculus or to various bacteria. No 
evidence of a putative plasmid sequence was found. 
 
Gene prediction. De novo gene prediction was conducted using the RAST server (10) with 
the frameshift correction option. Reference-based gene prediction was conducted using 
RATT (11) with annotations from M. avium subsp. paratuberculosis K-10 (NC_002944.2) 
and M. avium subsp. hominissuis TH135 (AP012555.1). All predictions were merged, and 
inconsistencies and large intergenic areas were manually checked by using BLAST to 
compare the problematic sequences against the protein database at NCBI. Gene predictions, 
shorter than 100 nucleotides in length and not conserved in the genomes of other M. avium 
species, were removed. The annotated genome was submitted to GenBank (accession 
number CP021238).  
 
Phylogenetic analyses. Two different strategies were used for the phylogenetic analysis to 
assure accuracy and consistency of the reconstructed tree topologies, as described below. 
 
Phylogenetic analysis of concatenated amino-acid sequences. A set of eleven genes was 
chosen for the analysis (12), (DnaN, RplI, GrpE, MetG, RplY, PheT, FtsQ, HolA, MiaA, 
FtsY, FtsX). To make sure to identify strains that are closely related to M. lepraemurium, 
the nucleotide sequence of M. lepraemurium corresponding to the abovementioned genes 
was used as dcBLASTn query against all available genome sequences and genome 
assemblies of the MAC available at NCBI as of June 2017. BLAST hits were translated into 
amino-acid sequence. Amino-acid sequences of additional genomes from the MAC 
complex as well as other mycobacteria were included. Analysis of the concatenated 
alignments was done in MEGA7 (13).  
 
Phylogenetic analysis of whole-genome alignments. Publically available genome data 
were acquired for comparative purposes for 16 mycobacterial species. Contigs or finished 
genomes of these species were aligned to the M. avium 104 reference genome using LAST 
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(14) with the following parameters: -u = 0, -e = 34, and -j = 5. The maf-convert program 
was used to covert the alignment file to a SAM file and SAMtools was used obtain a BAM 
file which was used for further analyses. SAMtools mpileup and bcftools call were used to 
produce the VCF files. VCF files for all strains were combined using the CombineVariants 
tool available in the Genome Analysis Toolkit (GATK) (15). The SelectVariants tool in 
GATK was used to output a VCF file containing the sites comprising SNPs. VCFtools (16) 
was used to remove InDels, tri-allelic sites, and sites with missing data. An SNP alignment 
was generated using a publically available perl script (17), which comprised a total of 
460,625 sites.  
Phylogenetic trees were constructed using the Maximum Likelihood (ML) method in 
RAxML v7.2.8 (18) and the Neighbor-Joining (NJ) and Maximum Parsimony (MP) 
methods in MEGA7 (13). The ML tree was generated using the GTR-GAMMA model and 
100 bootstrap replicates (Figure 1). The NJ tree was generated using the p-distance method 
and bootstrap support was estimated from 500 replicates (Figure S1). The MP tree was 
generated using the Subtree-Pruning-Regrafting (SPR) algorithm and 500 bootstrap 
replicates (Figure S2). 
 
Comparison of orthologous genes. Orthologs between M. lepraemurium and M. avium 
subsp. paratuberculosis were inferred by RATT and manually during the annotation 
process. Orthologs between M. avium, M. leprae and M. ulcerans were retrieved from 
http://www.pathogenomics.sfu.ca/ortholugedb/ 
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Figure S1: Maximum parsimony tree of M. lepraemurium and other mycobacterial species. The tree was created using 
MEGA7 from concatenated amino acid sequences (3,948 positions) of 11 proteins (DnaN, RplI, GrpE, MetG, RplY, PheT, 
FtsQ, HolA, MiaA, FtsY, and FtsX). Bootstrap support, estimated from 500 replicates, is given below each branch.  
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Figure S2: Phylogeny of M. lepraemurium and selected mycobacterial species based on whole-genome sequence 
alignments. Species belonging to the M. avium complex are highlighted in blue and M. lepraemurium is denoted in 
red. M. abscessus was used as the outgroup. (A) Maximum likelihood tree. The tree was created using RAxML based on 
460,625 variable nucleotide sites and a general time reversible (GTR) model with gamma distribution. Bootstrap support 
estimated from 100 replicates is given below each branch. (B) Neighbor-joining tree. The tree was created using MEGA7 
based on 460,625 variable nucleotide sites and the p-distance method. Bootstrap support estimated from 500 replicates is 
given below each branch. (C) Maximum parsimony tree. The tree was created using MEGA7 based on 460,625 variable 
nucleotide sites and the SPR algorithm. Bootstrap support estimated from 500 replicates is given below each branch.  
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Figure S3: Synteny plots between M. lepraemurium and selected members of the Mycobacterium avium complex. 
Genome sequences are represented as colored ideograms. Numbered ticks mark million bases. Transposable elements are 
shown as ticks in the second track, with the ISMsm2-like family in magenta. Inner links are LAST hits (see Text S1 in the 
supplemental material for details). 
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Abstract  
Studying ancient DNA allows us to retrace 
the evolutionary history of human pathogens, 
such as Mycobacterium leprae, the main 
causative agent of leprosy. Leprosy is one of 
the oldest recorded and most stigmatizing 
diseases in human history. The disease was 
prevalent in Europe until the 16th century and 
is still endemic in many countries with over 
200,000 new cases reported annually.  
Previous worldwide studies on modern and 
European medieval M. leprae genomes 
revealed that they cluster into five separate 
lineages of which two were present in 
medieval northwestern Europe. In this study, 
we analyzed 10 new medieval M. leprae 
genomes including the so far oldest M. leprae 
genome from one of the earliest known cases 
of leprosy in the United Kingdom—a skeleton 
from the Great Chesterford cemetery with a 
calibrated age of 415–545 AD. This dataset 
provides a genetic time transect of M. leprae 
diversity in Europe over the past 1500 years. 
We find four of the five known distinct M. 
leprae lineages to be present in the early 
medieval period, and three lineages were 
detected within a single cemetery from the 
high medieval period. Altogether these 
findings suggest a higher genetic diversity of 
M. leprae strains in medieval Europe at 
various time points than previously assumed. 
The resulting more complex picture of the 
past phylogeography of leprosy in Europe 
impacts current phylogeographical models of 
M. leprae lineages. It suggests alternative 
models for the past spread of leprosy such as a 
wide spread prevalence of different lineages in 
Eurasia already in Antiquity or maybe even an 
origin in Western Eurasia. Furthermore, these 
results highlight how studying ancient M. 
leprae strains improves understanding of the 
history of leprosy worldwide. 
 
Author’s Summary  
Many mysteries surround leprosy, which is 
one of the oldest recorded diseases of 
humankind. The origin and past spread of its 
main causative agent, Mycobacterium leprae, 
remain unknown although many attempts have 
been made to reconstruct its past from 
historical and archeological sources. Analysis 
of ancient M. leprae genomes reconstructed 
from archaeological remains can contribute 
greatly to reconstructing the origin and 
evolution of this pathogen. With a new set of 
ancient M. leprae genomes from Europe, we 
traced back a so far unrecognized past 
diversity, which places Europe as a key region 
for the early spread and worldwide 
dissemination of leprosy. Our results hint to 
the potential dynamic changes in the 
prevalence of different M. leprae strains in 
Europe during Antiquity, and highlight the 
need to study ancient pathogen genomes in 
order to better understand our past. 
 
Introduction 
 
Leprosy resulting from the infection with 
Mycobacterium leprae has been prevalent 
since early history. Signs of its existence occur 
in historical texts [1, 2] as well as in the 
osteological and archeological records [3-5]. 
Widespread in medieval Europe, and peaking 
between the 12th and 14th century, leprosy 
declined in the 16th century and subsequently 
disappeared from Europe [6, 7]. Nowadays M. 
leprae is prevalent worldwide except in 
Europe and is genetically represented by five 
distinct lineages with different geographic 
distributions. Lineage 0 is mainly found in 
Eastern Asia (Japan, China, New Caledonia) 
whereas lineage 1 is mostly detected in 
Southern and Eastern Asia (Thailand, India, 
Southern Japan)[8-12]. Lineage 2 is reported 
from the Near East [8], however, no such 
modern day example (genome) has been 
sequenced so far. Lineage 3 is present in Latin 
America and recently spreading in the 
southwestern USA nine-banded armadillo 
population [13] with occasional zoonotic 
transmission to humans [14]. Another non-
human M. leprae reservoir, also harboring a 
lineage-3 strain, is the red squirrel in England 
[15]. Finally, lineage 4 is present in West 
Africa and South America [8, 9, 16]. M. leprae 
lineages correspond to specific single 
nucleotide polymorphism (SNP) types or 
subtypes [9], a nomenclature widely used in 
comparative genomics, consisting of four SNP 
types (1-4) and 16 SNP subtypes (A to P) [8]. 
While SNP types are based on a limited 
amount of SNPs [8], M. leprae lineages 
include full genomes and therefore reflect 
more complexity [9]. 
Investigations on the evolutionary history 
of M. leprae have elucidated on the past 
phylogeography and diversity of the leprosy 
bacillus in Europe. Recently sequenced 
medieval M. leprae genomes reveal the 
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presence of at least two distinct M. leprae 
lineages in medieval Northwestern Europe [9]. 
Furthermore, the data indicate a high level of 
genetic conservation during the last 1000 
years. There appears to be a close relationship 
of a group of late medieval strains with 
contemporary strains present today in the 
Southwestern USA [9] infecting humans and 
armadillos [13] as well as red squirrels in 
England [15]. Two medieval genomes from a 
cemetery in the UK suggested a possible 
predominance of lineage 2 during the 10th to 
the 12th century in Northwestern Europe, while 
lineage 3 was more frequent during the late 
medieval era [17]. However, the past diversity 
and population structure of M. leprae at 
different time points in other parts of Europe 
still remain unclear.  
To address these key questions, we 
sequenced four whole genomes of M. leprae 
strains identified in early medieval leprosy 
cases from various parts of Europe -Italy, 
Hungary, Czech Republic and the 
UKincluding one of the oldest leprosy cases in 
the UK from an early Anglo-Saxon cemetery 
in Great Chesterford, radiocarbon dated to 
AD415-545 [18]. Furthermore, we sequenced 
six genomes from the Odense St. Jørgen 
cemetery in Denmark to assess the diversity of 
M. leprae in one location at a particular point 
in time. Our results reveal a high diversity of 
M. leprae lineages in early medieval Europe, 
where four of five known M. leprae lineages 
were identified. Furthermore, three lineages of 
M. leprae were found within the St. Jørgen 
cemetery alone, indicating a high level of 
strain diversity in medieval Europe. 
 
Results  
 
Sample collection and screening. The 
potential leprosy cases identified based on 
characteristic skeletal deformations that were 
analyzed in this study span different European 
countries and time periods (Figure 1 and Table 
S1 for details of all samples except the 
negative Danish ones): two from Italy (4th BC 
and 7th AD) [19-21], one from UK (5th to 6th 
century) [18], four cases from Hungary (7th to 
11th century) [20], one from the territory of 
today’s Czech Republic (9th to 12th century) 
[20], and 87 from Denmark (11th-14th century).  
The screening for the Danish samples was 
carried out with PCR [9] and direct shotgun 
sequencing of double-stranded Illumina 
libraries [22, 23] followed by metagenomics 
analysis using MALT [24]. Samples with more 
than 1% (n=6, Table S1) of all raw reads 
mapping to the M. leprae TN reference 
genome (RefSeq ID NC_002677.1) were used 
for whole genome sequencing by shotgun 
sequencing without any prior enrichment. For 
all other samples double-stranded Illumina 
libraries [22, 23] were created and screened for 
M. leprae DNA using a bead capture approach 
[25] on three genomic loci, gyrA, proS and 
RLEP, as detailed previously [9], yielding 
between 0.4x and 700x-fold average coverage 
for the enriched genes. DNA misincorporation 
patterns characteristic for ancient DNA were 
calculated to assess the authenticity of the 
retrieved DNA [26, 27]. As observed 
previously [9], ancient M. leprae DNA 
contained a lower percentage of 
misincorporation patterns, between 11 and 
21% (Table S1), compared to what is expected 
for human DNA of the same region and age 
[28]. This consistency underlines the 
exceptionally good long-term preservation of 
M. leprae DNA within cells as already 
commented previously [9].  
Figure 1: Worldwide distribution of the ancient and 
modern M. leprae strains analysed in this study. 
Skulls represent strains from osteological specimens
dated to the medieval area. Human silhouettes are
modern strains; squirrel and armadillo silhouettes are
strains from the red squirrel and the nine-banded 
armadillo. Skulls outlined in red are the new M. leprae 
genomes reconstructed in this study, while skulls
outlined in black represent previously sequenced ancient
genomes. Grey skulls (outlined in red) are leprosy
samples from this study that did not yield sufficient 
sequence for analysis. The main M. leprae lineages (see 
Figure 2) are color-coded. 
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Genome-wide enrichment, sequencing, and 
analysis. On the basis of the screening results 
(Table S1), samples containing M. leprae 
DNA were subjected to whole-genome 
enrichment and sequencing. The libraries were 
prepared using an enzymatic DNA damage 
repair [29]. Prior to sequencing, all libraries 
were enriched using an array spanning the M. 
leprae genome [9, 30], except for the Danish 
samples, which were directly shotgun 
sequenced. Between 406,241 and 12,227,587 
short reads were mapped to the M. leprae TN 
reference genome (RefSeq ID NC_002677.1) 
using the EAGER pipeline [31] and all 
samples with at least 7x-fold mean coverage 
were selected for further analysis (Tables 1, 
S2). For the resulting 10 samples, we used the 
Genome Analysis Toolkit (GATK) to generate 
a mapping assembly to call reference bases 
and variants from the mapping. 
 
Phylogenetic analysis. We reconstructed the 
phylogeny for the 10 newly sequenced and 
well-resolved medieval genomes together with 
the previously sequenced medieval [9, 17] and 
modern genomes [9, 10, 13-16, 32], from a 
total of 1071 SNP positions. The four early 
medieval genomes fall on different branches in 
the maximum parsimony tree (Figure 2A). The 
oldest M. leprae genome from Great 
Chesterford (GC96) belongs to lineage 3, as 
the armadillo, red squirrel, and other medieval 
and modern human strains [9, 15]. 
Interestingly, the M. leprae strains isolated 
from red squirrels from England [15] are 
placed tightly between GC96 from Great 
Chesterford (5th-6th century) and SK2 from 
Winchester (10th-11th century) (Figure 2). 
 The medieval genome from Italy (T18) falls 
within lineage 2, whereas SK11 from Hungary 
clusters with lineage 0 strains. The Body188 
strain from Czech Republic belongs to lineage 
4 and is ancestral to contemporary strains from 
Western Africa. The six individuals from the 
St. Jørgen cemetery in Denmark, which was 
established 1270 and existed to 1560, are 
14C-dated with overlapping periods and mean 
values from the 12th to the 14th century (Table 
S1), a period in which the majority of burials 
took place [33]. The six M. leprae genomes 
obtained from these individual cluster within 
three different lineages (Figure 2A): lineage 0 
(n=1), lineage 2 (n=1) and lineage 3 (n=4).  
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SNP analysis. We analyzed the 1071 SNP 
positions identified in the whole dataset for 
the effects that they might have on particular 
genes (Table S3). No polymorphisms specific 
only to all ancient strains were found. Non-
synonymous SNPs (nsSNPs) specific to each 
lineage are given in Table S4.  
 
BEAST analysis. Using the radiocarbon dates 
for the ancient samples and the isolation dates 
for the modern samples as tip calibration 
points we estimated the divergence time for 
all M. leprae strains using BEAST [34] 
assuming a constant population size [35] and a 
variable population size by application of a 
Bayesian Skyline model [36]. The age of the 
most recent common ancestor (MRCA) was 
estimated to 5,162 y BP (4,012–6,393 y 95% 
Highest Posterior Density (HPD)) under the 
constant population size model, and 4,946 y 
BP (3,868–6,147 y 95% HPD) assuming the 
variable population size (Bayesian Skyline) 
model (Figure 2B, Table 2). The estimated 
mean age of the MRCA is about 1,500 y older 
compared to the dating analysis previously 
performed [9] with fewer modern day and 
medieval genomes available. The shift was 
mainly due to the ancient genomes from 
lineage 0, which show a higher variability, 
compared to other lineages. However, the 
95% HPD intervals of both analyses overlap, 
increasing the confidence of the estimates. 
The age of the MRCAs of the main lineages 
varied between 4,745 y BP (3,620–5,951 y 
95% HPD) for lineage 0 and 1,771 y BP 
(1,383 – 2,225 y 95% HPD) for lineage 4 
(Table 2). The mutation rate for M. leprae was 
estimated to 6.05 x 10-9 (4.69 – 7.51 x 10-9 
95% HPD) and 6.25 x 10-9 (4.77 – 7.69 x 10-9 
95% HPD) substitutions per site per year for 
constant and variable population size, 
respectively. This rate can be also depicted as 
19-24 mutations per 1000 years and genome. 
 
Discussion 
 
The 10 newly sequenced medieval M. 
leprae genomes allow us to trace back the last 
1500 years of leprosy history in Europe and 
illustrate the high diversity of lineages 
circulating in Europe during this time transect. 
Figure 2: Phylogenetic analysis of ancient and modern M. leprae strains. (A) Maximum parsimony tree reconstructed 
from 1071 informative SNP positions. The tree is drawn to scale, with branch lengths representing number of substitutions. 
Note that the exceptionally long branch of S15 (thicker line) was reduced to 50% to save space. M. lepromatosis was used as
outgroup. Tip labels for each sample show the name, the country of origin (italic) and the SNP subtype (grey). Names of
strains are in bold, with the novel strains from this study in red. Animal symbols indicate strains isolated from red squirrels
or armadillos. Bootstrap values (500 replicates) are shown next to each node. (B) Bayesian phylogenetic tree calculated with
BEAST 1.8.1. Median divergence times are shown on each node in years before present (the 95% Highest Posterior Density
ranges are given in square brackets). Posterior probabilities for each node are shown in grey. 
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Previous genome wide data suggested the 
existence of only two lineages in medieval 
Europe, lineage 2 present at least from the 10th 
to the 12th century and lineage 3 in the late 
medieval era [9, 17]. Our results reveal a 
higher diversity in medieval Europe than 
anticipated. Strains belonging to the ancestral 
lineage 0 and associated with modern strains 
from East Asia were found in Hungary 
(SK11) and Denmark (Jorgen 507) confirming 
the assumed presence of this lineage in 
Europe since at least the 7-8th century [20]. 
The so far oldest M. leprae genome from 
Great Chesterford falls into lineage 3 
suggesting the existence of this lineage in 
Europe at least since the 5th century. With the 
T18 strain we can now also detect lineage 2 in 
early medieval Central Italy, which until now 
was found only in Northern Europe [9, 17]. 
The Body188 strain from Czech Republic on 
the other hand is ancestral to modern lineage 4 
strains from West Africa and Brazil. This 
strain belongs to the SNP subtype 3M, which 
has not yet been sequenced and is rarely 
identified in modern samples [8]. Based on 
our phylogenetic tree we can now group SNP 
subtype 3M together with modern SNP-type 4 
strains into lineage 4. Body188 provides 
therefore a link between Europe and West 
Africa, where the contemporary SNP-type 4 is 
predominant [8]. However, a higher resolution 
with more ancient and modern strains is 
needed before we can understand this link. 
The dynamics of leprosy transmission 
throughout human history is not fully resolved, 
but characterization and geographic 
association of the most ancestral strains are 
crucial for deciphering leprosy’s origin, which 
still remains elusive. This is in part due to the 
scarcity of convincing evidence of leprosy in 
historical records that predate the Common 
Era [37]. The earliest accepted written record 
of leprosy is in the Sushruta Samhita, an old 
Indian text on medicine and surgery dated 
around 600 BC [1], and with the exception of a 
limited amount of potential cases, such as the 
so far oldest one from India dated around 2000 
BC [3] or potential cases from Italy and 
Hungary dated to the 4th-3rd century BC [19, 
38]. However, all are not yet confirmed on the 
molecular level. The oldest osteological cases 
of leprosy that could be detected by molecular 
methods are from around the beginning of the 
Common Era [8, 20], when written records 
also become more abundant [2, 37]. Therefore, 
at present, we are limited to molecular 
methods to decipher the time of M. leprae’s 
origin and its early spread in humans. Having 
more ancient genomes in a dating analysis 
should result in more reliable estimates. In this 
study, every major M. leprae lineage had one 
or more representative ancient genomes 
present. This is the likely reason why the 
estimated oldest age of the MRCA of M. 
leprae is around 1,500 years older compared to 
the earlier calculations with fewer ancient 
genomes [9]. The new dating results justify 
searching for even older osteological cases of 
leprosy than currently available using well-
established methods for identification of 
potential cases [39]. 
The high diversity of M. leprae in medieval 
Europe, spanning almost all its major lineages 
including the most basal ones in the 
phylogeny, has not been found anywhere else 
worldwide. Based on this observation two 
antipodal models can be developed: an origin 
of leprosy in Western Eurasia, maybe even in 
Europe, and spread from there into the rest of 
the world (model 1), and the introduction of 
diverse M. leprae lineages to Europe from 
different regions in the world during and 
before the Medieval era (model 2) that likely 
displayed a high diversity of M. leprae strains. 
The main argument supporting both models is 
that Europe was an important socioeconomic 
hub from Classical Antiquity onwards. The 
dynamic geopolitical changes, wars and the 
well-established trading routes contributed to 
continuous contacts with the neighboring 
regions and migrations within and outside 
Europe and allow fast and multiple exchanges 
of pathogens in both directions. In favor of 
model 1 (Western Eurasian origin) is the 
argument that most medieval European M. 
leprae strains are ancestral to modern strains 
(Figure 2). On the other hand, supporting 
model 2 (multiple introductions into Europe) is 
the prevalence of the most ancestral lineage 0 
(subtype 3k) in modern day China, Japan and 
Korea [8, 40-42] and in the Middle East [8]. It 
has to be noted that strains from Central Asia 
are poorly analyzed to date. Overall, the 
current genomic data convincingly suggest 
Eurasia as a broad area of origin and of the 
early spread of M. leprae. Including more 
ancient strains from different parts of the 
world in a phylogenetic context may enable us 
to narrow down this area. This is especially 
important in areas where past events have 
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become blurred by extensive population 
mixing, bottlenecks or strain replacements.  
In summary, our results provide a genetic 
time transect for the diversity of M. leprae 
within the medieval period in Europe and 
allow us to gain a better understanding of the 
past phylogeography of this pathogen. 
Discovery of other ancient M. leprae strains, 
especially from Asia will provide new details 
on the diversity of M. leprae in the past and 
help develop models for its global spread. 
 
Methods 
 
Ancient DNA extraction and library 
preparation DNA extractions from the 
samples JK3187 to JK3195, GC96F and 
GC96C (Table S1) were conducted from 30-
50 mg bone powder for each sample in clean 
room facilities dedicated to ancient DNA 
work at the University of Tübingen. The 
Danish samples were processed separately at 
the University of Kiel following the same 
protocols as described below for the samples 
processed in Tübingen. A silica purification 
protocol was applied as previously described 
[43] using the following modifications: the 
Zymo-Spin V columns (Zymo Research) were 
UV irradiated for 60 minutes and the total 
elution volume was raised to 100 µl.  
Aliquots of 20 µl from JK3187 to JK3195, 
GC96F and GC96C were converted into 
double-stranded Illumina libraries [22]. The 
adapter-ligated fragments were quantified 
through a quantification assay using the 
primers IS7 and IS8 [22], the DyNAmo Flash 
SYBR Green qPCR Kit (Biozym) and the 
Lightcycler 96 (Roche). 
Following established protocols [22, 23] 
sample-specific indexes were added in the 
next step to both library adapters via 
amplification to create double indexed 
libraries. Extraction and library blanks were 
treated accordingly. These libraries were used 
in the following for initial screening 
approaches.  
For genome-wide enrichment and 
sequencing additional libraries were prepared 
from 30 to 50 µl aliquots of all DNA extracts 
according to the methods described above [22, 
23] with one modification: One additional 
stepthe treatment of all extracts and blanks 
with uracil-DNA glycosylase (UDG) and 
endonuclease VIIIwas included into library 
preparation to avoid potential sequencing 
artefacts caused by the characteristic ancient 
DNA damage profile produced by the 
deamination of cytosine to uracil over time 
[29].  
For all indexed libraries a subsequent 
amplification was performed as detailed in 
Schuenemann and colleagues [9]. 
 
Enrichment and sequencing for sample 
screening All samples except the Danish ones 
were screened for M. leprae preservation. 
Three M. leprae genes ML0006 (gyrA), 
ML1553 (proS) and RLEPwere selected as 
targets for DNA enrichment and converted 
into bait DNA using Long Range PCR 
products as described previously [9]. 
Following the bead enrichment protocol by 
Maricic and colleagues [25] a hybridization of 
the amplified libraries, pooled in an equimolar 
amount, to the DNA bait was carried out.  
Subsequently to the bead enrichment the 
libraries were sequenced on an Illumina HiSeq 
2500 platform using a paired-end dual index 
run with 2*101+8+8 cycles (for the samples 
GC96F and GC96C) and for 2*125+8+8 
cycles (for the samples JK3187 to JK3195) 
following the manufacturer’s protocols for 
multiplex sequencing (TruSeq PE Cluster Kit 
v3-cBot-HS). 
The screening for the Danish samples was 
carried out with PCR for parts of specific 
genes (18kDa antigenic protein gene and 
repetitive element RLEP gene)[9] and direct 
shotgun sequencing of double-stranded 
Illumina libraries [22, 23]. The sequencing for 
the shotgun data was performed on the 
Illumina HiSeq 4000 platform at the Institute 
of Clinical Molecular Biology, Kiel 
University, by 2×75 cycles using the HiSeq v4 
chemistry and the manufacturer’s protocol for 
multiplex sequencing. 
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Genome-wide enrichment and sequencing 
The UDG treated libraries (one from JK3187 
to JK3195, GC96F and two from GC96C) 
were enriched genome-wide with two rounds 
of hybridization capture following the 
protocol detailed before [44]. The design of 
the 1 million Agilent SureSelect arrays used in 
the study was described previously [9]. In a 
first approach equimolar pools of GC96F and 
GC96C1 were enriched on one array, in a 
second experiment equimolar pools GC96C1 
and GC96C2 on two arrays. In a third 
approach the samples JK3187 to JK3189 and 
JK3192 to JK3195 were enriched on one array 
and JK3190 and JK3191 on a separate one. In 
all three experiments the extraction and library 
blanks were enriched separately on an 
additional array. After the first round of 
hybridization, captured products were eluted 
in 490 µl H2O and quantified via a 
quantitative PCR with the IS5 and IS6 primer 
set [22], the DyNAmo Flash SYBR Green 
qPCR Kit (Biozym) and the Lightcycler 96 
(Roche). In a subsequent amplification the 
eluted products were amplified for 17 to 20 
cycles in 100 µl reactions using 24 µl 
template, 4 units of AccuPrime Pfx DNA 
polymerase (Invitrogen), 1 unit of 10× 
AccuPrime buffer (containing dNTPs) and 0.3 
µM of the primers IS5 and IS6 [22] and the 
following thermal profile: a 2-min initial 
denaturation at 95°C, 17 to 20 cycles 
consisting of 15 sec denaturation at 95°C, a 
30-sec annealing at 60°C and a 2-min 
elongation at 68°C, followed by a 5-min final 
elongation at 68°C. The amplified enriched 
library pools were purified using MinElute 
columns (Qiagen) following the 
manufacturer’s protocol and quantified via an 
Agilent 2100 Bioanalyzer DNA 1000 chip. 
All pools were then enriched in a second 
round of hybridization capture using the same 
number of arrays as in the first round. After 
the second round the capture products were 
eluted and subsequently processed as 
previously described with the following 
modification: 48 µl template was used per 
amplification reaction.  
After the enrichment paired-end dual 
indexing sequencing was performed on an 
Illumina HiSeq 2500 platform using 
2*101+8+8 cycles (for the samples GC96F 
and GC96C) and for 2*125+8+8 cycles (for 
the samples JK3187 to JK3195) using the 
manufacturer’s protocols for multiplex 
sequencing (TruSeq PE Cluster Kit v3-cBot-
HS). A second round of sequencing was 
conducted for the samples JK3187 to JK3195 
on an Illumina HiSeq 4000 platform using a 
single-end dual index run with 75+8+8 cycles. 
 
Genome-wide sequencing for the Danish 
samples The sequencing of the six Danish 
samples was carried out on the Illumina HiSeq 
4000 platform at the Institute of Clinical 
Molecular Biology, Kiel University, by 2×75 
cycles using the HiSeq v4 chemistry and the 
manufacturer’s protocol for multiplex 
sequencing. 
 
Data processing for screening analysis The 
data processing after screening for all samples 
was carried out as previously described [9] 
with modifications of using the EAGER 
pipeline [31]. For all samples except the 
Danish ones the processed reads were mapped 
to the three M. leprae loci gyrA, proS, and 
RLEP and characteristic damage profiles were 
calculated for the M. leprae DNA to assess the 
authenticity of the ancient DNA [26, 27].  
For the Danish samples a metagenomics 
analysis using MALT [24] was conducted 
after the processing through the EAGER 
pipeline [31]. In addition, the shotgun data 
was also mapped to the M. leprae TN 
reference genome (RefSeq ID NC_002677.1). 
 
Data processing for genome-wide analysis 
The sequenced reads from all samples 
subjected to genome-wide enrichment were 
analyzed with the EAGER pipeline [31].  
Read preprocessing of sequenced genome 
samples. The first step of the pipeline was 
adapter clipping, read merging and subsequent 
quality trimming using the tool 
"Clip&Merge". For all properly merged reads, 
only the merged consensus sequence was used 
for the subsequent mapping steps. On average 
about 89% of all paired-end reads were 
merged in each sample (see Table S2 for 
detailed results of all samples). For those read 
pairs that could not be merged because the 
overlap region was shorter than 10 nucleotides 
or for which the corresponding read was 
removed during the combined adapter 
clipping and quality filtering step, the 
respective single-end reads were first trimmed 
at the 3’end such that all bases have a Phred 
quality score of at least 20 and then mapped 
individually. 
? ? ??
 ???
Mapping. After adapter clipping, merging and 
quality trimming, the resulting reads for all 
samples were mapped using the M. leprae TN 
genome (RefSeq ID NC_002677.1) as a 
reference. All reads (merged and unmerged) 
were treated as single-end reads and mapping 
was performed using BWA [45] aln/samse 
subcommands, with an error rate (-n) of 0.2 to 
assure high specificity. The PCR duplicates 
were removed with MarkDuplicates from the 
Picard tools 
(https://broadinstitute.github.io/picard). The 
mapping was evaluated with QualiMap [46]. 
Mapping assembly. After mapping and 
duplicate removal, the Genome Analysis 
Toolkit (GATK) [47] was used to generate a 
mapping assembly for each sample that had at 
least 60% genome coverage and a minimum 
of 5 reads per base. For this procedure the 
UnifiedGenotyper module of GATK 
following the GATK Best Practice’s 
Guidelines was applied to call reference bases 
and variants from the mapping. The reference 
base was called if the genotype quality of the 
call was at least 30, the position was covered 
by at least 5 reads and at least 90% of the 
bases at this position agreed with the 
reference. A variant position (SNP) was called 
if the following criteria were met: i) the 
position was covered by at least 5 reads; ii) 
the genotype quality of the call was at least 30 
and III) the minimum SNP allele frequency 
was 90%. If neither of the requirements of a 
reference base call nor the requirements for a 
variant call were met, the character ‘N’ was 
inserted at the respective position. To keep the 
potential introduction of too many ‘N’ 
characters as low as possible in the case of 
low coverage genomes, in cases where a 
position had a coverage between 5-9 reads, the 
major allele was called if it was found in all 
but 1 read. For the generation of draft genome 
sequences we used the VCF2Genome tool, 
also available in EAGER. 
 
Processing of published modern samples. The 
reads for the modern samples S2, S10, S11, 
S13, S14, and S15, which were previously 
published [9], were single-ended. Thus these 
samples were not merged but only adapter-
clipped and quality trimmed. Afterwards the 
reads were treated exactly the same as the 
other samples. Furthermore a correction of the 
country of origin for strain S15 should be 
added in this context: Strain S15 corresponds 
to strain 92041 [48] and it was isolated from a 
lepromatous leprosy patient originally from 
Martinique. The origin of S15 was 
erroneously attributed to New Caledonia in 
Monot et al., 2009 (Monot et al., 2009, 
Supplementary Table S3) and the error was 
subsequently propagated in several 
publications [9, 10, 15, 16]. 
 
Processing of published genomes. In order to 
apply our analysis pipeline also to those 
samples for which complete genomic 
sequences are available in GenBank (Br4923, 
and TN) and Kyoto2 (Matsuoka personal 
communication), we produced artificial reads 
using an in-house tool (Genome2Reads). In a 
tiling approach, we produced reads of length 
150 nucleotides with a tiling offset of 2, 
resulting in an average genome coverage of 
75X. For the resulting samples we applied the 
same mapping, SNP calling and genome 
reconstruction procedure as for the sequenced 
samples in order to obtain consistent and 
comparable results. The genome sequence of 
Mycobacterium lepromatosis (GenBank 
JRPY00000000.1), used as the outgroup for 
the Maximum parsimony tree, was aligned 
against M. leprae using LAST with the 
gamma-centroid option [49]. 
Phylogenetic analyses. For the phylogenetic 
analysis, a SNP alignment based on 1071 
informative positions was generated. This 
alignment contained all positions where a 
SNP was called in at least one sample. 
Positions covered in a negative control [9] 
were excluded from subsequent phylogenetic 
analyses. From the resulting alignment of 
length 1071 bp a phylogenetic tree was 
created with MEGA [50] using the Maximum 
parsimony method, with partial deletion on a 
site coverage cutoff of 80% and 500 
bootstraps. 
 
Dating analysis We estimated divergence 
times and substitution rates by application of 
the Bayesian framework BEAST 1.8.1[36]. In 
this analysis we included all ancient and 
modern strains (Figure 2) except for strain 
S15 because of its extraordinary branch 
length, which is probably due to selection 
pressure from anti-leprosy treatment [9], strain 
SK27 because of its low coverage and strain 
Kyoto2 because raw data was not available 
and quality assessment was therefore not 
possible. We performed two analyses using a 
? ? ??
?????
constant population size coalescent prior [35] 
and a Baysian Skyline model [36] for variable 
population size, respectively. For both 
analyses we applied a lognormal relaxed clock 
and an HKY substitution model. For ancient 
strains tip dates were uniformly sampled from 
dating intervals [9, 17, 18, 20] (samples from 
this study Table S1) whereas for modern 
strains tip dates were set as isolation dates [8-
10, 13-16]. For each model an MCMC run 
was carried out with 300,000,000 iterations 
discarding the first 30,000,000 iterations as 
burn-in. 
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Abstract  
 
Genotyping and molecular characterization of drug 
resistance mechanisms in Mycobacterium leprae enables 
disease transmission and drug resistance trends to be 
monitored. In the present study, we performed genome-
wide analysis of Airaku-3, a multidrug-resistant strain 
with an unknown mechanism of resistance to rifampicin. 
We identified 12 unique non-synonymous single-
nucleotide polymorphisms (SNPs) including two in the 
transporter-encoding ctpC and ctpI genes. In addition, two 
SNPs were found that improve the resolution of SNP-
based genotyping, particularly for Venezuelan and 
South East Asian strains of 
M. leprae. 
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Introduction 
  
 
Despite a massive decline in leprosy prevalence in the last 
two decades, more than 200 000 new cases of leprosy 
are recorded each year globally, indicating active 
transmission of the infection [1]. Drug resistance to one or 
more anti-leprosy drugs has been reported but is rare. As 
the causative agent, Mycobacterium leprae, remains 
uncultivable, molecular drug susceptibility testing offers a 
practical alternative. This involves PCR-sequencing of the 
drug-resistance-determining regions of the rpoB, folP1 and 
gyrA genes associated with resistance to rifampicin, 
dapsone and ofloxacin, respectively [2]. However, a previous 
study described low-levels of rifampicin resistance in M. 
leprae Airaku-3, isolated from a Japanese patient who 
relapsed after multidrug therapy [3]. This strain 
exhibited phenotypic resistance to rifampicin and dapsone 
in a mouse footpad assay. Although the dapsone-resistance 
was attributable to the known folP1 mutation (Thr53Ile), 
Airaku-3 has a wild-type rpoB sequence; hence, an 
explanation for its rifampicin resistance is not available 
[2]. 
Alternative mechanisms of rifampicin resistance have been 
described in various bacterial species, for example, the rox 
gene mediated mono-oxygenation of rifampicin [4] and 
duplication of the rpoB gene as rpoB2 in Nocardia [5]. There is 
no orthologue of rox in Mycobacterium tuberculosis and M. 
leprae. Over-expression of RNA polymerase-binding 
protein A causes low level rifampicin resistance in 
Streptomyces coelicolor [6]. Its M. leprae orthologue 
ML1439 and other relevant genes sigA (rpoT) and sigE were 
all found to be wild-type in our PCR-based analysis. As per the 
M. leprae single nucleotide polymorphism (SNP) -
genotyping scheme [7], Airaku-3 belongs to SNP subtype 1D, 
which is the predominant genotype in many countries like 
Bangladesh, India, Nepal, Madagascar, Malawi and the French 
West Indies [7– 9] and has a significant representation in 
Japan [7], Yemen, Venezuela [10] and the USA [11]. 
However, the genome of only one strain (S11-Inde2 from 
India) of this subtype has been sequenced [12]. Therefore, 
the Airaku-3 strain was selected for genome-wide 
sequencing using the Illumina platform to investigate the 
genetic basis for resistance to rifampicin and to improve 
the resolutionof theexistingSNP-genotypingscheme for M. 
leprae. In our present study, a bacillary suspension 
containing.10E+08 cells of M. leprae Airaku-3 [2] in 
0.1 M NaOH was passed through a 1-mL insulin 
syringe (0.30-mm needle) three to five times, before 
DNA extraction [13]. Library preparation was by the 
TruSeq ChipSeq method (Illumina). Paired-end 
sequencing, with 101 cycles on a HiSeq2000 
instrument provided a total of 174.2 million reads of 
which 25% could be aligned with the M. leprae TN 
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genome [14], yielding > times coverage, using BOWTIE 
[15]. De novo assembly of these reads was performed using 
VELVET [16] with k-mer size of 91. SNPs were identified 
as described previously [7,12] by comparison with the 
other M. leprae strains using PCR sequencing or 
genome comparisons [7,11,12] to identify the unique 
SNPs of the Airaku-3 genome (see Supporting 
information, Tables S1, S2). The phylogenetic trees were 
obtained with SPLITSTREE v.4.13.1 [17] using uncorrected p 
distances, the Neighbour Joining method and 1000 times 
bootstrapping (Fig. 1). 
After de novo assembly of the reads the genome of M. 
leprae Airaku-3 comprised 114 contigs (n50 = 42 Kb) 
covering 98.85% of the TN genome. All the gaps 
corresponded to dispersed repeats. There was no 
evidence of structural variations compared with the M. 
leprae TN reference genome, thereby ruling out genome 
rearrangements or gene duplications as an explanation for 
rifampicin resistance in Airaku-3. Upon comparing the 
genome sequence of Airaku-3 with the M. leprae TN [14] 
reference genome, a total of 114 SNPs were identified. Of 
these, 46 SNPs were not present in any other indicated 
with a *. All bootstrap values are above 87 (average 99). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 1. Phylogenetic relationship of Mycobacterium 
leprae Airaku-3 with other M. leprae genomes [12]. For 
phylogeny, only the genomic positions in which all strains 
[12] had an unambiguous nucleotide call (674 positions) 
were considered. Mycobacterium leprae Airaku-3 is 
placed closest to another subtype 1D strain, S11-Inde2 
from India, both of which share 12 SNPs that were 
absent in any other SNP genotypes. The geographic 
origins and the SNP genotypes are indicated against 
each strain. The ancient strains from Europe are 
indicated with a *. All bootstrap values are above 87 
(average 99). 
M. leprae genomes. These included two non-synonymous 
substitutions in genes with predicted transporter 
function belonging to the P-type ATPase family: 
888973C>T in gene ctpC and 3209207G>A in ctpI. 
These two SNPs were also absent in the remaining M. 
leprae strains (Table S2). 
Airaku-3 shared 12 SNPs with the other SNP-type 1D 
strain S11-Inde2 (Table S1). We analysed two of these 
SNPs (953582C>T and 3262657C>T) in 24 strains 
belonging to SNP subtype 1D from different countries 
(Table S2). SNP 3262657C>T correctly identified all of 
these 1D strains from the remaining 42 strains of other 
genotypes. Furthermore, the SNP 953582C>G 
distinguished the Venezuelan 1D strains (n = 10) from the 
rest of the 1D strains originating from eight different 
countries (Table S2). The 100 bp flanking region of this 
SNP in other mycobacterial outgroup species (M. 
tuberculosis complex, M. avium complex, M. kansassi, M. 
marinum and M. ulcerans) revealed a ‘C’ at the 
corresponding base, thereby defining the ancestral base. 
Therefore, Venezuelan 1D strains with a ‘C’ at position 
953582 are designated as subtype 1D-1 while the 
remaining 1D strains with a derived base ‘G’ are termed 
1D-2. 
Though our present study does not reveal a clear 
explanation for the rifampicin resistance phenotype of 
Airaku-3, it has identified the unique SNPs, including two 
non-synonymous SNPs in transporter genes, ctpC and ctpI. 
However, a functional assay is required to determine 
whether either of these variant genes/transporters confers 
any degree of rifampicin resistance. Other transporters, for 
example, drrA (Rv2936), pstB (Rv0933) 
[18] and Rv1258c [19] reportedly confer low-levels of 
rifampicin resistance in M. tuberculosis. The Airaku-3 
genome revealed no mutations in its drrA (ML2352c) 
whereas the orthologs of the remaining two genes (pstB and 
ML1104c) are pseudogenes in M. leprae. Rifampicin-
resistant M. tuberculosis strains commonly possess 
compensatory mutations in the rpoC gene that restore their 
fitness [20]. This gene has a wild-type sequence in 
Airaku-3. 
The comparative genomics of 1D strains in this study has 
discovered two useful markers: SNP3262657C>T defines 
the 1D genotype while the SNP953582C>G can further 
resolve them into 1D-1 and 1D-2. We have also 
identified a phylogeographic association of the 1D-1 
genotype with Venezuela. These markers can be useful 
for molecular epidemiological studies in many countries 
where leprosy is endemic and the 1D genotype is 
predominant, and can also provide a possible explanation 
? ? ??
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for disease acquisition in other countries where sporadic 
cases are reported in the indigenous population or among 
immigrants or citizens who have lived in areas where 
leprosy is endemic. Previously, we had successfully 
resolved the subtype 3I strains into 3I-1 and 3I-2 using a 
similar approach [11]. Hence, our present study 
further exemplifies the value of genome-wide 
comparisons of a few strains to uncover reliable 
phylogeographic markers that can later be used for rapid 
PCR-based genotyping 
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BRIEF REPORT 
Abstract: Molecular drug susceptibility 
testing was performed on skin biopsies from 
24 leprosy patients from Guinea-Conakry for 
the rst time. We identied primary drug 
resistance in 4 cases and a dapsone-resistant 
cluster caused by the same strain. Primary 
transmission of drug-resistant Mycobacterium 
leprae, including a rifampicin-resistant strain, 
is reported. 
 
Keywords. drug resistance; leprosy; 
Guinea-Conakry.  
 
Despite a remarkable decline in the 
prevalence of leprosy following the World 
Health Organization’s (WHO) global 
implementation of multidrug therapy (MDT) 
in the 1980s [1, 2], well over 200 000 new 
leprosy cases are recorded annually 
worldwide. The incidence rate has stagnated 
since 2005, indicating continuation of active 
transmission of the disease. First-line drugs 
used for MDT against leprosy include 
dapsone, rifampicin, and clofazimine; second-
line drugs include ooxacin, minocycline, and 
clarithromycin. Because of the lack of 
effective alternative antileprosy drugs, 
resistance to the rst-line drugs could 
seriously affect leprosy-control programs. 
The resistance of Mycobacterium leprae to 
antileprosy drugs has been observed in several 
leprosy-endemic regions, which is reported 
by the Global Sentinel Surveillance for Drug 
Resistance in Leprosy program coordinated 
by WHO [3]. 
Drug-resistant leprosy can occur either by 
transmission of a resistant strain (primary 
resistance) or by mutation of the wild-type 
drug-susceptible strain during therapy 
(secondary resistance). Only a few cases of 
primary resistance to dapsone have been 
reported to date [4]. However, primary 
rifampicinresistant cases are more often 
described, and they are a cause of concern 
due to the limited availability of second-line 
drugs for leprosy [4]. 
Leprosy is endemic in Guinea-Conakry; 
313 cases were reported in 2014, making it a 
country with a moderate leprosy burden. No 
information about drug resistance in this 
region is available. Our aim was to obtain a 
preliminary estimation of the drug-resistance 
levels between relapses and primary leprosy 
cases from Guinea-Conakry using molecular 
methods. 
DNA was extracted from ethanol-xed skin 
biopsy specimens using the “freeze-boiling” 
method. The presence of mutations in drug 
resistance–determining regions (DRDRs) of 
rpoB, folP1, and gyrA genes, associated with 
rifampicin, dapsone, and quinolone 
resistance, respectively, was tested using M. 
leprae DRDR primers and a polymerase 
chain reaction (PCR) sequencing method [5]. 
Sequences obtained from the ABI3130xl 
genetic analyzer (Thermo Fisher Scientic, 
Waltham, Massachusetts) were aligned onto 
the M. leprae Tamil Nadu (TN) reference 
strain sequence using CodonCode Aligner 
software (Dedham, Massachusetts) in order 
to identify mutations. 
We performed whole-genome sequencing 
of 3 samples. For this, an additional biopsy 
was rst digested using collagenase/ dispase 
(Roche, Switzerland) and trypsin 
(AppliChem, Germany); DNA was extracted 
with the QIAmp microbiome kit (Qiagen, 
Netherland) using an adapted method. 
Briey, after human cell lysis and DNase 
treatment, bacilli were lysed with a mixture of 
20 mg/mL of proteinase K (Qiagen, 
Netherland) and lysozyme (Sigma, St Louis, 
Missouri) prior to DNA purication on silica-
based columns. DNA samples were 
subsequently sonicated to 400 bp-long 
fragments using S220 Covaris instruments. 
Illumina libraries were prepared using the 
Kapa hyper prep kit (Kapa Biosystems, 
Wilmington, Massachusetts) with the 
PentAdpters (Pentabases, Denmark) indexed 
adapters. After quality control (library 
concentration and fragment analyzer), 
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libraries were multiplexed and sequenced as 
100 base-long single-end reads on an 
Illumina HiSeq 2500 instrument. Raw reads 
were adapter trimmed and quality trimmed 
with Trimmomatic v0.33 [6] and mapped onto 
the M. leprae TN reference genome (NCBI 
a.n. AL450380.1) with Bowtie2 [7] (version 
2.2.5) followed by variant calling using 
VarScan v2,3,9 [8]. Single nucleotide 
polymorphisms (SNPs) were called after 
applying quality checks, namely, a minimum 
overall coverage of 5 nonduplicated reads, a 
minimum of 3 nonduplicated reads supporting 
the SNP, a mapping quality score >8, a base 
quality score >15, and a SNP frequency above 
80%. These cutoffs were chosen to avoid 
false positives. For phylogenetic analysis, the 
SNP type and subtype were inferred using the 
SNP-typing system described by Monot et al as 
well as the variable number of tandem repeats 
(VNTRs) prole [9, 10]. Finally, comparative 
genomics was performed on the 3 strains to 
identify unique and shared variants. 
Phylogenetic analysis was done as described 
by Schuenemann et al [11]. Illumina reads of 
M. leprae can be accessed from the Sequence 
Read Archive database (National Center for 
Biotechnology Information) under accession 
numbers SRX1677242 (Ml2-10), 
SRX1677243 (Ml6-50), and SRX1677244 
(Ml6-55). 
A total of 24 samples were collected 
between 2012 and 2015, including 1 from a 
relapse case with no history of monotherapy 
(Table 1) and 23 from new cases. Patients 
originated from regions of Boke (n = 4), 
Faranah (n = 2), Nzérékaré (n = 1), Mamou 
(n= 1), Kankan (n= 3), and Kindia (n = 13). 
There were 16 males and 8 females. All 
patients were multibacillary (MB) cases 
including 6 with grade 2 disabilities. The 
bacillary index ranged from 1+ to 6+ but was 
not available for 6 patients. MDT was 
prescribed for 12 months according to the 
WHO recommendation for MB leprosy. 
PCR sequencing of DRDRs revealed a 
mutation in rpoB codon 456 (Ser(TCG) ? 
Leu(TTG)) in 1 primary case. The patient was 
a male from Boke who presented with 
anesthetic patches on the back and trunk. A 
history of leprosy within the family was not 
available. This mutation has been associated 
with high-level rifampicin-resistant leprosy 
[3]. In addition, a missense mutation at codon 
53 in folP1 (Thr(ACC) ? Arg (AGA)) 
associated with dapsone-resistant leprosy was 
observed in 3 primary cases [3]. This 
dinucleotide mutation has been reported in 
clinical specimens from India and the 
Philippines (relapse case) as conferring high 
or intermediate resistance levels [12, 13]. 
This mutation has not been identied 
elsewhere. No mutations were identied in 
the gyrA DRDR associated with ooxacin 
resistance (Table 1). 
We investigated the 3 cases with the same 
folP1 mutation in more detail. The 3 patients 
shared the same prefecture of residence, 
Mandiana, in the Kankan region in the eastern 
part of the country. They all had MB leprosy 
and were diagnosed in 2011 (patient Ml2-10) 
and 2013 (patients Ml6-50 and Ml6-55). In 
addition, Ml2-10 and Ml6-55 were siblings; 
however, we could not establish contact with 
case Ml6-50.   
Table 1. Results of the Drug-Resistance 
Surveillance in the GuineaConakry 
 
Drug Resistance New 
Cases 
Relapse 
Cases 
Mutation in rpoB 
(Ser456Leu) 1 
0 
Mutation in folP1 
(Thr53Arg) 3 
0 
Mutation in gyrA 0 0 
Drug susceptible 19 1 
Total 23 1 
 
We obtained sufcient whole genome read 
coverage (54-58X) for the 3 strains for 
downstream analyses. All 3 strains belonged 
to SNP type 4N,which is a common genotype 
in West Africa and Brazil [9]. Phylogeny 
based on whole genome SNP alignments 
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unambiguously placed the 3 strains in 1 
individual subbranch compared with the 
previously published M. leprae genomes 
[14]. We identied only 2 SNPs between the 
3 genomes: 1 SNP was found in Ml2-10 but 
not in Ml6-50 and Ml6-55 and 1 SNP was 
found in Ml2-10 and Ml6-55 but not in Ml6-
50. In addition, we analyzed 31 microsatellite 
and 11 minisatellite loci in the 3 resistant 
strains and compared them with the VNTR 
proles of S13, Thai-53, Airaku-3, and 
Zensho-4 strains, respectively, genotypes 
4N, 1A, 1D, and 3K [10, 11]. The 3 strains 
displayed the same VNTR prole 
(Supplementary Tables 1 and 2) except for 4 
microsatellites loci (G)11, (G)12, (C)20, and 
(AGA)20 (Supplementary Table 1), thus 
corroborating the SNP analysis. From such a 
low level of sequence diversity we conclude 
that the 3 patients had been infected with the 
same strain and that Ml6-50 is ancestral to 
Ml2-10 and Ml6-55. However, the 
chronology of diagnosis in these patients 
does not t with the ancestry of the SNPs, 
since patient Ml2-10 developed leprosy a few 
years before the other 2 cases. While it is 
possible that the 3 patients contracted the 
disease from different sources, there is a 
theoretical possibility that Ml2-10 
contracted leprosy from either Ml6-50 or, 
more probably, from his/her sibling Ml6-55 
before the onset of symptoms in the 
transmitter. This is an important notion 
because the mechanism of leprosy 
transmission is still obscure, and it is 
unknown at which stage of the disease a 
person becomes infectious. 
Previous transmission studies of human 
and animal reservoirs of M. leprae showed a 
low level of sequence diversity between 
strains from the same geographical area (<3 
SNPs) [15]. With the high resolution of 
whole-genome sequencing applied in this 
study, we unambiguously conrmed that the 
same dapsone resistant strain was the 
causative agent of 3 leprosy cases in the area 
of Kankan in Guinea-Conakry. 
Overall, our ndings show, for the rst 
time, cases of primary dapsone and 
rifampicin resistance in West Africa. 
Although dapsone resistance is not 
considered a major threat for leprosy 
control, such cases are a good 
epidemiological indicator of active 
transmission of the disease. In addition, our 
results highlight the interest for a pilot study 
on adherence to MDT in endemic countries. 
National programs frequently use 
selftreatment by the patient with the 
assistance of families when supervised 
treatment is not possible. It is likely in the 
case of self-treatment that adherence is less 
effective than when patients are supervised 
by healthcare workers. Finally, the 
discovery of rifampicin-resistant strains, 
like the one reported here, is a bigger 
concern due to the limited alternatives in 
leprosy treatment of rifampicin-resistant 
cases. 
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Chapter 4.3 – Whole genome sequencing distinguishes 
between relapse and reinfection in recurrent leprosy 
cases 
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ABSTRACT 
BACKGROUND 
Since leprosy is both treated and controlled 
by multidrug therapy (MDT) it is important 
to monitor recurrent cases for drug resistance 
and to distinguish between relapse and 
reinfection as a means of assessing 
therapeutic efficacy. All three objectives can 
be reached with single nucleotide resolution 
using next generation sequencing and 
bioinformatics analysis of Mycobacterium 
leprae DNA present in human skin. 
METHODOLOGY 
DNA was isolated by means of optimized 
extraction and enrichment methods from 
samples from three recurrent cases in leprosy 
patients participating in an open-label, 
randomized, controlled clinical trial of 
uniform MDT in Brazil (U-MDT/CT-BR). 
Genome-wide sequencing of M. leprae was 
performed and the resultant sequence 
assemblies analyzed in silico. 
PRINCIPAL FINDINGS 
In all three cases, no mutations responsible 
for resistance to rifampicin, dapsone and 
ofloxacin were found, thus eliminating drug 
resistance as a possible cause of disease 
recurrence. However, sequence differences 
were detected between the strains from the 
first and second disease episodes in all three 
patients. In one case, clear evidence was 
obtained for reinfection with an unrelated 
strain whereas in the other two cases, relapse 
appeared more probable.  
CONCLUSIONS/SIGNIFICANCE 
This is the first report of using M. leprae 
whole genome sequencing to reveal that 
treated and cured leprosy patients who remain 
in endemic areas can be reinfected by another 
strain. Next generation sequencing can be 
applied reliably to M. leprae DNA extracted 
from biopsies to discriminate between cases 
of relapse and reinfection, thereby providing 
a powerful tool for evaluating different 
outcomes of therapeutic regimens and for 
following disease transmission.  
 
AUTHOR SUMMARY 
Leprosy, one of the most ancient human 
infectious diseases, affects skin and nerves 
and is caused by Mycobacterium leprae 
infection. Despite the effective use of 
multidrug therapy/MDT since the 80´s, over 
200,000 new cases are reported yearly, 
indicating active transmission, especially in 
India and Brazil. Although rare, recurrent 
clinical manifestations after MDT can occur 
due to leprosy reactions, relapse by drug 
resistance, insufficient treatment or 
reinfection. Relapse and reinfection cannot be 
differentiated clinically and molecular 
genotyping of a predefined set of loci have 
limited resolution due to exceptional M. 
leprae genome conservation and low 
sequence diversity between strains from the 
same geographical area. This is the first 
report that has compared whole genome 
sequences of M. leprae strains from original 
and recurrent leprosy episodes. M. leprae 
genome differences were detected between 
the strains from the first and second episodes 
in the three patients. In one patient, there was 
clear evidence for reinfection with an 
unrelated strain whereas the other two were 
considered true relapses due to minor strain 
differences. No known drug resistance 
mutations were detected, excluding drug 
resistance as the recurrence cause. Next 
generation sequencing of M. leprae DNA 
discriminates relapse from reinfection 
representing a powerful tool for evaluating 
different disease outcomes and transmission. 
 
Introduction 
Leprosy is a complex dermato-neurologic 
and systemic disease [1] primarily caused by 
Mycobacterium leprae or to a much lesser 
extent by Mycobacterium lepromatosis.[2] 
Despite a strong decrease in leprosy 
prevalence since the systematic 
implementation of multidrug therapy (MDT) 
in the 1980’s, the incidence of disease, the 
major indicator of active transmission, remains 
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high in many countries, especially in India and 
Brazil, showing that transmission continues 
unabated.[3] Overall, more than 200,000 new 
leprosy cases are reported each year 
worldwide.[3] 
The MDT regimen for leprosy consists of 
different antibiotic combinations that are 
prescribed based on the number of skin 
lesions: a six-month regimen of rifampicin 
and dapsone for paucibacillary (PB) patients 
(<5 skin lesions) and a twelve month regimen 
of rifampicin, dapsone and clofazimine for 
multibacillary (MB) patients (>5 skin 
lesions).[4] In 2002, WHO proposed that a 
uniform MDT regimen (U-MDT) should be 
considered to treat all types of leprosy in order 
to facilitate leprosy control. In 2007, an open-
label randomized and controlled clinical trial 
(uniform multidrug therapy for leprosy 
patients in Brazil, U-MDT/CT-BR) was 
initiated to compare U-MDT with the regular 
MDT for PB and MB patients.[5, 6] Clinical 
monitoring is still taking place with special 
emphasis on disease recurrence and leprosy 
type 1 and type 2 reactions (T1R/T2R). 
An increased relapse rate and the possible 
emergence of drug resistance are major 
concerns for the shortened MDT proposal for 
MB patients. It is therefore important to 
address this issue by analyzing in depth all 
recurrent cases from the U-MDT/CT-BR trial. 
Molecular genotyping techniques, such as 
typing selected single nucleotide 
polymorphisms (SNP) or counting variable 
number tandem repeats (VNTR) have been 
used to differentiate reinfection from relapse. 
[7–11] However, the resolution of such 
techniques is often limited because of the 
exceptional level of genome conservation in 
M. leprae and the limited sequence diversity 
between strains from the same geographical 
area in particular.[12] In contrast, genome-
wide approaches provide higher resolution 
and accuracy compared to genotyping based 
on a predefined set of loci, but are technically 
more complex. High throughput sequencing is 
becoming increasingly efficient and cost-
effective with purified DNA but is more 
challenging with clinical specimens such as 
DNA extracted directly from skin biopsies, 
especially from formalin-fixed 
paraffinembedded (FFPE) samples. 
In this study, we investigated three 
recurrent cases of leprosy from the U-
MDT/CT-BR trial to determine whether 
recurrence was due to drug resistance, 
bacterial persistence or to reinfection. To 
achieve this, we compared whole genome 
sequencing analysis of M. leprae collected 
from skin lesions at the initial diagnosis and 
during the recurrence of the disease and 
correlated the sequence data with the 
clinical, microbiologic and serologic 
findings. 
Methods 
Ethics statement 
This study was approved by the regional 
research ethical committees, by the National 
Committee for Ethics in Research (CONEP, 
National Health Council/ Ministry of Health, 
Brazil, protocol # 001/06) and by the human 
and animal research ethics committee from the 
Federal University of Goia´s 
(CEMHA/HC/UFG protocol # 166/2011). 
Written informed consent was obtained from 
all adult subjects and a parent or guardian of 
participants under the age of 18 years, 
provided informed consent on their behalf 
prior to inclusion in the study 
(ClinicalTrials.gov identifier: NCT00669643). 
Study design 
Three recurrent cases of leprosy identified 
in the U-MDT/CT-BR trial were investigated 
(Table 1). Clinical diagnosis and monitoring 
were carried out at the National Reference 
Canter in Ceara´ state, Northeast Brazil. 
Leprosy diagnosis was confirmed by 
bacteriological analysis of slit skin smears 
and by histopathological examination of 
biopsies taken from active skin lesions.[6] At 
the first visit, patients had a complete 
dermato-neurological examination by a 
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dermatologist with expertise in leprosy 
diagnosis, when the number and the body 
distribution of skin lesions and affected 
nerves were registered. Biopsy of skin lesion, 
venous blood and skin smear material from 
six sites for bacilloscopy were collected. 
During the clinical monitoring, patients 
attended the established schedule for 
clinical/laboratory monitoring (monthly 
appointment during the first year and 
thereafter, yearly). All patients were advised 
to return to an urgent appointment at the 
reference center in case any discomfort or 
new clinical manifestation appeared. In this 
study, the following case definitions for 
leprosy reactions were employed: T1R was 
defined as an acute clinical manifestation, 
usually characterized by the exacerbation of 
pre-existing lesions, or the appearance of 
new lesions. T2R was characterized by the 
sudden appearance of tender erythematous 
skin nodules (erythema nodosum 
leprosum/ENL) mainly accompanied by 
fever and other systemic symptoms such as 
joint pain, bone tenderness, neuritis, edema, 
malaise, anorexia with or without 
lymphadenopathy. In the clinical diagnosis 
of reactions, skin signs were obligatory, 
nerve and systemic signs were 
noncompulsory while neuritis, malaise, and 
fever could be present in both types of 
reaction. Treatment for leprosy reactions 
followed the guidelines from the Brazilian 
Ministry of Health. 
Patients with clinical manifestations not 
fulfilling these previously described criteria 
were considered suspected cases of relapses 
and were clinically examined by the assistant 
dermatologist, by the PI (GOP) and by an 
expert member of the independent steering 
committee (Dr. Sinesio Talhari). 
Additionally, in these patients skin smears 
and biopsies were collected from new lesions 
and used to investigate drug susceptibility 
(inoculation in BALB/c mice, sequencing of 
the rpoB, folP1, gyrA and gyrB genes and 
whole genome sequencing). 
As part of the U-MDT/CT-BR trial, a 
well-prepared biobank of biopsies from 
leprosy skin lesions and serum samples, 
collected at various time points during 
treatment and monitoring, was assembled 
and has been properly maintained at 
recruitment sites and an extra back-up has 
been kept at the coordination center. For this 
study, we used skin biopsies from the first 
episode that were formalin-fixed and 
paraffin-embedded to allow long-term 
storage and serum samples collected at 
diagnosis and at various time-points during 
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and after treatment (Table 1 and S1 Table). 
Serum IgM antibodies to M. leprae-specific 
PGL-1 antigen (0.01?g/ mL NT-P-BSA) and 
serum IgG antibodies to the synthetic LID-1 
(1?g/mL LID-1) antigen were detected by 
enzyme-linked immunosorbent assay 
(ELISA).[13, 14]  
Patients showing recurrent symptoms 
after treatment had biopsies taken from new 
lesions (Table 1 and S1 Table), which were 
used as the source of M. leprae for drug 
susceptibility testing in BALB/c mice [15] 
(treated with dapsone, rifampicin or no drug) 
and for partial [16] and whole genome 
sequencing. 
DNA extraction from tissue 
A truXTRACTM FFPE DNA kit (Covaris) 
was used following the manufacturer’s 
recommendation with some optimization. 
Briefly, ten 20?m FFPE tissue sections for 
each sample were pooled in a screw-cap 
microTUBE in duplicate or triplicate. 
Paraffin was removed and the tissue 
rehydrated with 100?l of tissue SDS buffer 
using a focused-ultrasonicator series S2 with 
the following settings: intensity = 5, cycles 
per burst = 200, time = 300s, temperature = 
20C. Digestion was done using a 40?l 
mixture of proteinase K (20 mg/ml) and 
lysozyme (10 mg/ml) using a focused-
ultrasonicator with the same settings as above 
except for the time set at 10s. 
Digestion occurred at 56C overnight 
followed by 1 h at 80C to reverse the 
formaldehyde crosslinks. Finally, DNA was 
isolated from lysates using the columns of 
the truXTRAC FFPE DNA kit and eluted in 
50?l of Covaris BE buffer. DNA was 
quantified using a Qubit fluorometer 
(ThermoFisher). For samples 1126–2011 and 
2188–2014, which had been passaged in 
mice, DNA was extracted from mouse 
footpad suspensions then sheared to ~600 bp 
by ultrasonication and purified with AMPure 
beads, before library preparation. 
The quantity of DNA was assessed after 
each critical step i.e. DNA extraction, library 
preparation and amplification post-array 
capture (S2 Table). Since the quality of 
DNA is known to be low after FFPE 
extraction, we did not fragment the DNA 
with the Covaris method as it was already 
fragmented nor did we size select our 
libraries to avoid losing too much DNA. 
Library preparation and sequencing 
DNA from each extract was used to 
prepare Illumina libraries using a Kapa 
Hyper Prep kit (Kapa Biosystem) as 
described elsewhere.[17] To remove host 
DNA from the libraries, we used a custom-
synthesized oligonucleotide array (Agilent) 
spanning the entire M. leprae genome.[18] 
Quality of the captured and re-amplified 
library was assessed using the Fragment 
Analyzer system (Advances Analytical 
technologies, Inc). The size of the captured 
library was 180bp and the concentration 
52ng/?l. Sequencing was performed on an 
Illumina Hi-Seq 2500 instrument. 
Sequence analyses 
Raw reads from the same sample were 
merged and processed as described elsewhere 
[17] by adapterand quality-trimming and 
alignment with the M. leprae TN reference 
genome (NCBI a.n. AL450380.1). To avoid 
false positive SNP calls the following cutoffs 
were applied: minimum overall coverage of 5 
non-duplicated reads, minimum of 3 non-
duplicated reads supporting the SNP, 
mapping quality score greater than 8, base 
quality score greater than 15 and a SNP 
frequency above 80%. 
SNPs and short insertions and deletions 
(InDels) were compared between index and 
second episodes for each recurrent case. 
Unique sets of SNPs for each genome were 
established by comparison with the list of 
SNPs from 20 M. leprae genomes published 
elsewhere (S3 Table). [9, 18, 19] All unique 
and/or discriminatory variants were manually 
visualized using the IGV browser [20] to 
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check for possible alignment inconsistencies. 
We additionally genotyped all samples using 
the SNP model described in Monot et al. and 
inferred in silico the VNTR copy number for 
33 out of 44 known VNTR loci (11 loci were 
too large to be spanned with Illumina reads). 
[9, 11, 21] 
Results 
Demographics and diagnosis 
The U-MDT/CT-BR study initially 
enrolled 858 patients of whom 78.4% were 
classified as MB. During follow-up, four of 
the treated patients presented with new 
symptoms between four and eight years after 
completion of U-MDT and three of these 
were re-investigated in this study. These 
participants were three young male leprosy 
patients (# 1126, 2188 and 3208) from 
Fortaleza, Ceara´, Northeast Brazil, an
endemic city for leprosy. The main clinical 
and laboratory characteristics of these three 
patients with recurrent signs of leprosy after 
U-MDT are shown in Table 1. In all three 
cases, leprosy was first diagnosed in 2007 
but the patients displayed new clinical signs, 
which were not associated with leprosy 
reactions, between 2011 and 2015. 
In these three patients, original leprosy 
skin lesions detected at diagnosis, 
disappeared after specific treatment and upon 
suspicion of relapse/reinfection, new skin 
lesions were observed in previously 
unaffected body areas. The timelines of 
clinical events presented by these patients 
during follow up (S1 Fig) highlight their 
high propensity to develop leprosy reactions, 
especially T2R, although all of them also 
developed T1R. These records also 
demonstrate that leprosy reactions and 
relapse/reinfection occurred at different time 
points. The timelines also illustrate the 
evolution of bacilloscopic index (BI) during 
follow up. In one case, the BI at the second 
episode was higher than the BI at the first 
episode. 
In addition, the first diagnosis revealed that 
the three MB patients showed high IgM and 
IgG antibody levels to PGL-1 and LID-1 
antigens, respectively (S1 Fig). Since these 
biomarkers have been used to monitor the 
disease state, we measured antibody levels by 
ELISA before, during and after U-MDT. 
Overall, the antibody titers gradually declined 
but remained above the threshold for 
positivity for at least one of the antigens 
during the study period except for patient 
1126. This patient showed an antibody titer 
below the threshold just before the recurrence 
of the disease (39 months after U-MDT) and 
then both antibody titers increased by the time 
of recurrent disease. By contrast, despite 
oscillating levels of PGL-1 antibody for 3208, 
Figure 1: Summary of the whole genome sequencing analysis (WGS) between the M. leprae strains investigated at the 1
st
 
and 2
nd
 disease occurrences. 
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antibody titers, especially to LID-1, remained 
high for 3208 and 2188 during the entire 
study period. 
Drug susceptibility results 
M. leprae from the recurrent lesions 
(1126–2011, 2188–2014) was inoculated into 
mice and only multiplied in the untreated 
animals, indicating that the bacilli were 
viable but susceptible to dapsone and 
rifampicin. It was not possible to inoculate 
mice with the sample from 3208– 2015. 
Analysis of the rpoB, folP1, gyrA and gyrB 
genes revealed a wild-type sequence in all 
six strains, confirming susceptibility to 
rifampicin, dapsone, and fluoroquinolones, 
respectively, in all cases. 
Whole-genome analysis 
Sufficient whole genome read coverage 
was obtained from the six M. leprae samples 
for genotyping and comparative genomic 
analyses (S4 Table). 
The recurrent strain 1126–2011 was 
clearly distinct from the primary strain 
1126–2007, and differed in 44 SNPs, 4 
InDels and 6 VNTR loci (Fig 1 and S5 
Table). Furthermore, 1126– 2007 and 1126–
2011 share no SNPs that might indicate 
close relatedness or direct ancestry. 
Strains 3208–2007 and 3208–2015 
differed in only two SNPs and one VNTR 
locus (Fig 1 and S5 Table). Both SNPs 
(T1740863C in an intergenic region and 
C1803024T in a pseudogene) were present in 
3208–2015, indicating that 3208–2015 was 
certainly the direct progeny of 3208–2007. In 
addition, eight unique variant nucleotides 
were restricted to these two samples 
(compared to the SNPs from 20 previously 
published M. leprae genomes [9, 18, 19] and 
those from this study), confirming the 
identity of the strains (S6 Table). 
Interestingly, a cluster of three SNPs leads to 
missense mutations, in codons 495 and 496 
of asn1, encoding an Lasparagine permease, 
which contributes to virulence in 
Mycobacterium tuberculosis [22]. Analysis 
of 2188–2007 and 2188–2014 revealed 
identical genome sequences (Fig 1). 
Curiously, both strains belong to a new SNP 
subtype intermediate between subtypes 4N 
and 4O. The only difference between the two 
genomes was found in the (GTA)9 VNTR 
locus (S5 Table), which harbored 11 repeats 
in 2188–2007 and 12 repeats in 2188–2014. 
Genome comparisons revealed that both 
strains share 28 unique variant nucleotides 
(S7 Table). Among them are two missense 
mutations in ML0411, encoding a PPE 
protein and in ribD (ML1340), the riboflavin 
biosynthesis protein. An insertion of 9 
nucleotides (GGACATCTA at position 
1,219,061) was found in ML1052, a putative 
PucR-like transcriptional regulator, which 
leads to a modification of the protein. 
Interestingly this mutation was present at 
only 30% frequency in 2188–2007, while it 
was fixed in 2188–2014. 
Another frame-shift arising from a 
dinucleotide insertion was found in 
ML0825c, the ortholog of rv2358 in M. 
tuberculosis that codes for the protein SmtB, 
a zinc-sensing transcriptional regulator and 
member of the AsrR/SmtB family.[23, 24]. 
The C-terminal part of SmtB is essential for 
the protein dimerization, zinc binding and 
DNA recognition. Furthermore, a specific 
histidine residue (H138 in ML0825c and 
H117 in Synechococcus StmB) is important 
for the allosteric coupling of the zinc and 
DNA binding sites in the protein.[25] 
Modeling of M. leprae StmB in silico (S2 
Fig) showed that the frame-shift leads to loss 
of H138 and should thus impair protein 
function. 
 
Discussion 
The relapse rate is considered to be the 
most important indicator of the efficacy 
of a given MDT. On the other hand, 
reinfection is an indicator of active 
transmission and the susceptibility of 
leprosy convalescents to new infections. 
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This investigation provided a unique 
opportunity to apply high-resolution whole-
genome tools to differentiate relapse from 
reinfection and to evaluate the impact of U-
MDT on antibody levels to two M. leprae 
antigens. MDT affects both cellular and 
humoral M. leprae specific immunity. In MB 
patients, there is a decline in antibody levels 
during MDT and patients remain unable to 
mount a protective Th1 type immunity to M. 
leprae after treatment.[26] Levels of 
antibodies to PGL-1 and LID-1 were high in 
all three MB cases at diagnosis, then 
declined during and after treatment but 
nonetheless remained above the cut-off point 
for positivity, especially antibodies to LID-1. 
Our data is in accordance with previous 
studies showing decay in antibody titers 
while sero-reversion is rare in leprosy 
patients after regular MDT [26, 27]. By the 
time of recurrent disease, the antibody titers 
to at least one of the antigens had risen. In our 
study, patients were carefully monitored for 
treatment compliance and all completed the 
U-MDT treatment. 
In our study the three MB patients had 
several episodes of leprosy reactions during 
follow up including T1R and mainly T2R, in 
accordance with the reports showing 
increased propensity of MB patients to 
develop reactions. [28, 29] In fact, several 
studies have shown that in some endemic 
areas the occurrence of T1R in BL/LL 
patients is higher than T2R. A study about 
risk factors for leprosy reactions in patients 
from three endemic countries (Philippines, 
Nepal, Brazil) showed that among all LL and 
BL patients, T1R was more frequent than 
T2R. Another study from Thailand showed 
that T2R was slightly more prevalent than 
T1R in lepromatous patients. [31] T1R 
primarily affects immunologically unstable 
borderline patients (BL, BT, BB), while 
although sporadic, it also occurs in LL 
patients. T1R is characterized by an 
increased inflammatory Th1-type cell-
mediated immunity in pre-existing skin 
lesions and systemically, in serum and in 
circulating leukocytes. The capacity of 
BL/LL patients, who have a predominant 
Th2 response, to develop T1R was elucidated 
by studies showing leukocytes with a Th0 
profile that produce IFN?, IL2 and IL4 or a 
polarized shift to Th1 type response with 
IFN? and IL-12p40 mRNA in lesional skin 
and in leukocytes. [32, 33] 
In both leprosy and tuberculosis, host genetic 
factors and immunological mechanisms 
determine the outcome of infection so that 
susceptibility varies among individuals. Case 
1126 was unambiguously identified as 
reinfection because of the extensive 
polymorphisms between the two strains. 
Reinfection has long been suspected as a 
cause of new leprosy episodes and it has 
been suggested that individuals who have 
already had leprosy are more likely to be 
reinfected after treatment due to their 
inherent immunogenetic susceptibility.[34–
36] Around 30% of relapse cases in Recife, 
northeast Brazil, were reported to be in 
contact with other leprosy patients and more 
often from the same family or household.[8] 
Leprosy case 1126 is an example of “family 
disease”, because both of the patient’s parents 
had leprosy around five years before his 
diagnosis, his daughter and partner had PB 
leprosy and the partner’s cousin, who lives in 
the same household, was diagnosed with MB 
leprosy but failed to complete MDT due to 
alcohol addiction. 
The extremely limited genomic variability 
detected between strains from the same 
geographical origin poses a challenge in 
distinguishing between relapse or reinfection 
with a closely related strain. In a recent 
paper, Avanzi et al. showed that a strain 
infecting three patients in the same region of 
Guinea Conakry differed in only two SNPs 
[17] and four VNTRs. In our study, two 
SNPs and one polymorphic VNTR were 
found. While individual VNTRs carry 
virtually no ancestral information due to the 
risk of homoplasy and mutation reversion, 
the fact that only two SNPs were found 
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strongly indicates that the recurrent strain 
was directly derived from the original 
infection. It should be recalled that in our 
study skin biopsies were taken from two 
different lesions in different body areas. 
Likewise, in the case of 2188 only one 
polymorphic VNTR locus distinguished 
between the first and the recurrent infection, 
and the absence of SNPs confirms the 
strain’s identity. Furthermore, there was no 
history of leprosy in either patient 3208’s or 
2188’s households, and both patients had 
high antibody titers during the study period 
suggesting continued immunological 
stimulation by bacterial antigens after 
treatment. Therefore, based on the genomic 
analysis, the patients’ epidemiologic history 
and serological data, we consider that the 
recurrence of leprosy in both patients 3208 
and 2188 was due to relapse. 
Leprosy presents a variable incubation 
period which can range from 2–15 years. 
Although more prevalent in adults, leprosy 
also occurs in children <15 years, with 
reports of cases in patients younger than 1 
year of age [37] indicating at least in 
children, short incubation period of the 
disease. However, nothing is known about 
the incubation period of reinfection, 
especially in genetically susceptible 
individuals who remain exposed to the bacilli 
in endemic areas. In this study, the 
reinfection case was observed 4 years after 
the conclusion of treatment, indicating a 
relatively short incubation period but which 
is in accordance with the reported range of 
the incubation period of the disease. The 
availability and larger use of whole genome 
sequencing studies of M. leprae in recurrent 
leprosy and leprosy reinfection can clarify 
the duration of incubation period in such 
cases. Further investigations of other such 
cases will give us a more definitive picture of 
characteristics of reinfection. 
It is theoretically possible that the original 
infection in leprosy could involve more than 
one strain of M. leprae and, that the 
recurrence could be a relapse due the 
regrowth of one of the sub-populations of M. 
leprae, that had been under-treated by the 
first course of MDT. However, although 
possible, in our study this probability was 
implausible, since in all three patients 
investigated, including the reinfection case, 
genomic sequences of the M. leprae strains 
responsible for the original infections showed 
no mutation associated with drug resistance. 
Therefore, even if the original infection had 
involved more than one strain of M. leprae, 
these strains were MDT susceptible. 
To conclude, this study is the first to 
demonstrate that it is possible to differentiate 
reinfection from relapse in leprosy in a field 
setting with a follow up period extended to 
eight years. This provides a proof-of-concept 
and emphasizes the value of whole genome 
sequencing in clinical follow up of leprosy. 
Importantly, the extended observation period 
allowed identification of relapses/reinfection. 
M. leprae grows very slowly and has a 
relatively long incubation time, so shorter 
periods of monitoring would be unlikely to 
provide sufficient clinical evidence to 
suspect relapse or reinfection. Also the two 
relapse cases in this study exemplify the 
superiority of whole-genome sequencing 
over genotyping a limited subset of loci or 
VNTR typing. For instance, the current SNP 
genotyping scheme can only detect distinct 
M. leprae lineages [9], which is not useful 
for analyzing closely related strains. VNTRs 
can distinguish such strains but do not reflect 
the overall genetic distance (Fig 1) nor 
convey information about strain ancestry. 
Improvements in sample preparation have 
made whole-genome sequencing more 
applicable routinely and we expect that 
recent technological advances will culminate 
in sequencing platforms that can be used to 
deliver whole genome coverage at the point 
of diagnosis within days of seeing the 
patient.[38] 
All raw sequence read files have been 
deposited in the trace archive of the National 
Center for Biotechnology Information 
Sequence Read Archive under accession no. 
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SRP078228. 
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S1 Table. Patient samples used for 
sequencing whole genome of M. leprae 
strains. FFPE: formalin fixed paraffin 
embedded skin biopsy—MFP: mouse 
footpad bacilli suspension.  
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extraction from the FFPE biopsy samples and 
MFP samples and after library preparation. 
FFPE: formalin-fixed paraffin-embedded; 
MFP:mouse foot pad; LOD: limit of detection.  
S3 Table. List of 20 M. leprae genomes 
used to infer unique SNPs in recurrent 
cases. SNP: single nucleotide 
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genome sequences. 1 Fraction of total 
reads that aligned to the reference 
genome TN.  
S5 Table. Allelic diversity of VNTR loci 
in the recurrent leprosy cases. VNTR: 
variable number tandem repeats; NA: not 
available because of low coverage at that 
locus; mixture of multiple alleles; loci 
where VNTR number varied between the 
first and second strain are highlighted.  
S6 Table. Specific SNPs restricted to 3208–
2007 and 3208–2015 strains compared to 24 
other M. leprae genomes. SNP: single 
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S7 Table. List of 28 unique SNPs in strains 
2188–2007 and 2188–2014. SNP: single 
nucleotide polymorphism. 1At 30% 
frequency in 2188–2007. 
S1 Fig. M. leprae specific anti-phenolic 
glycolipid 1 (PGL-1) immunoglobulin M 
(IgM) and anti-LID-1 IgG serology and 
timelines of clinical events and BI evolution 
of multibacillary (MB) leprosy patients that 
had recurrent disease after treatment. 
Serological data and timelines of clinical 
events and bacilloscopic index (BI) evolution 
are depicted in panels A-F: patient # 1126 (A, 
B); patient # 3208 (C, D); patient # 2188 (E, 
F). The first serum sample was collected at 
diagnosis before treatment and sequential 
samples were collected monthly during 
treatment and at different times during the 
follow-up as indicated. 
S2 Fig. Structure and polymorphisms in 
SmtB. Panel A shows the sequence 
alignment of SmtB homologs. The locations 
of the ?5 metal-binding sites are highlighted 
in blue and pink. In red is the mutated 
sequence of SmtB. Panel B shows the 
structure of the CzrA dimer from 
Sthaphylococcus aureus. Zn, in orange, 
binds at the interface between the two 
monomers. Panel C shows a model of the 
effect of the mutation in ML0825 on the 
dimer, which compromises the binding of 
Zn ions. The mutated part is represented in 
red lines. The protein was modeled using the 
homology modeling webserver SWISS-
MODEL and the structure of the 
transcriptional repressor CzrA from 
Sthaphylococcus aureus (PDB code 1R1V) 
as template.  
S1 Reference list. 
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S1 Table: Patient samples used for sequencing whole genome of M. leprae strains  
Patient # 
Type of sample for whole genome 
sequencing 
Year of 
collection 
Sample 
codes 
 1126 
FFPE 2007 1126-2007 
MFP 2011 1126-2011 
 
3208  
FFPE 2007 3208-2007 
FFPE 2015 3208-2015 
 
2188 
FFPE 2007 2188-2007 
MFP 2014 2188-2014 
 FFPE: formalin fixed paraffin embedded skin biopsy MFP: mouse footpad bacilli suspension 
 
S2 Table: DNA Quantification after DNA extraction from the FFPE biopsy samples and MFP samples 
and after library preparation. 
 DNA concentration 
(ng/?l) 
Volume used for library 
preparation (?l) 
Library concentration 
(ng/?l) 
1126-2007_1 <LOD 50 81.7 
1126-2007_2 0.058 50 83.4 
1126-2007_3 <LOD 50 25.3 
1126-2011 <LOD 50 40.9 
2188-2007_1 0.411 50 92.9 
2188-2007_2 0.318 50 65.1 
2188-2007_3 8.64 50 78 
2188-2014 0.216 50 54.4 
3208-2007_1 0.842 50 129 
3208-2007_2 0.136 50 145 
3208-2015_1 20.8 50 59.2 
3208-2015_2 25.4 42 82.9 
FFPE: formalin-fixed paraffin-embedded; MFP: mouse foot pad; LOD: limit of detection. 
 
S3 Table: List of 20 M. leprae genomes used to infer unique SNPs in recurrent cases SNP: single 
nucleotide polymorphism. 
Name Genotype Described in 
TN 1A 1 
Thai53 1A 2 
S2 1B 3 
S11 1D 3 
3077 2F 3 
Refshale_16 2F 3 
SK8 2F 3 
Jorgen_625 3I 3 
SK2 3I 3 
NHDP98 3I 4 
NHDP55 3I 4 
I30 3I 4 
NHDP63 3I 2 
S9 3K 3 
Kyoto-2 3K 5 
S10 3K 3 
S15 3L 3 
S13 4N 3 
S14 4O 3 
Br4923 4P 2 
Mx1-22 (M. lepromatosis) Outgroup 6 
 
  
  ???
  
S4 Table: Statistics of M. leprae whole genome sequences 
 Alignment rate (%)
1
 Average read depth coverage
1
 
1126-2007 38.98 6.27 
1126-2011 23.47 11.21 
3208-2007 42.33 37.19 
3208-2015 66.41 31.38 
2188-2007 72.36 123.86 
2188-2014 16.74 58.25 
1 Fraction of total reads that aligned to the reference genome TN.  
 
S5 Table: Allelic diversity of VNTR loci in the recurrent leprosy cases.  
Locus ID Coordinates 
1126 2188 3208 
1126-2007 
1126-
2011 
2188-
2007 
2188-
2014 
3208-
2007 
3208-
2015 
(T)8, & 
(A)6 
337466-337473, 
337474-337479 
8 & 6 8 & 6 8 & 6 8 & 6 8 & 6 8 & 6 
(T)6 & 
(N)7 & 
(T)8 
514181-514186, 
514187-514193, 
514194-514200 
6 & 7 & 8 6 & 7 & 
8 
6 & 7 & 
8 
6 & 7 & 
8 
6 & 7 & 
8 
6 & 7 & 
8 
(A)9 1414666-1414674 8 8 8 8 8 8 
(G)9 976857-976865 9 10 9 9 9 9 
(C)9 2658192-2658200 9 11 9/10 9/10 8/9 8/9 
(G)10a 347280-347289 10 9 9 9 13 13 
(G)10b 442993-443002 NA ? 9 9 ? 9/10 
(G)11 1309544-1309554 NA 11 9 9 10/11 12 
(G)12 1116443-1116454 9/10 10 9/10 9 11 11 
(CG)6 2947291-2947302 6 6 6 6 6 6 
(AC)8a 1531185-1531200 9 8 8 8 9 9 
(AC)8b 2211035-2211050 7 7/8 7/8 7/8 7 7 
(AC)9 1452573-1452590 8 NA 7/8 7/9 8 8 
(CA)6 2507097-2507108 6 6 6 6 6 6 
(TA)8 3221617-3221632 9 NA 10 10 ? 8/9 
(TA)9 2844971-2844988 7 6 ? ? 7 7 
(TA)10 1744091-1744110 8/10 8/9 10/11 10/11 10 10 
(AT)10 2951821-2951840 NA NA 5 5 6 6 
(AT)15 948935-948964 NA NA ? ? ? ? 
(AT)17 2597735-2597768 NA NA ? 13 13 13 
(ACC)5 1980049-1980063 5 5 5 5 5 5 
(GGT)5 2567251-2567265 4 4 4 4 4 4 
(AGT)5a 1237528-1237542 5 5 5 5 5 5 
(GTA)9 2583814-2583840 9 10 9/10 11 9 9 
(CACCG)3 2562391-2562405 3 3 3 3 3 3 
6-3a 1190341-1190358 3 3 3 3 3 3 
6-3b 2302531-2302548 3 3 3 3 3 3 
6-7 1816857-1816892 6 6 ? 8 7 7 
7-3 285076-285096 3 3 3 3 3 3 
10-4 1139035-1139074 4 NA 4 4 4 4 
12-5 1381661-1381723 5 5 5 5 5 5 
15-3 2928131-2928175 3 3 3 3 3 3 
27-5 687026-687160 5 5 5 5 5 5 
VNTR: variable number tandem repeat; NA: not available because of low coverage at that locus; mixture of multiple alleles; 
loci where VNTR number varied between the first and second strain are highlighted. 
  
  ????
S6 Table: List of 28 unique SNPs in strains 2188-2007 and 2188-2014.  
 
SNP: single nucleotide polymorphism. 1At 30% frequency in 2188-2007.  
  
Positio
n 
Name Type TN base (ref) 
Alternate 
allele 
SNP effect 
Amino-acid 
change 
509409 ML0411 
protein_codi
ng G A 
 missense 
Asp219Asn 
978294 ML0825 
protein_codi
ng G GAT 
 frameshift  
Val128fs 
121906
1 ML1052 
protein_codi
ng G 
GGGACATCT
A1 
 codon 
insertion 
Leu253-Val255 
dup 
159900
4 
ML1340 / 
ribD 
protein_codi
ng C T 
missense 
Gly62Asp 
14226 ML0302 Intergenic C CAT  -  
46129 ML0038 Pseudogene C T  -  
47405 ML0039 Pseudogene C T  -  
223657 ML0159 
protein_codi
ng C T 
 synonymous 
Ser336Ser 
417955 PPE Pseudogene C T -  
428724 - Intergenic C T -  
534530 ScoA Pseudogene C T -  
657961 - Intergenic C T -  
676219 - Intergenic C G -  
809458 - Intergenic G A -  
109171
6 Ag84 
protein_codi
ng C T 
synonymous 
Leu123Leu 
123253
2 ML1068 Pseudogene C T 
- 
 
132078
4 hom 
protein_codi
ng C T 
synonymous 
Ser381Ser 
143715
4 ML1214 
protein_codi
ng G A 
synonymous 
Thr165Thr 
145075
0 - Intergenic G A 
- 
 
159938
0 ML1341 Pseudogene C T 
- 
 
182791
1 - Intergenic C CG 
- 
 
253634
7 fprB 
protein_codi
ng G A 
synonymous 
Arg378Arg 
262295
2 mce1 Pseudogene AC A 
- 
 
268111
7 ML2256 Pseudogene T TC 
- 
 
287848
5 ML2407 
protein_codi
ng G A 
synonymous 
Pro67Pro 
295181
9 - Intergenic 
GTATATATA
TA G 
- 
 
297284
7 dnaK 
protein_codi
ng G A 
synonymous 
Ser194Ser 
318749
2 ML2661 
protein_codi
ng C T 
synonymous 
Ser5Ser 
  ???
S1 Fig: M. leprae specific anti-phenolic glycolipid 1 (PGL-1) immunoglobulin M (IgM) and anti-LID-1 IgG 
serology and timelines of clinical events and BI evolution of multibacillary (MB) leprosy patients that had 
recurrent disease after treatment. Serological data and timelines of clinical events and bacilloscopic index (BI) 
evolution are depicted in panels A-F: patient # 1126 (A, B); patient # 3208 (C, D); patient # 2188 (E, F). The 
first serum sample was collected at diagnosis before treatment and sequential samples were collected monthly 
during treatment and at different times during the follow-up as indicated. 
  
  ????
 
S2 Fig. Structure and polymorphisms in SmtB. Panel A shows the sequence alignment of SmtBhomologs. The 
locations of the ?5 metal-binding sites are highlighted in blue and pink. In red is the mutated sequence of SmtB. 
Panel B shows the structure of the CzrA dimer from Sthaphylococcus aureus. Zn, in orange, binds at the 
interface between the two monomers. Panel C shows a model of the effect of the mutation in ML0825 on the 
dimer, which compromises the binding of Zn ions. The mutated part is represented in red lines. The protein was 
modeled using the homology modeling webserver SWISS-MODEL7 and the structure of the transcriptional 
repressor CzrA from Staphyloccocus aureus (PDB code 1R1V) as template. 
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Abstract: Leprosy is a chronic human disease 
caused by the yet-uncultured pathogen 
Mycobacterium leprae. Although readily 
curable with multidrug therapy (MDT), over 
200,000 new cases are still reported annually. 
Here, we obtain M. leprae genome sequences 
from DNA extracted directly from patients’ skin 
biopsies using a customized protocol. 
Comparative and phylogenetic analysis of 154 
genomes from 25 countries provides insight 
into evolution and antimicrobial resistance, 
uncovering lineages and phylogeographic 
trends, with the most ancestral strains linked to 
the Far East. In addition to known MADT-
resistance mutations, we detect other 
mutations associated with antibiotic 
resistance, and retrace a potential stepwise 
emergence of extensive drug resistance in the 
pre-MDT era. Some of the previously 
undescribed mutations occur in genes that are 
apparently subject to positive selection, and 
two of these (ribD, fadD9) are restricted to 
drug-resistant strains. Finally, nonsense 
mutations in the nth excision repair gene are 
associated with greater sequence diversity and 
drug resistance 
 
Mycobacterium leprae is the main causative 
agent of leprosy, a disease that affects the 
skin, nerves, and mucosa of the upper 
respiratory tract in humans1. A second, 
distantly related leprosy bacillus, 
Mycobacterium lepromatosis, was recently 
discovered in humans and red squirrels 
(Sciurus vulgaris)2. Leprosy is curable with 
multidrug therapy (MDT), but remains a 
public health problem in South America, 
Africa, South and Southeast Asia, and 
Micronesia, where over 200,000 new leprosy 
cases are reported each year3. MDT, 
comprising rifampicin, dapsone, and 
clofazimine, has been used intensively since 
the 1980s and a few second-line drugs, 
ooxacin, minocycline, and clarithromycin, 
are sometimes employed as therapeutic 
agents4. The emergence of drug-resistant (DR) 
and multidrug-resistant (MDR) M. leprae is 
increasingly reported5–12. For dapsone, 
rifampicin and ooxacin, the resistance 
mechanism has been attributed to missense 
mutations in the drug resistance determining 
regions (DRDR) of the folP1, rpoB, and gyrA 
genes, respectively. 
M. leprae is an obligate intracellular 
pathogen that has never been cultured 
axenically but can infect wild or 
experimental animals. The nine-banded 
armadillo (Dasypus novemcinctus) or the 
mouse footpad (MFP) can be used to produce 
bacilli, but both methods are cumbersome and 
time-consuming13. The genome of M. leprae 
is the smallest among mycobacteria (3.3 Mb) 
with 1614 genes encoding proteins and a 
remarkable 1300 pseudogenes14. Such 
reductive evolution is a hallmark of bacteria 
that have changed their lifestyle from free-
living to strictly hostassociated15. Due to its 
14-day generation time and the absence of 
horizontal gene transfer, the genome of M. 
leprae is highly conserved, with <300 single-
nucleotide polymorphisms (SNPs) observed 
between distantly related strains, and only a 
few SNPs between close relatives5,16–18. Four 
SNP types (branches 1–4) and 16 SNP 
subtypes (A–P) were dened by surveying 78 
informative SNPs and six single-base 
insertion/deletions (InDels)16,19. Genotyping 
a large panel of M. leprae strains revealed 
strong geographical associations and 
suggested possible routes of dissemination of 
leprosy16 whereas, a recent phylogenetic 
analysis of 16 whole-genome sequences of 
modern and ancient M. leprae strains, 
implicated the 3K subtype (branch 0) as the 
most ancestral17. Leprosy seems to have 
appeared during the Iron Age (1200–600 BC) 
and the date of the most recent common 
ancestor of M. leprae was estimated to be 
from 2543 BC to 36 AD, based on whole-
genome sequence analysis17. Similarly, the 
earliest accepted written record of leprosy 
is from 600 BC20, and the earliest 
osteological evidence dates from around 300 
BC21–25. The oldest genomic evidence of 
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leprosy is for samples from 80 to 240 AD in 
Central Asia26. In this study, we develop and 
apply methods to isolate and purify M. leprae 
DNA that enable whole genome sequences to 
be obtained directly from human biopsy 
material, thus removing the necessity for 
passage through animals. This approach was 
successfully used to generate 120 new M. 
leprae genome sequences from drug-
susceptible and DR strains from around the 
world, thereby enabling detailed phylogenetic 
and phylogeographic comparisons to be 
performed, new mutations associated with 
antimicrobial resistance to be detected, and 
the likely origin of leprosy to be proposed. 
Results 
Isolating M. leprae DNA from human skin 
biopsies. Genome sequencing has become 
routine practice in microbiology27, especially 
for micro-organisms that can be readily 
isolated, which is not the case of the leprosy 
bacillus. For decades, the sole source of M. 
leprae DNA suitable for genomics was from 
bacteria isolated 12 months after infection of 
armadillos or mice. Recently, we have 
developed and optimized methods that enable 
M. leprae DNA to be extracted directly from 
fresh or formalin-xed skin biopsies from 
leprosy patients28. These methods include 
enrichment of M. leprae DNA by array 
capture17 but this is less practical for large 
population-based investigations. The DNA 
extraction method used in this study was 
applied directly to punch biopsies from 
clinically well-characterized patients of 
known bacillary index (BI) and exploits the 
fact that M. leprae resides intracellularly. Host 
cells are rst disrupted and their DNA 
degraded, leaving the bacilli intact. The bacilli 
are then lysed and their DNA extracted and 
used for library preparation. This approach 
was applied to 106 biopsies whose BI ranged 
from 0 (no bacilli visible) to 6 (>1000 bacilli 
per microscopic eld) thereby enabling a 
relationship between BI and sequencing 
efciency to be established (Fig. 1). As 
expected, there was a direct correlation 
between genome coverage and the BI but, 
surprisingly, successful coverage could even 
be achieved with some specimens whose BI 
was as low as 1+. 
Genome analysis of patient and animal 
cohort. We analyzed a total of 154 M. leprae 
genomes from 25 countries (Fig. 2, 
Supplementary Data 1), of which 120 were 
newly sequenced and 34 were previously 
published (Supplementary Data 1). The cohort 
comprised 147 human samples, 6 from red 
squirrels and 1 from an armadillo that were all 
naturally infected. Genome sequences were 
obtained directly from 109 human samples, 30 
from bacilli passaged in mice, and 8 from 
armadillos. Thirty of these strains were from 
patients who had relapsed or not responded to 
MDT the remainder (124) were from 
supposedly drug-susceptible strains (87 were 
from conrmed primary cases, while disease 
history was unknown for the others). 
Figure 1: 
content of M. leprae
DNA in sequencing libraries derived from human 
skin biopsies was determined and found to be 
proportional to the bacillary index (not available for
all samples). Empty circles are samples that were
not included in the study due to insufcient genome
coverage. Sample count and sequencing success
rates are given at the top of each category 
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A total of 3053 SNPs and 219 InDels 
(excluding tandem repeats) was found 
(Supplementary Data 2). The average SNP 
difference among the 154 genomes was 114. 
We found a total of 988 non-synonymous 
alleles (0.62 per protein-coding gene, or 0.61 
per kb of protein-coding genes) and 530 
synonymous SNPs (0.33 per protein-coding 
gene or 0.33 per kb of protein-coding genes), 
and 1763 mutations in intergenic regions 
andpseudogenes (1.07 mutations per kb of 
intergenic regions and pseudogenes). The 
SNP density for each gene is given in 
Supplementary Data 2. Of the 219 InDels, 58 
(27%) were in protein-coding genes.  
 
Phylogeny of M. leprae. Phylogenetic 
analysis using both maximum parsimony 
(MP) and Bayesian inference resulted in 
consistent tree topologies and revealed distinct 
lineages and sublineages of M. leprae (Fig. 3). 
Strains belonging to the same SNP subtypes16 
clustered within single branches, with the 
exception of SNP subtype 3K, which is 
represented by a newly discovered ancestral 
lineage, termed here 3K-1, and the ancestral 
lineage referred to earlier as branch 017 and 
termed here 3K-0 (Fig. 3a). All strains from 
the two most ancestral lineages, 3K-0 and 3K-
1, originated from Japan (8), China (1), Korea 
(1), the Marshall Islands (1), and New 
Caledonia (1), in agreement with earlier 
genotyping studies of hundreds of M. leprae 
strains which conrmed the predominance of 
the 3K genotype in East Asia, notably in 
Japan, China, and Korea16,29–31. M. leprae in 
East Africa showed higher diversity with 
subtypes 2E, 2F, and 2H representing distinct 
lineages (Fig. 3a). The geographic distribution 
of those lineages corroborates earlier studies 
reporting the presence of SNP type 2 in 
Medieval Europe, the Middle East and East 
Africa16. Two Ethiopian isolates, belonging to 
the 2F subtype, clustered closely with 
medieval European strains dating from the 
11th to 12th century (Fig. 3), which supports 
the hypothesis that the ancient Greek and 
Roman routes32 connecting Europe, the 
Middle East, East Africa, and South Asia16,33–
35 contributed to the dissemination of SNP type 
2M. leprae. West Africa, on the other hand, 
harbors exclusively SNP type 4, suggesting 
that overland migration between East and 
West Africa was limited. SNP subtypes 4N, 
4O, and 4P, albeit sharing the same ancestor, 
do not form a monophyletic clade as 
previously hypothesized16. Rather, the 4O and 
4P subtypes cluster together in a branch 
Figure 2: Geographic distribution of the M. leprae samples used in this study. World map shows the number of 
registered cases of leprosy per 10,000 
html). Blue numbers indicate ancient M. 
leprae strains 
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distinct from 4N (Fig. 3). 
Brazil, as expected, 
contains a great diversity of 
several M. leprae lineages, 
with the SNP type 4 and 
SNP subtype 3I being the 
most prevalent36. The 3I 
genotype was common in 
medieval Europe17,21,37,38, 
and is still present in red 
squirrels in the United 
Kingdom2. The modern 
Brazilian strain Br2016-45 
branched between two 
medieval strains from 
Europe (Fig. 3), making it 
the most ancestral 
contemporary 3I strain in 
the Americas to date. The 
broad diversity of 3I 
genotypes from Brazil 
probably derives from 
multiple introductions from 
Europe. On the other hand, 
the strains circulating in the 
Southern USA and 
associated with 
zoonosisfrom the nine-
banded armadillo, I-30, 
NHDP-55 and NHDP-6318, 
originated much more 
recently (Fig. 3b), in agreement with the rapid 
expansion and spread of the armadillo 
population since its introduction to this region 
about 150 years ago39. Good representation of 
most M. leprae lineages enabled identication 
of lineage-specic markers. A set of 235 
SNPs and 25 InDels were specic to single 
lineages or groups of related lineages 
(Supplementary Data 2), of which 73 non-
synonymous SNPs and 5 InDels were within 
protein-coding genes. These new lineage-
specic markers can be used for future 
genotyping schemes.  
 
Dating analysis. Dating analysis of M. 
leprae (Fig. 3b and Supplementary Figure 1) 
was done using BEAST v2.4.440 and the 
results were very similar to those obtained 
from a ten-fold smaller  
number of contemporary isolates17. The most 
recent common ancestor (TMRCA) of all M. 
leprae strains was estimated to be 3699 years 
old (95% Highest Posterior Density (HPD) 
2731–4838 ya) and the substitution rate was 
7.8 × 10-9 per site per year. Overlapping 
results were obtained when using different 
models (Supplementary Note and 
Supplementary Table 1), indicating that the 
data set was robust and sufciently 
informative. 
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A striking observation is the relative youth 
of the SNP type 1 lineage and its association 
with South Asia (Fig. 3b). Earlier studies 
revealed a predominance of SNP subtype 1D 
in India and Nepal, followed by 1C, 1A16, and 
2E, 2G, and 2H33–35. SNP type 1 predominates 
in Thailand41, Bangladesh, Indonesia, and 
Philippines16. The current phylogeography of 
M. leprae implies that humans brought 
leprosy to South Asia from other parts of the 
continent. 
 
Hypermutated M. leprae strains. Eight M. 
leprae strains (85054, S15, Amami, Zensho-4, 
Zensho-5, Zensho-9, Br14-3, and Br201615), 
belonging to ve different SNP subtypes, had 
unusually long branches in the MP tree (Fig. 
3a) because they contained on average 92 
 more SNPs than the other strains but 
approximately the same number of InDels. 
Comparative analysis revealed one unique 
feature linking the observed “hypermutated” 
strains, namely deleterious mutations in the 
endonuclease III gene nth (ML2301) due to 
frameshifts and premature stop codons (Table 
1).  
 
Drug resistance. DR-associated SNPs were 
detected in the DRDR in 24 strains for folP1, 
11 strains for rpoB, and 2 strains for gyrA (in 
bold in Table 1). Previously described 
mutations were identied in folP1 at codons 
53 (n = 7) and 55 (n = 17), except in one 
isolate (Bn8-52), which had mutations at 
codons 55 and 145. Eleven strains had known 
mutations that confer rifampicin resistance in 
their rpoB-DRDR, while two strains (Kutatsu-
6 and S15) harbor one additional mutation, 
and one (Br14-3) has two additional 
mutations in the DRDR (Table 1). One of  
  ???
?  
Figure 3: 
mutations in the corresponding gene as given in Table 1. b 
Bayesian phylogenetic tree of 146 genomes of M. leprae calculated with BEAST 2.4.4. 
of 
age. Samples were binned according to geographic origin as given in the legend. Posterior probabilities for each node are 
shown in gray. Location probabilities of nodes were inferred by the Discrete Phylogeny model 
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these additional mutations (G432S) does not 
confer rifampicin resistance to recombinant 
Mycobacterium smegmatis42 whereas no 
information is available for the remaining 
three (T433I, G448D, and T508I) except that 
the G448A substitution does confer rifampicin 
resistance in M. tuberculosis43. Also, 5 of the 
11 rifampicin-resistant strains had additional 
missense mutations in rpoB (85054, Br14-4, 
Zensho-4, Zensho-5, and Zensho-9) while 2 
strains (ARLP_08 and S9) presented non-
synonymous SNPs outside the DRDR (Fig. 4). 
Compensatory mutations in rpoA and rpoC, 
encoding the alpha and beta-prime subunits of 
RNA polymerase, can occur in rifampicin-
resistant M. tuberculosis44. We found one non-
synonymous SNP in rpoA, substitution T187P 
in the rifampicin-resistant strain Br14-5, and 
seven nonsynonymous SNPs in rpoC 
(Supplementary Data 2), of which two 
occurred in the drug-resistant strains S15 
(A258T) and Zensho-4 (H1133Y). 
Two strains had known quinolone 
resistance mutations in the DRDR of gyrA and  
six harbored different single mutations 
elsewhere in the gene. Three isolates had a 
missense mutation in gyrB, including two 
within the DRDR (Table 1). Five strains 
harbor deleterious mutations in the ethA gene, 
encoding a monooxygenase that activates 
thioamide prodrugs in M. tuberculosis45,46. 
Interestingly, in addition to ethA and nth, three 
genes (fadD9, ribD, pks4) were mutated 
almost exclusively in MDR strains occurring 
18, 19, and 4 times, respectively (Table 1). 
 
Retracing the emergence of drug resistance 
in leprosy patients. Prior to the introduction 
of MDT in the 1980s, patients were treated 
with dapsone or other antimicrobials as 
Figure 4: Mutations of M. leprae genes associated with antimicrobial resistance. Triangles point to the location 
of the mutation in the protein. Black triangles indicate known resistance-conferring mutations identied in this study 
that are situated in the drug resistance determining regions (DRDR): D dapsone, Q quinolone, R rifampicin. Orange 
border means the mutation was found to be homoplasic. Triangle size reects the number of isolates from this study
harboring the mutation, ranging from 1 to 17. Frameshifts and premature stop codons are in turquoise. Substitutions 
predicted to have an impact on the biological function of the protein75 are in bold. Proteins are drawn to scale ?
  ???
monotherapies of varying duration7,8. Since 
genomics uncovered new mutations that are 
associated with antimicrobial resistance in 
other bacteria, such as those in ethA and gyrB, 
this prompted us to try and retrieve the clinical 
records of six patients whose strains displayed 
resistance to three or more drugs (dapsone, 
rifampicin, quinolones, and thioamides). Four 
of these extensively drug-resistant (XDR) 
strains were from multibacillary patients in 
Japan who had received a succession of 
monotherapies in the pre-MDT era and our 
genome analysis enabled the chronology of 
resistance emergence to be retraced. This is 
illustrated in Fig. 5, and sadly exemplied by 
the strain from patient Zensho-4 who was 
diagnosed in 1963 and rst treated with 
protionamide followed by thiambutosin, both 
of which show cross-resistance and likely 
require activation by the EthA mono-oxidase 
that acquired the A25T missense mutation47; 
then treatment began with dapsone leading to 
emergence of the T53I mutation in folP1, 
followed by rifapentine that selected the 
S456L mutation in rpoB, and continued with 
ooxacin, to which resistance arose from the 
A91V mutation in gyrA and D464N in gyrB. 
Molecular drug susceptibility testing was 
performed in 1998 and the patient nally 
cured by a regimen comprising clofazimine, 
minocycline, chloramphenicol and 
levooxacin/sparoxacin. The fth XDR 
strain was from a newly diagnosed Brazilian 
case (Br2016-15) with no history of treatment 
for leprosy, conrming the ongoing 
transmission of primary antimicrobial 
resistance, while details of the sixth case could 
not be recovered. 
 
Genes under positive selection. We also 
identied genes containing an unusually high 
number of polymorphisms, multiple alleles, 
and homoplasies (Supplementary Figure 2), 
which could be indicative of positive 
selection48. Strikingly, the distribution of these 
polymorphic sites around the genome was not 
random as they were often clustered, 
especially proximal to either side of the origin 
of replication (Supplementary Figure 3). 
Protein-changing mutations were found in 540 
genes, with an average of 1.77 mutations per 
gene (STD 2.12). Table 2 contains a ranking 
of genes with at least ve non-synonymous 
mutations or regions with one or more 
homoplasy (excluding VNTRs). The most 
polymorphic gene by far was ML041149 
encoding the serine-rich antigen, a member of 
the immunogenic, surface-exposed PPE 
protein family. Two other known T-cell 
antigens whose genes display variability are 
Lsr2 and EsxA (Table 2). Other than nth, three 
other polymorphic genes (ML1040c, 
ML1750c, and ML1512c) code for proteins 
that appear to function in nucleic acid or 
cyclic nucleotide metabolism (Table 2). 
 
Discussion  
 
Here we have optimized and applied 
highly sensitive procedures to extract M. 
leprae DNA directly from human skin 
biopsies that is suitable for whole-genome 
sequencing. The resultant genome sequences 
were analyzed phylogenetically and used to 
retrace the origin of the leprosy bacillus, and 
to identify polymorphisms that had been 
positively selected during evolution. Such 
polymorphisms might reect pressure from 
the human immune system, from MDT or 
other forces. 
It is striking that the ancestral lineages of 
M. leprae predominate in East Asia, although 
we should keep in mind that Central Asia has 
been understudied, so it would be interesting 
to sequence more samples spanning the East–
West axis of Asia, including the Middle East, 
where the 3K genotype is also present16. 
Nevertheless, given the current data on the 
distribution of the 3K subtype we can deduce 
that the ancestor of M. leprae originated 
within Eurasia, probably in the Far East. 
Endonuclease III (Nth) and the 
formamidopyrimidine and endonuclease VIII 
family (Fpg/Nei) of DNA glycosylases are 
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central to the base excision repair pathway in 
bacteria50. Mycobacterial genomes usually 
contain a single nth and two fpg/nei genes but 
M. leprae has lost both fpg/nei orthologues and 
retained the nth gene. Nth, Fpg, and Nei may 
have overlapping functions and, in enteric 
bacteria, mutator phenotypes were observed 
when nth was inactivated in combination with 
the fpg and nei genes51– 53. In M. smegmatis, 
deletion of nth and both the nei homologs 
resulted in elevated spontaneous mutation 
frequencies and increased sensitivity to 
oxidative stress54. Therefore, in the absence of 
Nei, inactivation of nth in M. leprae should 
lead to increased sequence variability, which 
is consistent with our results.  
Strikingly, all nth mutants were also drug-
resistant so Nth loss likely favors emergence 
of drug resistance, and nth mutations might 
serve as a surrogate marker for potential drug 
resistance and treatment failure. A link 
between a higher mutation rate and drug 
resistance was observed in strains of M. 
tuberculosis (which has nth and two fpg/nei 
genes) belonging to lineage 2, but the 
molecular basis for this is unknown55. For a 
pathogen with an extremely reduced genome 
such as M. leprae, a hypermutator phenotype 
could be detrimental and ultimately lethal.  
Drug resistance is alarming for leprosy 
control. There is growing evidence for 
primary quinolone resistance in strains of M. 
leprae from patients who have never been 
treated with quinolones for leprosy but may 
have received this drug for other infections56. 
Five new GyrA mutations were identied in 
this study, but their effect on FQ resistance 
remains to be determined. Since two of them 
arose independently in the GyrA intein, which 
is removed by protein splicing, they may not 
impact quinolone activity (Fig. 4). Three non-
synonymous mutations were found in gyrB 
(Table 2) and experimental evidence exists for 
two of them conferring quinolone resistance in 
in vitro assays or in M. tuberculosis57,58. To 
our knowledge, this is the rst report of M. 
leprae clinical isolates harboring mutations in 
gyrB. Thus, despite their apparent rarity, 
mutations in gyrB should be systematically 
assessed in drug resistance screening. A range 
of known and new mutations was detected in 
the DRDR and elsewhere in rpoB (Fig. 4; 
Table 1). Some of these might have a 
compensatory role in restoring tness, that is 
known to be reduced to various degrees in 
rifampicin-resistant mutants of M. 
tuberculosis59,60. Similarly, compensatory 
mutations in rpoA and rpoC can occur in 
rifampicin-resistant M. tuberculosis44. The 
rpoA substitution T187P in the rifampicin-
resistant M. leprae strain Br14-5 was shown 
to be compensatory in M. tuberculosis44. 
Rifampicin-resistant isolates of M. 
tuberculosis harbor more mutations in rpoC 
Figure 5: Timeline of the leprosy treatment and
emergence of drug resistance in the XDR strains.
Mutated genes conferring resistance to the
corresponding drugs are shown in red. Arrows
span from the onset of disease to the end of
treatment. Horizontal lines show the period when a 
drug was given. Dotted lines mean irregular
treatment. CAM chloramphenicol, CLO
clofazimine, DDS dapsone, DPT thiambutosine
levooxacin, MIN
minocycline, OFX ooxacin, PTO protionamide,
RIF rifampicin, SMP sulfamethoxypyridazine,
SPX sparoxacin, STR streptomycin, TZA
thiozamin 
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compared to rifampicinsusceptible 
isolates44,61. In our case, we observed no clear 
correlation between rifampicin resistance and 
mutations in rpoC, which occurred in two 
resistant and two wild-type strains.  
Arguably the most intriguing nding of the 
present investigation was the remarkably high 
frequency of mutations in the fadD9 and ribD 
genes and in 19/23 cases these occur in strains 
that have at least one mutation that is 
associated with resistance to a leprosy drug 
(Fig. 4; Table 1). Functional information for 
fadD9 is scarce and the mutations found are 
predicted to either abolish protein production 
(8/16) or to cause detrimental amino acid 
changes (Fig. 4). In the case of ribD, 14 
different missense mutations were found in a 
group of 17 variant alleles, indicating that this 
is likely an essential function. From studies 
with M. tuberculosis it is known that ribD 
encodes an alternative dihydrofolate 
reductase, with relatively low activity 
compared to that conferred by the bona de 
dihydrofolate reductase gene, dfrA62. In 
clinical isolates of M. tuberculosis, a promoter 
mutation causes overexpression of ribD that is 
associated with resistance to the old drug, 
para-amino salicylic acid (PAS), and to 
certain DHFR inhibitors63. This suggests that 
the mutations detected in the M. leprae ribD 
gene may also confer resistance to PAS and 
support for this is provided by the fact that 
vadrine (2-pyridyl-(4)-1,3,4oxydiazolone-(5)-
p-aminosalicylate) was used as a drug to treat 
leprosy before dapsone became widely 
available64. It is thus possible that the ribD 
mutations we report here arose nearly 60 years 
ago following treatment with vadrine or 
another PAS derivative. Our discovery of 
these mutations and those in fadD9 should 
encourage further experimentation in order to 
establish their true role and contribution to 
antimicrobial resistance, especially to 
clofazimine. 
Methods 
 
Sample collection. Samples were taken from 
leprosy patients as punch biopsies of skin 
(preserved in 70% ethanol or formalin-xed 
and parafn-embedded (FFPE)), which is 
standard diagnostic procedure for leprosy, or 
from mouse foot-pads. Details about the 
samples used in this study are given in 
Supplementary Data 1 and below. 
Origin of S15: Strain S15 corresponds to strain 
9204165, which was isolated from a 
lepromatous leprosy patient originally from 
Martinique. The origin of S15 was 
erroneously attributed to New Caledonia in 
Monot et al.16, and the error was subsequently 
propagated in several publications2,17,66,67. 
DNA extraction and library preparation. 
DNA was extracted from 101 human skin 
biopsies with known BI using a customized 
in-house protocol combining host tissue 
digestion and the QIAmp microbiome kit for 
host DNA depletion, strong bacterial cell lysis 
and silica-based purication. Punch biopsies 
(6 mm) in 70% ethanol were rst rehydrated 
in Hank’s balanced solution prior to mincing 
with scissors. Cells were detached from the 
tissue by 30 min incubation at 37 °C with a 
mixture of 0.5 U of collagenase and dispase, 
followed by incubation at 56 °C with 10 
mg/ml of trypsin until complete digestion. 
Free cells were then suspended in 1 ml of 
phosphate-buffered saline (PBS) and DNA 
was extracted using the QIAmp DNA 
microbiome extraction kit according to the 
manufacturer’s recommendations. Each run of 
extraction included a batch of ve to nine 
samples and one blank control (500 ?l of 
Hank’s balanced solution). The presence of M. 
leprae was assessed by PCR using RLEP 
primers2 prior to library preparation. Libraries 
were prepared from 50 µl of extracted DNA 
using the Kapa Hyperprep kit as described 
previously2,5. DNA from FFPE samples was 
extracted using the truXTRACTM FFPE DNA 
kit (Covaris) as described previously28. 
Libraries prepared from the extracted DNA 
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were used directly for shotgun sequencing. M. 
leprae DNA extraction quality was assessed 
from the percentage of M. leprae DNA present 
in the library inferred by alignment to the 
reference genome sequence, with a minimum 
threshold set at 1%. This threshold was chosen 
because it yields an average genome coverage 
of at least 5× per sample in a multiplexed run 
of 10 samples on one HiSeq 2500 lane 
(yielding around 20 million reads per sample 
and 100 bases per read). 
Library enrichment. Libraries with low M. 
leprae content underwent enrichment using 
whole-genome tiling arrays as described 
previously17. Briey, Illumina libraries were 
hybridized onto custom Agilent SureSelect 
Capture Arrays containing ca. one million 
DNA probes (60 bp) spanning the entire M. 
leprae genome (tiled every 4 bp), followed by 
elution and PCR amplication. 
Sequencing. Sequencing was performed on 
Illumina Hi-Seq 2000, Hi-Seq 2500, or Mi-Seq 
instrument. 
Sequence processing. We took precautions in 
analyzing the data to avoid falsepositive SNP 
calls. All raw reads were adapterand quality-
trimmed with Trimmomatic v0.3368. The 
quality settings were 
“SLIDINGWINDOW:5:15 MINLEN:40”. 
Paired-end (PE) data were additionally 
processed with SeqPrep 
(https://github.com/jstjohn/SeqPrep) to merge 
overlapping pairs. This increases the accuracy 
of sequence in the overlapping area, avoids 
problems in estimating coverage and creates 
longer reads, which facilitates InDel calling. 
Duplicate reads were omitted from 
downstream analyses. This is especially 
important for libraries with insufcient M. 
leprae DNA fragments, which is not 
uncommon for low BI samples or samples that 
are difcult to process, like FFPE samples. In 
these cases, library enrichment with array-
capture, or very deep sequencing often 
produce a high number of duplicate reads 
(DNA fragments that were sequenced multiple 
times, seemingly increasing the overall 
genome coverage), with each read having 
dozens or even hundreds of copies. Such reads 
will amplify possible artefacts and sequence 
errors, resulting in false SNP calls. 
Sequence analysis. Preprocessed reads were 
mapped onto the M. leprae TN reference 
genome (GenBank AL450380.1) with Bowtie2 
v2.2.569. We ltered out all reads with mapping 
quality below 8 and omitted repetitive regions 
in the reference sequence. We also omitted 
ribosomal RNA (rRNA) genes because 
alignments in these regions tend to be error 
prone. This is because rRNA genes are highly 
conserved in bacteria, so sequences from other 
species could map to the M. leprae reference 
sequence. This usually happens when the 
content of M. leprae DNA in a sequencing 
library is scarce and is even more pronounced 
when libraries with low leprae content 
undergo array-capture. However, because 
lineage-specic mutations were previously 
observed in the M. leprae rrs gene30, we 
manually checked the alignments 
corresponding to the rRNA genes and added 
the curated results to Supplementary Data 2. 
SNP calling was done using VarScan v2.3.970. 
To avoid false-positive SNP calls the 
following cutoffs were applied: minimum 
overall coverage of ve nonduplicated reads, 
minimum of three non-duplicated reads 
supporting the SNP, mapping quality score >8, 
base quality score >15, and a SNP frequency 
above 80%. 
InDel calling was done using Platypus 
v0.8.171 followed by manual curation. 
Completed genome sequences of M. leprae 
Br4923 and Mycobacterium lepromatosis 
(GenBank JRPY00000000.1) were aligned 
against the M. leprae TN reference using 
LAST72 using the default parameters for the 
former and the gamma-centroid option for the 
latter. 
 
Mixed samples. A large number of missing 
values, especially in lineage-specic loci, 
  

points to the presence of more than one strain 
in a sequencing library. 
Although not thoroughly tested, in our opinion 
mixed data sets are mostly due to technical 
problems or contamination because in some 
cases we were able to identify the problematic 
strains. The possible presence of multiple M. 
leprae strains in single skin lesions was not 
tested in this study, but we expect it to be 
extremely low. Overall, a few mixed data sets 
were detected and some were removed from 
this study, except for samples that we deemed 
important and describe below. Nevertheless, 
results were not biased because loci with 
mixed alleles were treated as missing values. 
Zensho-4 seems to contain a fraction of 
another strain (possibly around 40%) that is 
closely related to it. Only a few loci had 
mixed alleles, and these include the A91V 
substitution in gyrA (supported by 62% of 
reads) and the D464N substitution in gyrB 
(supported by 41% of reads). The latter was 
attributed to Zensho-4 for simplicity. 
Similarly, Zensho-5 seems to contain around 
30% of Zensho-4. This is the main reason why 
we could not detect SNPs speciﬁc only to 
Zensho-5 (Fig. 3a), since such SNPs would be 
“diluted” with wild-type alleles from Zensho-4 
and could not pass the SNP “purity” 
threshold. We included these two samples in 
this study because they are multi-drug-
resistant and belong to the SNPtype 3K-0. 
Furthermore, mutations in genes conferring 
drug resistance from this study match with 
those from earlier reports of these samples, 
conﬁrming their identity73. 
Thai-311 contains <20% of an unidentiﬁed 
3K-0 strain that belongs to the Kyoto-
1/Zensho-5 cluster of strains (Fig. 3a). SNP 
calling was not signiﬁcantly affected. 
Finally, sample Ye2-3 contained around 
25% of an unidentiﬁed strain belonging to 
SNP-type 4. Because we only have few 
samples from Yemen, we decided to keep 
Ye2-3 in this study. 
 
Phylogeny and dating analysis. Concatenated 
SNP alignments were used for the analyses. 
MP trees were constructed in MEGA674 using 
500 bootstrap replicates. Sites with missing 
data were partially deleted (80% coverage 
cutoff), resulting in 3046 variable sites used 
for the tree calculation. The Subtree-Pruning-
Regrafting algorithm was used as the MP 
search method. Dating analysis and discrete 
phylogeography were done using BEAST2 
v2.4.440. Details are given in the 
Supplementary Note. 
 
Data availability. Sequence data are available 
from the NCBI Sequence Read Archive (SRA) 
under accession number SRP072827. 
Accession numbers for all samples used in this 
study are given in the Supplementary Data 1. 
Other relevant data supporting the ﬁndings of 
the study are available in this published article 
and its Supplementary Information ﬁles, or 
from the corresponding author upon request. 
  ????
References 
 
1. Britton, W. J. & Lockwood, D. N. J. 
Leprosy. Lancet 363, 1209–1219 
(2004). 
2. Avanzi, C. et al. Red squirrels in the 
British Isles are infected with leprosy 
bacilli. Science 354, 744–747 (2016). 
3. World Health Organization. Global 
leprosy update 2015: time for action, 
accountability and inclusion. Wkly 
Epidemiol. Rec. 91, 405–420 (2016). 
4. Scollard, D. M. et al. The continuing 
challenges of leprosy. Clin. Microbiol. 
Rev.19, 338–381 (2006). 
5. Avanzi, C. et al. Transmission of 
drug-resistant leprosy in Guinea-
Conakry detected using molecular 
epidemiological approaches. Clin. 
Infect. Dis. 63, 1482–1484 (2016). 
6. Cambau, E., Perani, E., Guillemin, I., 
Jamet, P. & Ji, B. Multidrug-resistance 
to dapsone, rifampicin, and ooxacin 
in Mycobacterium leprae. Lancet 349, 
103–104 (1997). 
7. Maeda, S. et al. Multidrug resistant 
Mycobacterium leprae from patients 
with leprosy. Antimicrob. Agents 
Chemother. 45, 3635–3639 (2001). 
8. Matsuoka, M., Kashiwabara, Y. & 
Namisato, M. A. Mycobacterium 
leprae isolate resistant to dapsone, 
rifampin, ooxacin and sparoxacin. 
Int. J. Lepr. Mycobact. Dis. 68, 452–
455 (2000). 
9. Matsuoka, M., Kashiwabara, Y., 
Liangfen, Z., Goto, M. & Kitajima, S. 
A second case of multidrug-resistant 
Mycobacterium leprae isolated from a 
Japanese patient with relapsed 
lepromatous leprosy. Int. J. Lepr. 
Mycobact. Dis. 71, 240–243 (2003). 
10. Matsuoka, M. et al. The frequency of 
drug resistance mutations in 
Mycobacterium leprae isolates in 
untreated and relapsed leprosy patients 
from Myanmar, Indonesia and the 
Philippines. Lepr. Rev. 78, 343–352 
(2007). 
11. da Silva Rocha, A. et al. Drug and 
multidrug resistance among 
Mycobacterium leprae isolates from 
Brazilian relapsed leprosy patients. J. 
Clin. Microbiol. 50, 1912–1917 
(2012). 
12. You, E.-Y., Kang, T. J., Kim, S.-K., Lee, 
S.-B. & Chae, G.-T. Mutations in genes 
related to drug resistance in 
Mycobacterium leprae isolates from 
leprosy patients in Korea. J. Infect. 
50, 6–11 (2005). 
13. Lahiri, R. & Adams, L. B. International 
Textbook of Leprosy (2016). 
14. Cole, S. T. et al. Massive gene decay in 
the leprosy bacillus. Nature 409, 
1007–1011 (2001). 
15. Moya, A., Peretó, J., Gil, R. & Latorre, 
A. Learning how to live together: 
genomic insights into prokaryote–
animal symbioses. Nat. Rev. Genet. 9, 
218–229 (2008). 
16. Monot, M. et al. Comparative genomic 
and phylogeographic analysis of 
Mycobacterium leprae. Nat. Genet. 
41, 1282–1289 (2009). 
17. Schuenemann, V. J. et al. Genome-wide 
comparison of medieval and modern 
Mycobacterium leprae. Science 341, 
179–183 (2013). 
18. Truman, R. W. et al. Probable zoonotic 
leprosy in the southern United States. 
N. Engl. J. Med. 364, 1626–1633 
(2011). 
19. Monot, M. et al. On the origin of leprosy. 
Science 308, 1040–1042 (2005). 
20. Dharmendra Leprosy in ancient Indian 
medicine. Int. J. Lepr. 15, 424–430 
(1947). 
21. Taylor, G. M. et al. Mycobacterium 
leprae genotype amplied from an 
archaeological case of lepromatous 
leprosy in Central Asia. J. Archaeol. 
  ???
Sci. 36, 2408–2414 (2009). 
22. Donoghue, H. D. et al. Co-infection of 
Mycobacterium tuberculosis and 
Mycobacterium leprae in human 
archaeological samples: a possible 
explanation for the historical decline 
of leprosy. Proc. Biol. Sci. 272, 389–
394 (2005). 
23. Blau, S. & Yagodin, V. 
Osteoarchaeological evidence for 
leprosy from western Central Asia. 
Am. J. Phys. Anthropol. 126, 150–158 
(2005). 
24. Tayles, N. & Buckley, H. R. Leprosy and 
tuberculosis in Iron Age Southeast 
Asia? Am. J. Phys. Anthropol. 125, 
239–256 (2004). 
25. Mariotti, V., Dutour, O., Belcastro, M. 
G., Facchini, F. & Brasili, P. Probable 
early presence of leprosy in Europe in 
a Celtic skeleton of the 4th–3rd 
century BC (Casalecchio di Reno, 
Bologna, Italy). Int. J. Osteoarchaeol. 
15, 311–325 (2005). 
26. Donoghue, H. D. et al. A migration-
driven model for the historical spread 
of leprosy in medieval Eastern and 
Central Europe. Infect. Genet. Evol. 
31, 250–256 (2015). 
27. Loman, N. J. & Pallen, M. J. Twenty 
years of bacterial genome sequencing. 
Nat. Rev. Microbiol. 13, 787–794 
(2015). 
28. Stefani, M. M. A. et al. Whole genome 
sequencing distinguishes between 
relapse and reinfection in recurrent 
leprosy cases. PLoS Negl. Trop. Dis. 
11, e0005598 (2017). 
29. Weng, X. et al Molecular, ethno-spatial 
epidemiology of leprosy in China: 
Novel insights for tracing leprosy in 
endemic and non endemic provinces. 
Infect. Genet. Evol. 14, 361–368 
(2013). 
30. Yuan, Y. et al. Characterization of 
Mycobacterium leprae genotypes in 
China— identication of a new 
polymorphism C251T in the 16S 
rRNA gene. PLoS ONE 10, e0133268 
(2015). 
31. Kim, J. P. SNP genotypes of 
Mycobacterium leprae isolated in 
Korea. Korean Lepr. Bull. 45, 3–19 
(2012). 
32. McLaughlin, R. Rome and the Distant 
East: Trade Routes to the Ancient 
Lands of Arabia, India and China 
(A&C Black, 2010). 
33. Lavania, M. et al. Single nucleotide 
polymorphisms typing of 
Mycobacterium leprae reveals focal 
transmission of leprosy in high 
endemic regions of India. Clin. 
Microbiol. Infect. 19, 1058–1062 
(2013). 
34. Lavania, M. et al. Genotyping of 
Mycobacterium leprae strains from a 
region of high endemic leprosy 
prevalence in India. Infect. Genet. 
Evol. 36, 256–261 (2015). 
35. Das, M., Chaitanya, V. S., Kanmani, K., 
Rajan, L. & Ebenezer, M. Genomic 
diversity in Mycobacterium leprae 
isolates from leprosy cases in South 
India. Infect. Genet. Evol. 45, 285–289 
(2016). 
36. Fontes, A. N. B. et al. Genotyping of 
Mycobacterium leprae present on 
ZiehlNeelsen-stained microscopic 
slides and in skin biopsy samples from 
leprosy patients in different 
geographic regions of Brazil. Mem. 
Inst. Oswaldo Cruz. 107, 143–149 
(2012). 
37. Inskip, S. A. et al. Osteological, 
biomolecular and geochemical 
examination of an early Anglo-Saxon 
case of lepromatous leprosy. PLoS 
ONE 10, e0124282 (2015). 
38. Mendum, T. A. et al. Mycobacterium 
leprae genomes from a British 
medieval leprosy hospital: towards 
understanding an ancient epidemic. 
  ????
BMC Genom. 15, 270 (2014). 
39. Taulman, J. F. & Robbins, L. W. Recent 
range expansion and distributional 
limits of the nine-banded armadillo 
(Dasypus novemcinctus) in the United 
States. J. Biogeogr. 23, 635–648 
(1996). 
40. Bouckaert, R. et al. BEAST 2: a software 
platform for Bayesian evolutionary 
analysis. PLoS Comput. Biol. 10, 
e1003537 (2014). 
41. Phetsuksiri, B. et al. SNP genotypes of 
Mycobacterium leprae isolates in 
Thailand and their combination with 
rpoT and TTC genotyping for analysis 
of leprosy distribution and 
transmission. Jpn J. Infect. Dis. 65, 
52–56 (2012). 
42. Nakata, N., Kai, M. & Makino, M. 
Mutation analysis of mycobacterial 
rpoB genes and rifampin resistance 
using recombinant Mycobacterium 
smegmatis. Antimicrob. Agents 
Chemother. 56, 2008–2013 (2012). 
43. Bahrmand, A. R., Titov, L. P., Tasbiti, A. 
H., Yari, S. & Graviss, E. A. High-
level rifampin resistance correlates 
with multiple mutations in the rpoB 
gene of pulmonary tuberculosis 
isolates from the Afghanistan border 
of Iran. J. Clin. Microbiol. 47, 2744–
2750 (2009). 
44. Comas, I. et al. Whole-genome 
sequencing of rifampicin-resistant 
Mycobacterium tuberculosis strains 
identies compensatory mutations in 
RNA polymerase genes. Nat. Genet. 
44, 106–110 (2012). 
45. DeBarber, A. E., Mdluli, K., Bosman, 
M., Bekker, L. G. & Barry, C. E. 
Ethionamide activation and sensitivity 
in multidrug-resistant Mycobacterium 
tuberculosis. Proc. Natl Acad. Sci. 
USA 97, 9677–9682 (2000). 
46. Baulard, A. R. et al. Activation of the 
pro-drug ethionamide is regulated in 
mycobacteria. J. Biol. Chem. 275, 
28326–28331 (2000). 
47. Pattyn, S. R. & Colston, M. J. Cross-
resistance amongst thiambutosine, 
thiacetazone, ethionamide and 
prothionamide with Mycobacterium 
leprae. Lepr. Rev. 49, 324–326 (1978). 
48. Hedge, J. & Wilson, D. J. Practical 
approaches for detecting selection in 
microbial genomes. PLoS Comput. 
Biol. 12, e1004739 (2016). 
49. Kai, M. et al. Characteristic mutations 
found in the ML0411 gene of 
Mycobacterium leprae isolated in 
Northeast Asian countries. Infect. 
Genet. Evol. 19, 200–204 (2013). 
50. Zharkov, D. O. Base excision DNA 
repair. Cell. Mol. Life Sci. 65, 1544–
1565 (2008). 
51. Jiang, D., Hatahet, Z., Blaisdell, J. O., 
Melamede, R. J. & Wallace, S. S. 
Escherichia coli endonuclease VIII: 
cloning, sequencing, and 
overexpression of the nei structural 
gene and characterization of nei and 
nei nth mutants. J. Bacteriol. 179, 
3773–3782 (1997). 
52. Saito, Y. et al. Characterization of 
endonuclease III (nth) and 
endonuclease VIII (nei) mutants of 
Escherichia coli K-12. J. Bacteriol. 
179, 3783–3785 (1997). 
53. Suvarnapunya, A. E. & Stein, M. A. 
DNA base excision repair potentiates 
the protective effect of Salmonella 
Pathogenicity Island 2 within 
macrophages. Microbiol. Read. Engl. 
151, 557–567 (2005). 
54. Moolla, N., Goosens, V. J., Kana, B. D. 
& Gordhan, B. G. The contribution of 
Nth and Nei DNA glycosylases to 
mutagenesis in Mycobacterium 
smegmatis. DNA Repair 13, 32–41 
(2014). 
55. Ford, C. B. et al. Mycobacterium 
tuberculosis mutation rate estimates 
from different lineages predict 
  ???
substantial differences in the 
emergence of drugresistant 
tuberculosis. Nat. Genet. 45, 784–790 
(2013). 
56. Linder, J. A., Huang, E. S., Steinman, M. 
A., Gonzales, R. & Stafford, R. S. 
Fluoroquinolone prescribing in the 
United States: 1995 to 2002. Am. J. 
Med. 118, 259–268 (2005). 
57. Malik, S., Willby, M., Sikes, D., 
Tsodikov, O. V. & Posey, J. E. New 
insights into uoroquinolone 
resistance in Mycobacterium 
tuberculosis: functional genetic 
analysis of gyrA and gyrB mutations. 
PLoS ONE 7, e39754 (2012). 
58. Yokoyama, K. et al. Impact of amino 
acid substitutions in B subunit of DNA 
gyrase in Mycobacterium leprae on 
uoroquinolone resistance. PLoS 
Negl. Trop. Dis. 6, e1838 (2012). 
59. Gagneux, S. et al. The competitive cost 
of antibiotic resistance in 
Mycobacterium tuberculosis. Science 
312, 1944–1946 (2006). 
60. Mariam, D. H., Mengistu, Y., Hoffner, S. 
E. & Andersson, D. I. Effect of rpoB 
mutations conferring rifampin 
resistance on tness of 
Mycobacterium tuberculosis. 
Antimicrob. Agents Chemother. 48, 
1289–1294 (2004). 
61. de Vos, M. et al. Putative compensatory 
mutations in the rpoC gene of 
rifampin-resistant Mycobacterium 
tuberculosis are associated with 
ongoing transmission. Antimicrob. 
Agents Chemother. 57, 827–832 
(2013). 
62. Cheng, Y.-S. & Sacchettini, J. C. 
Structural insights into 
Mycobacterium tuberculosis Rv2671 
protein as a dihydrofolate reductase 
functional analogue contributing to 
para-aminosalicylic acid resistance. 
Biochemistry 55, 1107–1119 (2016). 
63. Zheng, J. et al. Para-aminosalicylic acid 
is a prodrug targeting dihydrofolate 
reductase in Mycobacterium 
tuberculosis. J. Biol. Chem. 288, 
23447–23456 (2013). 
64. Jopling, W. H. & Ridley, D. S. Vadrine 
(S. 131) in the treatment of 
lepromatous leprosy: a preliminary 
report. Lepr. Rev. 29, 143–147 (1958). 
65. Honoré, N., Perrani, E., Telenti, A., 
Grosset, J. & Cole, S. T. A simple and 
rapid technique for the detection of 
rifampin resistance in Mycobacterium 
leprae. Int. J. Lepr. Mycobact. Dis. 61, 
600–604 (1993). 
66. Singh, P. et al. Insight into the evolution 
and origin of leprosy bacilli from the 
genome sequence of Mycobacterium 
lepromatosis. Proc. Natl Acad. Sci. 
USA 112, 4459–4464 (2015). 
67. Singh, P. et al. Genome-wide re-
sequencing of multidrug-resistant 
68. Mycobacterium leprae Airaku-3. Clin. 
Microbiol. Infect. 20, O619–O622 
(2014). 
69. Bolger, A. M., Lohse, M. & Usadel, B. 
Trimmomatic: a exible trimmer for 
Illumina sequence data. 
Bioinformatics 30, 2114–2120 (2014). 
70. Langmead, B. & Salzberg, S. L. Fast 
gapped-read alignment with Bowtie 2. 
Nat. Methods 9, 357–359 (2012). 
71. Koboldt, D. C. et al. VarScan 2: Somatic 
mutation and copy number alteration 
discovery in cancer by exome 
sequencing. Genome Res. 22, 568–
576 (2012). 
72. Rimmer, A. et al. Integrating mapping-, 
assemblyand haplotype-based 
approaches for calling variants in 
clinical sequencing applications. Nat. 
Genet. 46, 912–918 (2014). 
73. Kie?basa, S. M., Wan, R., Sato, K., 
Horton, P. & Frith, M. C. Adaptive 
seeds tame genomic sequence 
comparison. Genome Res. 21, 487–
  ????
493 (2011). 
74. Matsuoka, M. The history and 
characteristics of isolates maintained 
at the leprosy research center. Nihon 
Hansen. Gakkai Zasshi 79, 247–256 
(2010). 
75. Tamura, K., Stecher, G., Peterson, D., 
Filipski, A. & Kumar, S. MEGA6: 
molecular evolutionary genetics 
analysis version 6.0. Mol. Biol. Evol. 
30, 2725–2729 (2013). 
76. Choi, Y. & Chan, A. P. PROVEAN web 
server: a tool to predict the functional 
effect of amino acid substitutions and 
indels. Bioinformatics 31, 2745–2747 
(2015). 
Acknowledgements 
We thank the Genomic Technologies 
Facility at the University of Lausanne for 
Illumina sequencing and technical support 
and all the patients and clinical staff who 
participated in the study. This work was 
supported by the Fondation Raoul 
Follereau, the Swiss National Science 
Foundation grant IZRJZ3_164174, the 
Swiss Cooperation and Development Center 
(CODEV), the Heiser Program of the New 
York Community Trust for Research in 
Leprosy (grant numbers P15-000827 and 
P16-000976), and grants CNPq 
428964/2016-8 and CAPES 
PROAMAZONIA 3288/2013. 
 
Author contributions 
S.T.C., P.S., C.A., and A.B. designed the 
study. C.A., P.S., S.G., A.N.B.F., and P.B. 
processed the samples, extracted DNA, and 
prepared sequencing libraries. A.B. and 
C.L. processed the data. A.B. analyzed the 
data and prepared gures and tables. A.B., 
C.A., and S.T.C. interpreted the results and 
wrote the manuscript with input from other 
authors. S.G., Y.M., M.N., K.B., C.G.S., 
M.B.S., R.C.B., M.A.C.F., F.B.F., J.G.B., 
J.A.C.N., S. B.-S., A.L., A.R.A.-S., Y.A.-Q., 
A.S.A., G.B., L.V.C., F.S., C.R.J., M.Ko., 
A.F., S.O.S., M.G., O.K., M.M.A.S., G.O.P., 
P.N.S., E.N.S., M.O.M., P.S.R., I.M.F.D.B., 
J.S.S., A.A., M.M., and M.Ka. participated in 
identication of leprosy cases, patient 
management, sample collection and 
preparation, and microscopy. 
 
 
Additional information 
Supplementary Information 
accompanies this paper at 
https://doi.org/10.1038/s41467- 
017-02576-z. 
 
  
  ???
Supplementary Note 
Dating analysis 
Dataset 
Concatenated SNPs for each sample were used for tip dating analysis. We omitted strains with 
mutations in the nth gene because of their hypermutated genomes, which would interfere with the 
clock models in the Bayesian inference. Also, we removed highly mutated genes associated with drug 
resistant strains (Table 1) because they might contain mutations that arose from artificial selection 
during antibiotic treatments. Analysis was done in BEAST2 v2.4.4 1. Sites with missing data were 
included in the analysis because they contain valuable evolutionary signals and missing data are 
properly handled in BEAST22. Constant (invariable) sites were also included as these contribute to 
better estimates of population size and branch lengths (https://groups.google.com/forum/#!topic/beast-
users/-67kIqZEJf8). We included only unambiguous constant sites, i.e. loci where the reference base 
was called in all samples. These corresponded to A=230627, C=275179, G=279428, T=231694. Each 
BEAST run had between 50 M and 100 M MCMC steps to assure convergence and high ESS values 
for all indicators. 
Substitution model 
We used the BEAST package bModelTest v0.3.33 to infer the best substitution model that fits our 
data. Strict Clock and Constant Coalescent were used as clock and tree models. Best support resulted 
for the “123124” model after exploring all reversible models, or only the “transition/transversion split” 
models (Supplementary Figure 4). The “123124” model (A?C = C?G and A?G = C?T, 
Supplementary Figure 5) was used in subsequent BEAST analyses, although using the simpler HKY 
or the more complex GTR model produced similar results. bModelTest also supported invariable sites 
and gamma rate heterogeneity, so “hasGammaRates” and “hasInvariableSites” were used in all 
BEAST analyses. 
Clock model 
Mutation rates are not expected to vary significantly among closely related intraspecies taxa, so using 
the Strict Clock model is generally recommended for such cases2. To test whether a strict clock model 
should be rejected we performed an analysis in BEAST2 under the Log-Normal Relaxed Clock model 
and two population models, Constant Coalescent and Exponential Coalescent models. The mean 
coefficient of variation of the relaxed clock was 0.2035 (95% HPD 0.083-0.3256) under the Constant 
Coalescent model, and 0.1845 (95% HPD 0.0586-0.3086) under the Exponential Coalescent. In both 
cases, the marginal posterior distribution of the coefficient of variation of the relaxed clock extended 
down to zero, which means that the strict clock cannot be rejected for our data2. 
Root age under different models 
To check for consistency of the dating analysis, we compared the estimates of the divergence time of 
TMRCA for all M. leprae strains under different clock and substitution models. Results remained 
consistent (Supplementary Table 1), indicating that the dataset has a strong clock signal and 
estimates are not affected by model priors. 
M. leprae population size through time 
We used the Bayesian Skyline plot (BSP)4 and the extended Bayesian skyline plot (EBSP)5 in 
BEAST2 to infer changes in M. leprae population size through time. For the BSP, five and ten 
dimensions were used, which resulted in overlapping results. BSP resulted in a modest population size 
change of M. leprae, with no evidence of bottlenecks (Supplementary Figure 6). The first and last 
population size intervals in the Bayesian skyline analysis did not overlap, indicating population 
changes, but the separation was relatively small (4766 – 92708 vs. 94 – 4570) suggesting only a 
modest change of M. leprae population size through time. EBSP did not support a change of 
population size through time, which is not surprising for single locus data and relatively weak signals 
of population sizes in the data2.  
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Supplementary Table 1 Estimated divergence times for the TMRCA for all M. leprae strains under different models in 
BEAST2. 
Substitution 
model 
Clock model Population model Mean root age 
(years ago) 
95% HPD interval 
(years ago) 
123124 Strict Coalescent Constant 3697 2693 – 4878 
123124 Strict Coalescent Constant 
(with Discrete phylogeography) 
3699 2731 – 4838 
123124 Strict Coalescent Exponential 3459 2568 – 4467 
123124 Strict Coalescent Bayesian Skyline 
(5 dimensions) 
3544 2694 – 4497 
123124 Strict Coalescent Bayesian Skyline 
(10 dimensions) 
3489 2692 – 4418 
123124 Strict Coalescent Bayesian Skyline 
Extended 
3872 2814 – 5181 
123124 Relaxed 
Log Normal 
Coalescent Constant 3774 2492 – 5354 
123124 Relaxed 
Log Normal 
Coalescent Exponential  3395 2419 – 4525 
bModelTest Strict Coalescent Constant 3702 2723 – 4844 
HKY Strict Coalescent Constant 3692 2648 – 4797 
HKY Strict Coalescent Exponential 3462 2553 – 4459 
GTR Strict Coalescent Constant 3684 2685 – 4859 
GTR Strict Coalescent Exponential 3445 2546 – 4436 
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Supplementary Figure 1 Bayesian phylogenetic tree of 146 genomes of M. leprae calculated with BEAST 
2.4.4. Hypermutated samples with mutations in the nth gene were excluded from the analysis. The tree is drawn 
to scale, with branch lengths representing years of age. Blue horizontal bars show the 95% Highest Posterior 
Density range of the age for each node. Samples were binned according to geographic origin as given in the 
legend. Location probabilities of nodes were inferred by the Discrete Phylogeny model and represented by line 
thickness, and values for the main basal nodes (note that the Discrete Phylogeny model can be influenced by 
sampling bias2, therefore results should be interpreted with caution).   
  ????
 
 
Supplementary Figure 2 Homoplasic sites detected in this study, excluding polymorphic VNTRs and 
homopolymeric tracts, and genes associated with drug resistance given in Figure 4 in the main text. 
  ???
 
Supplementary Figure 3 Distribution of the mutations found in 154 strains for M. lepreae. Outer lane, highly 
polymorphic genes and genes with homoplasic mutations; 2nd lane (blue), SNPs; 3rd lane (red), InDels; inner 
lane, variant density per 50-base region. 
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Supplementary Figure 4 Substitution model evaluation using the bModelTest tool in BEAST2. Models with 
blue circles are inside 95% HPD, red outside, and grey circles have 0.00% posterior support. Within each circle 
is the name of the substitution model, while blue circles also show the posterior support.   
  ???
 
Supplementary Figure 5 Marginal posterior densities for the relative substitution rates in M. leprae, supporting 
the “123124” substitution model (A?C = C?G and A?G = C?T). Inferred in BEAST2 using the bModelTest 
tool. 
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Supplementary Figure 6 Analysis of the effective population size of M. leprae using the Bayesian Skyline plot 
in BEAST2. Black line is the mean; blue lines indicate the 95% HPD boundaries. 
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Research | Report 
Leprosy, caused by infection with 
Mycobacterium leprae or the 
recently discovered Mycobacterium 
lepromatosis, was once endemic in 
humans in the British Isles. Red 
squirrels in Great Britain (Sciurus 
vulgaris) have increasingly been 
observed with leprosy-like lesions on 
the head and limbs. Using genomics, 
histopathology, and serology, we 
found M. lepromatosis in squirrels 
from England, Ireland, and Scotland, 
and M. leprae in squirrels from 
Brownsea Island, England. Infection 
was detected in overtly diseased and 
seemingly healthy animals. 
Phylogenetic comparisons of British 
and Irish M. lepromatosis with two 
Mexican strains from humans show 
that they diverged from a common 
ancestor around 27,000 years ago, 
whereas the M. leprae strain is 
closest to one that circulated in 
Medieval England. Red squirrels are 
thus a reservoir for leprosy in the 
British Isles. 
 
Often considered a disease of the 
past, leprosy remains a public health 
problem in certain lowand middle-
income countries, with ~220,000 new 
cases reported annually (1). Leprosy was 
rife in Europe in the 15th and 16th 
centuries, probably because of social 
segregation, other infectious diseases such 
as plague, or changes in host immunity (2–
5). Today, all British clinical cases occur in 
individuals with a history of residence in a 
leprosy-endemic country (6). The disease 
manifests indifferent forms, ranging from 
multibacillary (or lepromatous) to 
paucibacillary (or tuberculoid), depending 
on the immunogenetics of the host (4). In all
forms, skin lesions are accompanied by 
peripheral nerve damage, which causes 
sensory loss and may lead to deformities. 
It had generally been accepted that 
leprosy resulted solely from interhuman 
transmission of Mycobacterium leprae. 
But in recent years, compelling evidence 
emerged from the south-ern United States 
for zoonotic cases after exposure to infected 
nine-banded armadillos (Dasypus 
novemcinctus) (7–9). Furthermore, M. 
leprae was considered to be the sole 
causative agent of leprosy until 2008, when a 
new species, Mycobacterium lepromatosis, 
was identified in patients with diffuse 
lepromatous leprosy (DLL) (10). Such 
cases were primarily associated with 
Mexico and the Caribbean region (11). 
Comparison of the genome sequences of M. 
lepromatosis and M. leprae revealed that 
Figure 1: 
  ???
despite separating millions of years ago, the 
two genomes are remarkably similar in 
their size, organization, and (pseudo)gene 
content, but show only 88% sequence 
identity (11). 
The Eurasian red squirrel Sciurus 
vulgaris is a widespread Palearctic species 
found from Ireland in the west to 
Kamchatka in the east (12, 13). However, 
in the United Kingdom, theS. vulgaris 
population of ~140,000 is severely 
threatened by habitat loss, squirrel poxvirus 
infection, and competition with >2.5 
million gray squirrels, Sciurus carolinensis, 
introduced from North America (14, 15). 
Because of their endangered status, red 
squirrels are now protected (16). Recent 
detection of mycobacterial infection in red 
squirrels was reported in Scotland, with 
lesions and histopathology characteristic of 
DLL and evidence for M. lepromatosis 
being the etiological agent (17). Similarly 
affected squirrels were observed on the Isle 
of Wight and Brownsea Island in southern 
England (18), and observations of squirrel 
leprosy in Scotland are increasing (Fig. 1). 
Here, we investigated the leprosy outbreak 
using 70 red squirrel cadavers from Great 
Britain, with or without disease signs; 40 
cadavers from Ireland, where no sightings 
of squirrels with leprosy signs have been 
reported; and four Scottish gray squirrel 
cadavers. 
A differential polymerase chain reaction 
(PCR) screen was implemented to detect M. 
leprae and M. lepromatosis DNA (11). We 
analyzed a total of 172 tissue samples from 13 
animals with leprosy features and 101 
without leprosy features (tables S1 and S2) 
(19). Six Scottish squirrels (two without 
clinical signs) (17), two from Ireland (no 
clinical signs), and one from the Isle of Wight, 
England (18) contained M. lepromatosis in 
several tissue samples from different 
anatomical sites, whereas all 25 red squirrels 
(17 without clinical signs) tested from 
Figure 2: 
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Brownsea Island were infected with M. 
leprae (Fig. 1 and table S3). No cases of co-
infection were observed (table S3). From the 
combined results, we concluded that 21% 
[21/101; 95% confidence interval (CI), 13 to 
30%] of the squirrels without clinical signs 
and all 13 of the animals with clinical signs 
harbored leprosy bacilli. 
Serological tests were performed on 
nine diseased and 14 healthy red squirrels 
from Scotland and England, as well as the 
four gray squirrels. The grays were all 
seronegative, whereas 13 of 23 blood 
samples from red squirrels contained 
antibodies for the leprosy-specific antigen 
PGL-1 (phenolic glycolipid–1) (20) (table 
S4). Serology is useful to confirm the 
disease and to predict infection in live 
animals but cannot be used for species 
identification, as both M. leprae and M. 
lepromatosis produce this cell wall 
antigen (11). Diseased Scottish squirrels 
infected with M. lepromatosis displayed 
a range of macroscopic lesions, including 
alopecia and extensive swelling of the 
snout, lips, eyelids, ear pinnae, and limb 
extremities (Fig. 1, Fig. 2A, fig. S1, and 
tables S2 and S5) (19). Histopathological 
examination of four such squirrels (Fig. 
2B) revealed granulomatous dermatitis, 
sheets of epithelioid macrophages, and 
large numbers of acid-fast bacilli (AFB). 
There was neural involvement with the 
presence of AFB in nerve endings; 
neuritis was patchy and more frequently 
perineural (Fig. 2C). Inflammation was not 
focused exclusively around nerves and 
was mostly dermal. There were no signs 
of vasculitis, but AFB were present 
intravascularly (Fig. 2C). Similar lesions 
were observed in eight squirrels from 
Brownsea Island infected with M. leprae, 
although these animals also harbored 
numerous AFB in the spleen (Fig. 2C). 
Overall, the macroscopic signs and 
histopathology were characteristic of 
Figure 3: 
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lepromatous leprosy (Fig. 2, A and B, and 
figs. S2 and S3). From post mortem 
inspection of diseased squirrels, it was 
not possible to distinguish between 
infection with 
M. lepromatosis or M. leprae, as is the 
case in human leprosy (11, 21, 22). 
To obtain deeper insight into the strains 
responsible and to perform phylogenetic 
analyses, we used a variety of DNA 
enrichment techniques (table S6) prior to 
Illumina sequencing, which was 
necessary because neither M. leprae 
norM. lepromatosis can be cultured (19). 
Sufficient sequence coverage of M. 
lepromatosis genomes from seven 
squirrels was obtained (table S7). In 
parallel, we sequenced an additional 
genome ofM. lepromatosis, Pl-02, froma 
PGL-1–seropositive patient from Sinaloa, 
Mexico (tables S1 and S4). The resultant 
sequence reads were mapped against the 
reference M. lepromatosis genome 
sequence from a patient from Monterrey, 
Mexico (11) to identify polymorphisms. 
Consistent with previous M. leprae genome 
comparisons (9, 11, 23), there was an 
exceptionally high level of sequence 
conservation between M. lepromatosis 
strains (99.99% identity) despite their 
different geographic origins. The two 
Mexican patient isolates differed by only 
seven single-nucleotide polymorphisms 
(SNPs), whereas the number of SNPs in the 
six British and Irish strains ranged from 1 to 
17 on pairwise comparisons (table S8). 
Overall, there are roughly 400 SNPs that 
distinguish M. lepromatosis strains from 
Mexico and the British Isles (table S8). 
Clustering of Mexican and British M. 
lepromatosis strains into two distinct 
lineages was supported by 
maximumparsimony (fig. S4) and neighbor-
joining (fig. S5) phylogenetic 
reconstructions. On the basis of the M. 
leprae mutation rate (19) and using the 
Bayesian inference software BEAST (24), 
we estimated that the British Isles and 
Mexican strains diverged from their most 
recent common ancestor around 27,000 years 
ago, whereas the Irish and British strains 
diverged as recently as 200 years ago (Fig. 
3A). The latter estimate is consistent with 
the date of the first campaign to reintroduce 
the red squirrel into Ireland from England 
between 1820 and 1856, following its 
extinction in the 17th century (12, 25). This 
suggests that these animals may already have 
been infected with M. lepromatosis when 
they were reintroduced. Finding M. 
leprae in red squirrels in England was 
unexpected, because leprosy was 
eradicated from the British Isles several 
centuries ago, thus demonstrating that a 
pathogen can persist in the environment 
long after its clearance from the human 
reservoir. Furthermore, this is only the 
second report of M. leprae in nonprimate 
species. From Bayesian and maximum-
parsimony analysis (Fig. 3B and fig. 
S4A), we note that the two closest 
relatives to the strain of M. leprae found 
on Brownsea Island were both from 
medieval Europe. Intriguingly, one of these 
(SK2) originated from the skeletal remains 
of a leprosy victim buried about 730 years 
ago in Winchester, a city situated a mere 
70 km from Brownsea Island (Fig. 1). 
Like SK2, the Brownsea Island strain of 
M. leprae belongs to sequence type 3I, 
which forms a distinct M. leprae branch 
(Fig. 3B) (3) and is now endemic in wild 
armadillos in the southern United States 
(9). Thus, M. leprae with this particular 
sequence type is capable of infecting at 
least three different hosts: humans, red 
squirrels, and armadillos. Because there 
were no obvious genomic polymorphisms 
restricted to the M. leprae 3I type that 
might account for this broad host range 
(tables S9 and S10), we explored the 
possibility that these three species might 
share a major susceptibility gene and 
focused on TLR1. This candidate gene, 
encoding the surface-exposed Toll-like 
receptor 1 (TLR1) displayed on various 
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epithelial and immune cells, is known to 
be associated with susceptibility to 
leprosy (Fig. 4A). A dysfunctional TLR1 
allele encoding an Ile602 ? Ser variant 
with an altered transmembrane domain is 
prevalent in Caucasians and is asso ciated 
with a decreased risk for leprosy (5, 26). 
By contrast, the TLR1 Asn248 ? Ser 
variant is associated with an increased 
risk of leprosy in humans. This mutation 
is located in the ninth repeat of the 
extracellular leucine-rich repeat (LRR) 
region of TLR1 (27). Furthermore, in 
ninebanded armadillos, an Arg627 ? Gly 
change in TLR1 [close to the Toll-
interleukin receptor (TIR) domain; Fig. 
4A] seemingly confers resistance to 
leprosy (28). Using PCR, the coding 
exon of TLR1 was amplified and 
sequenced from 58 red squirrels (with or 
without lesions) and three gray squirrels 
(tables S11, S12, and S14) (19). Upon 
comparison of the sequences and TLR1 
alignments (table S13), no polymorphisms 
were observed at the same sites 
associated with leprosy in humans and 
armadillos. However, in some red 
squirrels, two distinct polymorphic sites 
exist: a single SNP leading to a Ser494 ? 
Asn mutation in the 19th repeat of the 
LRR region, and a cluster of linked 
mutations that produce Ser657 ? Asn 
(S657N), Leu660 ? Val (L660V), and 
Asn662 ? Cys (N662C) variants in helix 1 
of the TIR domain (Fig. 4B). These 
mutations were found less frequently in 
squirrels infected with leprosy bacilli than in 
healthy animals, which suggests that they 
may confer protection (for S494N, odds 
ratio = 5.77; 95% CI, 1.42 to 23.41; P = 
0.01; for S657N-L660V-N662C, odds ratio 
= 4.89; 95% CI, 0.98 to 24.53; P = 0.05).  
It is unclear whether leprosy is 
contributing to the demise of the red 
squirrel population or how these animals 
became infected with M. lepromatosis or 
M. leprae. Because M. lepromatosis has  
 
only recently been discovered as a 
human pathogen (10) and few detailed 
case reports have been published (10, 11, 
21, 29), further investigation is required to 
establish its relative prevalence in wildlife 
compared to humans. M. leprae was long 
considered to be an obligate human 
pathogen that was introduced to the 
Americas by European settlers, prior to 
anthroponotic infection of armadillos, 
because there are no human skeletal 
remains with signs of leprosy from the 
pre-Columbian era (9). The discovery that 
the strain of M. leprae in red squirrels on 
Brownsea Island today is essentially the 
same as one that circulated in medieval 
England and Denmark, and is highly 
related to the extant North American 
armadillo strain, raises the possibility of a 
second anthroponotic introduction in 
Europe. If this were the case, it must have 
occurred several centuries ago, as leprosy 
became increasingly scarce in the British 
Isles after the 17th century (3). It is also 
conceivable that humans may have been 
infected through contact with red squirrels 
bearing M. leprae, as these animals were 
prized for their fur and meat in former 
times (30). Our findings show that further 
surveys of animal reservoirs of leprosy 
bacilli are warranted, because zoonotic 
infection from such reservoirs may 
Figure 7: 
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contribute to the inexplicably stubborn 
plateau in the incidence of the human 
leprosy epidemic despite effective and 
widespread treatment with multidrug 
therapy (1). 
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Abstract  
Background 
Diagnosis of leprosy mainly relies on clinical 
examination due to the inconsistent sensitivity 
and poor reproducibility of the current 
laboratory tests. Utilisation of alternative 
methods to the standard Ziehl Neelsen (ZN), 
Fite-Faraco (FF) and Haematoxylin and Eosin 
(H&E) staining procedures may eventually 
improve leprosy diagnosis. 
 
Methodology/ Principal findings 
 In this comparative study, the performance of 
the fluorescent Auramine O (AO) staining and 
polymerase chain reaction (PCR) was assessed 
with different skin samples using a 
combination of ZN, FF and H&E staining as 
the gold standard. AO, ZN, FF, H&E and PCR 
tests were performed on slit skin smears (SSS) 
and/or punch biopsies collected from 141 
clinically confirmed leprosy cases and 28 non-
leprosy skin samples. DNA was extracted from 
punch biopsies using two different methods 
with or without mechanical lysis. 
Sensitivities were 87.6%, 59.3% and 77% for 
H&E, ZN and FF, respectively, whereas they 
reached 65.5% and 77.9% for AO in SSS and 
tissue sections and 91.1% for PCR in tissue 
sections. Also, among samples with low 
bacillary index, sensitivities of AO staining 
(58.6%) was similar to FF (56.9%, p >0.05) 
and lower than PCR (79.3%, p <0.05). 
Sensitivity of PCR also increased (96.8%, p 
<0.05) when mechanical lysis was used during 
DNA extraction compared to enzymatic 
treatment alone (86.7%).  
Conclusions/Significance 
Our results showed that for diagnostic 
purposes, analysis of skin section is more 
sensitive than SSS, especially for samples with 
a low bacillary load. AO staining on SSS and 
tissue sections was not significantly better than 
other routine diagnostic tests but was 
considerably more user friendly. The 
sensitivity of PCR was higher than current 
standard methods and increased when 
combined with more efficient DNA extraction 
using mechanical and chemical lysis. 
Therefore, we recommend AO staining for the 
diagnosis of leprosy in lower health 
institutions and PCR diagnosis at the referral 
level. 
 
Authors' Summary  
Leprosy is one of the oldest reported infectious 
diseases in the history of humanity, with a 
remarkably high rate of active transmission 
still reported annually, but mainly in resource-
limited endemic countries. The primary tool 
for leprosy transmission prevention is 
diagnosing the disease at an early stage. 
However, this is a challenging activity in 
resource-limited disease-endemic countries 
with the currently available microscopic 
routine diagnostic tests. We found that 
Auramine O staining can alternatively be used 
for leprosy diagnosis using light-emitting 
diode fluorescence microscopy on both slit 
skin smear and tissue section samples with a 
potential of replacing the routine light 
microscopic examination. Also, we showed 
that a combination of highly efficient DNA 
extraction with a single run of conventional 
PCR outperformed standard microscopy 
methods for all samples with high and low 
bacillary index.  
 
Introduction  
Mycobacterium leprae is the causative 
agent of leprosy, a chronic granulomatous 
infectious disease affecting the skin and 
peripheral nerves (1). Leprosy manifests in 
various forms based on the immunological 
profiles and bacterial load in patients (1). 
According to Ridley and Jopling, leprosy is 
classified as indeterminate (IND), tuberculoid 
(TT), borderline tuberculoid (BT), borderline 
(BB), borderline lepromatous (BL) and 
lepromatous leprosy (LL) (2). More recently, 
for therapy purposes, the World Health 
Organization (WHO) implemented another 
classification depending on the number of 
lesions. Patients with <5 skin lesions are 
considered as paucibacillary (PB) cases and 
are treated for six months with two antibiotics 
?? ???
whereas those with 6 or more lesions are 
regarded as multibacillary (MB) and receive 
three drugs for one year (3, 4).  
In 2016, 214,783 new cases of leprosy were 
reported worldwide (5) including 19,384 (9% ) 
in Africa. With 3,692 new cases, Ethiopia was 
the African country with the second highest 
prevalence. The trend of new cases reported 
for the last ten years is stable with 4,086 per 
year on average (5). This data indicated the 
ongoing active transmission despite intense 
efforts to eliminate leprosy as a public health 
problem and the widespread use of multidrug 
therapy (MDT) (6). Lack of reliable diagnostic 
tools especially for the early stage of the 
disease is of major concern (7, 8). Hence 
efforts to improve diagnosis are being 
undertaken and WHO has also set early 
detection of leprosy as a priority in leprosy 
control strategy (9, 10).  
Since M. leprae cannot be cultivated in 
vitro, clinical signs such as presence of lesions, 
sensory loss, and thickened peripheral nerves, 
serve as the primary tool of leprosy diagnosis. 
However, the disease can easily be confused 
with other skin pathologies indicating the need 
for a differential leprosy diagnosis especially 
by less experienced physicians (3, 5, 11) For 
this reason, along with clinical examination, 
identification of the bacteria and the 
histopathological classification in skin samples 
is necessary to confirm leprosy diagnosis. The 
most popular tools are Ziehl-Neelsen (ZN) and 
Fite-Faraco (FF) staining performed on clinical 
samples such as slit-skin smears (SSS), nasal 
swabs and formalin fixed paraffin embedded 
(FFPE) tissue samples (12-16). Even though 
ZN and FF are available at lower level health 
institutions of resource-limited countries, their 
performance in detecting M. leprae bacilli is 
low, particularly in PB patients (17). 
Therefore, for these problematic cases, the 
clinician mostly relies on clinical examination 
which requires experience. In return, this 
highlights the need for more sensitive 
techniques to support clinical diagnosis. 
Auramine O (AO) staining is a fluorescence-
based method widely used to detect 
mycobacterial species such as M. tuberculosis 
and M. leprae (18, 19). AO has been 
previously evaluated to be more sensitive for 
M. leprae detection in tissue sections 
compared to FF and is less time-consuming 
(20, 21). Molecular methods such as 
conventional PCR are even more sensitive, and 
can help with leprosy diagnosis (13, 22-25). 
However, such techniques are not widely 
available. Hence, this study was designed to 
determine the diagnostic utility of AO staining 
and conventional PCR in routine diagnosis in 
comparison with the standard protocol.  
 
Methods  
Ethical Consideration 
Ethical clearance was obtained from the 
AHRI/ALERT Ethical Review Committee, 
Addis Ababa University College of Health 
Science, Department of Medical Laboratory 
Science Ethics and Research Review 
Committee and Ministry of Science and 
Technology, National Research Ethics Review 
Committee. Written informed consent was 
obtained from participants and parents or 
guardians of participating children. 
 
Study population 
A total of 141 leprosy cases comprising 136 
newly diagnosed treatment naïve and five 
relapse leprosy patients with any form of the 
disease, were enrolled in this comparative 
cross-sectional study at the All African 
Leprosy, Tuberculosis and Rehabilitation 
(ALERT) center from January 2015 to April 
2016. All cases were clinically diagnosed and 
confirmed by a dermatologist. Non-leprosy 
patients (n=28) visiting the minor surgery 
department of the ALERT hospital were 
enrolled in the study as a control group. 
 
Data and sample collection  
Sociodemographic and clinical parameters  
Nurses collected sociodemographic data and 
clinical information of study participants using 
a structured questionnaire at the ALERT Red 
Medical Clinic before the participants went to 
?? ???
the sample collection area. Participants in the 
control group were recruited before their 
admission for routine surgical treatment.  
 
Sample collection 
Slit skin smears (SSS) from were collected 
from three different body sites (right and left 
earlobes, and either an eyebrow, the forehead 
or one of the arms) of leprosy patients to 
increase the probability of detecting acid-fast 
bacilli. While collecting SSS for routine ZN 
diagnosis, a duplicate slide was prepared from 
the same site at the same time and sent to the 
AHRI pathology laboratory for AO staining 
(26). 
One 6 mm skin punch sample was collected 
by well-trained nurses for each leprosy patient. 
Punch biopsy collection was not performed on 
cosmetic and sensitive body parts like the face 
and scrotal area (27, 28). For the non-leprosy 
control group, skin biopsy samples of ~10 mm 
were collected from discarded skin specimens 
after routine surgical treatment. After 
collection, each punch biopsy was divided into 
two parts; one was placed in 10% buffered 
formalin solution to be processed for staining 
and the other in 70% ethanol for DNA 
extraction.  
 
Sample processing  
 
ZN and AO staining on SSS 
One of the slides containing SSS was dried 
for 15 min at room temperature and fixed from 
below by passing slowly through the flame of 
a spirit burner three times. The slide was then 
stained with 1% carbolfuchsin solution, heated 
as above until vapor begins to rise for 5 min. 
The slide was then washed with running tap 
water and destained with 1% acid-alcohol for 
10-20 s, rinsed with tap water gently, 
counterstained with 0.2% methylene blue for 1 
min, washed again with tap water and air 
dried. Finally, it was examined under a 100X 
objective of a conventional light microscope 
(26). 
For AO staining, the slide was flooded with 
0.1% AO (MERCK, Germany, prepared 
locally) solution for 20 min, destained with 0.5 
% acid-alcohol for 2 min, counterstained with 
locally prepared 0.5% potassium permanganate 
(Riedel-deHaen, Germany) for 4 min, then air 
dried. The slide was rinsed with sterile water 
between each step. Then, bacilli examination 
was carried out using a light-emitting diode 
fluorescence microscopy (ZEISS Primo Star 
iLED fluorescence microscope, Germany) with 
a 40X objective (17, 29).  
 
Tissue processing, embedding, and sectioning  
Punch biopsies in 10% formalin were kept 
for 48-72 h before tissue processing was 
performed overnight using an automated tissue 
processor (LEICA ASP 300S, Germany) as 
explained elsewhere (15). The following day, 
the tissue was embedded in real-paraffin wax. 
A series of 4 ?m thick tissue sections were 
prepared using a rotary microtome (LEICA 
RM2255, Germany) and fixed on one end of a 
frosted slide coated with 50% egg albumin – 
glycerol prepared locally. A total of three 
slides, each containing four consecutive 
sections from the same tissue were prepared 
for AO, FF and H&E staining (15). 
 
H&E staining 
One of the slides containing tissue sections 
was deparaffinized and rehydrated using a dry 
oven at 600 C for 30 min and in two changes of 
xylene for 10 min, in a series of decreasing 
concentrations of alcohol and finally in tap 
water. The slide was stained for 8 min in 
Harris’s hematoxylin reagent, destained in 
0.5% acid-alcohol for 3 s and washed in 
running tap water. It was then counterstained 
with 0.5% eosin for 1 min. After dehydration 
with alcohol and xylene treatment, it was 
mounted with DPX mounting medium for 
histopathologic examination to be examined by 
a pathologist. Histopathologic features of 
leprosy like granulomas, epithelioid cells, 
foamy macrophages, giant cells, type of cell 
infiltration, and inflammation were used to 
?? ???
diagnose and classify the disease into its 
different forms (15, 30). 
 
FF and AO staining of tissue sections 
Slides were warmed in an oven at 600 C for 
10 min and deparaffinized twice with two parts 
xylene and one part of vegetable oil, for 15 
min, then blotted well with absorbent paper to 
remove the xylene-oil remnant and hydrated in 
a jar containing distilled water. For FF 
staining, the slide was flooded with filtered 1% 
calbolfuchsin for 20 min followed by 
destaining with 10% H2SO4 for 2 min. Tissue 
sections were then counterstained with 0.25% 
methylene blue solution for 20 s. The slide was 
rinsed with sterile water between each step. 
AO staining was performed as outlined above. 
Finally, for both staining procedures, after a 
final wash with water, slides were blotted, 
cleared with xylene, mounted with mounting 
medium (DPX mountant for histology, Sigma) 
and examined under the 100X objective of the 
microscope or using LED-FM under the 40X 
objective, respectively (28, 31, 32). 
 
DNA extraction 
DNA was extracted using three different 
methods. The first method called host 
depletion (HD) (33) (Benjak et al, 2017, Nat 
Comm, accepted), removes host DNA and is 
therefore mainly used for whole-genome 
sequencing applications, but it can be also used 
for PCR application. HD was applied to 35 
skin biopsies (S1 Table). The second method 
used the QIAmp UCP Pathogen Mini kit 
(QiagenGmbH, Hilden, Germany) with an 
adapted protocol on 40 skin biopsies (S1 
Table). Briefly, biopsies were cut into small 
pieces in a 1.8 mL micro-centrifuge tube. AHL 
Lysis buffer (500 ?l) containing 20 ?l of 
proteinase K (20 mg/mL) was added to the 
disrupted tissue and incubated for 1 h at 56°C. 
After mechanical lysis twice with 200 µl of 0.1 
mm zirconium beads (Bertin Technology) at a 
velocity of 6.5 m/s for 45 s with 5 min 
incubation on ice in a Precellys® 24 
Instrument), a second round of enzymatic lysis 
was performed using 40 ?l of proteinase K (20 
mg/mL) prior to incubation with APL2 buffer 
for 10 min at 70°C. DNA was precipitated and 
purified on QIAamp UCP Pathogen Mini silica 
column followed by elution in 100 ?l of 
elution buffer. In the third method, DNA was 
extracted from 95 skin biopsies (S1 Table) 
using the QIAmp Fast DNA Tissue kit 
(QigenGmbH, Hilden, Germany) without 
mechanical lysis. Briefly, biopsies were cut 
into small pieces in a 1.8 mL micro-centrifuge 
tube. AHL Lysis buffer (500 ?l) containing 20 
?l of proteinase K (20 mg/mL) was added to 
the disrupted tissue and incubated 1h at 56°C, 
then for 10 min at 70°C, as above. DNA was 
then precipitated, purified on QIAamp silica 
column and eluted in 100 ?l of elution buffer. 
 
Polymerase chain reaction (PCR) 
Conventional Polymerase Chain Reaction 
(PCR) was performed using primer pairs to 
detect the M. leprae specific repetitive region 
RLEP and the specific region in hemN from M. 
lepromatosis in M. leprae PCR negative 
samples (33, 34). For each reaction, 3 5 ?l of 
extracted DNA was mixed with each primer 
(200 nM final), 25 ?L of Accustart Master Mix 
and water in a final volume of 50 ?L. 
Amplification cycles started with a 
denaturation step at 95°C for 5 min, followed 
by 40 cycles at 95°C for 30 s, annealing at 
58°C for 40 s and extension at 72°C for 30 s. 
The reaction ended with an additional 10 min 
extension step at 72°C. The amplified PCR 
product was then examined by agarose gel (1% 
w/v) electrophoresis. 
 
Quality Control  
Samples known to be positive or negative 
for M. leprae were used as positive and 
negative controls during the staining 
procedures and PCR.  
 
Data Analysis 
Based on previous experience of similar 
studies to develop a reference standard (35), 
we have established a combination of ZN, FF 
and H&E staining tests for this specific study. 
Clinical diagnosis was the necessary part of 
?? ???
this combination supported by at least one or 
more positive test results of H&E, ZN and FF 
staining. This test panel was chosen due to 
their routine application in diagnosing leprosy 
in our laboratory and worldwide.  
However, since the specificity of all these 
methods is known to be low, we will consider 
samples obtained from non-leprosy patients as 
truly negative for the specificity of AO 
staining in tissue, FF and PCR methods. A 
“true positive” will be a sample with one or 
more positive test results of H&E, ZN and FF 
staining. For ZN and AO in SSS, “true 
negatives” will be the negative samples 
obtained with the alternative gold standard 
method since SSS samples were not obtained 
from the non-leprosy patients (S1 and S2 
Tables).  
Socio-demographic data, clinical 
information and laboratory results were 
introduced into Stata SE version 11 for 
statistical analysis. Data obtained from four 
samples of leprosy cases were excluded from 
analysis due to incompleteness. Sensitivity, 
specificity, positive predictive value (PPV) and 
negative predictive value (NPV) were 
calculated including 95% confidence intervals 
(CI) against the designed alternative gold 
standard (Fig S1). For statistical significance 
between the different detection methods, a 
binomial test (MacNemar test or the exact 
binomial test) and Fisher’s test were calculated 
in R when applied on the same group of 
samples and in case of independent groups, 
respectively. 
Moreover, in other studies, patients 
commonly classified as TT, BT and INT are 
usually considered as PB patients with low BI 
whereas LL, BL and BB are classified as MB 
cases with high BI (36). However, the WHO 
classification is based on the number of skin 
lesions and is not linked to the R&J 
classification because BI is either high or low. 
Moreover, it is also commonly accepted that 
TT, BT and BB samples are associated with 
low bacillary index whereas LL, BL and BB 
have higher bacillary index even if some 
exceptions can be observed. Thus, the MB and 
PB classification of this study is only relative 
to the number of skin lesions found per patient. 
Nevertheless, to compare the diagnostic 
performance of the methods described here 
with others published elsewhere, we have 
classified the patients based on the R&J 
classification as follows: TT, BT, IND and 
negative (NEG) will be considered as low BI 
samples (LB) and LL, BL and BB as high BI 
samples (HB).  
 
Results 
 
Socio-demographic characteristics and 
clinical features 
A total of 169 participants were involved in 
the study from January 2015 to April 2016 at 
ALERT center, Addis Ababa, Ethiopia. There 
were 141 leprosy cases and 28 in the non-
leprosy control group (S1 and S2 Tables). 
Male study participants comprised 63.9 % 
(108/169) with a male to female ratio of 1.7:1. 
The mean age and SD of study participants 
was 35. 8 ± 14.6 years with age ranging 
between 15 and 75 years.  
 
Clinical features 
Among the clinically confirmed leprosy 
cases, 19.9% (28/141) showed ⩽5 skin lesions 
and about 80.1 % (113/141) presented with >5 
skin lesions and were classified accordingly as 
PB and MB (S1 Table). Visible physical 
disability was seen in 59.6% of the leprosy 
patients. Five (3.5%) participants who had 
completed MDT were categorized as relapse 
cases based on clinical criteria. A total of 32 
(22.5%) participants presented with leprosy 
reactions classified as pure neuritis 15.6% 
(5/32), reversal reactions 68.8% (22/32) and 
15.6 % (5/32) with erythema nodusum 
leprosum. Regarding family history, 25.5 % 
(36/141) of the leprosy cases used to live with 
a leprosy patient. 
Among the non-leprosy control group, 32.1 
% (9/28) came to the hospital for surgical 
treatment of skin cancer, while the remaining 
67.9% (19/28) came for different surgical 
?? ???
treatment including corrective amputation but 
with no history of leprosy (S2 Table). 
 
The gold standard method 
Among the 141 clinically confirmed 
leprosy cases, four samples were excluded 
from the analysis because of the absence of 
data for the microscopy methods (S1 Table). A 
total of 137 clinically confirmed cases were 
analyzed and 113 were positive according to 
the gold standard method including 99 positive 
and 14 negative by histopathology (H&E) 
(Table 1). A total of 58 and 55 cases belonged 
to the HB and LB sample groups (S3 Table). 
All 28 samples from non-leprosy patients were 
negative using the gold standard method 
classification.  
 
Performance of leprosy diagnosis using 
Auramine O staining and PCR 
 
Auramine O staining 
On analysis of the 137 SSS, the sensitivity 
of AO in SSS (65.5%) was slightly higher 
(p>0.05) than ZN (59.3%) while specificity 
was 100% for both tests (Table 2, S4 Table). 
The sensitivity and specificity of 137 tissue 
sections stained with FF staining were 77% 
and 100%, respectively (Table 2), while other 
statistical parameters, PPV and NPV were 
100% and 51.8%, respectively. Sensitivity and 
specificity of AO-tissue staining are similar 
(p>0.05) to FF with 77.9% and 100%, 
respectively, using the established gold 
standard method (Table 2, S4 Table).  
The overall sensivity of both AO in tissue 
and FF is significantly higher (p<0.05) than 
AO in SSS and ZN (S4 Table). In addition 
sensitivity of the different tests is higher in HB 
compared to LB groups (p<0.05) as expected 
(Table 3, S4 table).  
 
DNA extraction and PCR 
DNA samples extracted from all of the non-
leprosy control groups were negative. PCR 
was positive for 104/113 gold standard 
positive leprosy cases. All DNA samples that 
were PCR-negative for M. leprae were also 
PCR-negative M. lepromatosis.  
The global sensitivity and specificity of the 
method were 91.1% and 100%, respectively 
(Table 2). Also, the performance of different 
DNA extraction methods (with or without 
mechanical lysis) was compared. For samples 
where DNA was extracted with mechanical 
lysis (HD and Qiamp UCP Pathogen kit), the 
overall sensitivity is statistically higher 
(96.8%, p<0.05) compared to samples where 
DNA was extracted without mechanical lysis 
(Qiamp fast Pathogen) with 86.7% (Table 2, 
S4 Table). The disparity between the two 
methods mainly occurs in the LB group (BT, 
TT, IND and NEG) with a sensitivity of 95.5% 
with mechanical lysis and 76.7% without 
mechanical lysis (p>0.05) (Table 3, S4 Table).  
 
Diagnostic performance of laboratory test 
when leprosy cases are histopathologically 
classified and confirmed  
Among the 58 (51.3%) histopathologically 
confirmed samples collectively classified 
under BB, BL or LL and expected to have high 
bacterial concentration, all laboratory tests 
gave similar results ranging from 84.5% to 
98.3% with the highest sensitivity (p<0.05) 
recorded for PCR (Table 2, S4 Table). On the 
other hand, of the 55 (48.7%) samples 
classified as BT, TT, INT or Neg and thus 
expected to have few or no bacilli count (S1 
Table), the sensitivity of AO in SSS (43.1%) is 
slightly higher than ZN (31%, p>0.05) whereas 
the sensitivity of AO in tissue (58.6%) is 
similar to FF (56.9%, p>0.05) but statistically 
lower than PCR (79.3%, p<0.05) (Fig. 1, Table 
3 and Fig S1).  
 
Negative cases 
A total of 24 cases with clinical signs of 
leprosy were considered negative using the 
gold standard method. Regarding the number 
of lesions, 11 and 13 patients were classified as 
MB and PB, 17 presented with disabilities and 
nine reported a family history of leprosy (S1 
Table). While ZN, FF and AO in SSS showed 
negative results, AO in tissue and PCR were 
?? ???
positive for six and ten cases, respectively, 
including four positive samples common to 
both methods (Fig. 1, S3 Table). 
 
Discussion 
Current leprosy diagnosis relies upon 
clinical examination of the patient, recognition 
of skin lesions and peripheral neuropathy, in 
addition to identification of acid-fast bacilli 
and histopathology typical of the active lesion. 
However, the identification of a true leprosy 
case when disabilities are not yet visible, 
especially for PB patients, is a challenge for 
the clinician (25). Therefore, histopathology is 
still mostly used as the gold standard for the 
diagnosis, with some limitations (25). This 
method is less specific compared to the 
mycobacterial staining methods, but different 
reports describe a valuable sensitivity of 
histopathologic analysis for some doubtful 
cases (37). In this study, 72% (99/137) of the 
clinically identified leprosy patients would 
have been considered positive based solely on 
H&E staining and clinical signs (Table 1). 
Using a combination of methods, as suggested 
by Reja et al, including in this case the H&E 
staining and FF on tissue with ZN on SSS, 
increased the number of positives to 82% 
(113/137) (25). 
 ZN is uncomplicated, cost-effective 
and the most frequently used method for the 
detection of AFB especially in resource limited 
settings. The sensitivity of ZN is inconsistent 
ranging from 18% to 56%, depending on the 
study (23-25, 38). We reported a sensitivity of 
59.3% respectively, with a low negative 
predictive value demonstrating the probable 
high rate of false negative for ZN. An 
acceptable alternative would be AO staining 
on SSS with a slightly higher percentage of 
positivity (64.9%, p>0.05). While the 
difference is not significant, AO staining is 
simpler due to the ease of detection of 
fluorescently stained bacilli and the ability to 
screen the entire field within a short period 
(Fig. 2). 
 FF staining is another widely-accepted 
laboratory diagnostic test for leprosy on tissue 
sections. Though its specificity is usually high 
as suggested by our results and others (20), the 
sensitivity of FF is affected by the type of 
disease, as are most of the other laboratory 
tests for leprosy. Nayak et al. reported an FF 
sensitivity of 44.6% and 60%, respectively for 
PB and MB patients, whereas we report 61.8% 
and 93.1% for LB (BT, TT, IND and NEG) 
and HB (LL, BL and BB) cases, respectively 
(20). The ALERT hospital is specialized in 
diagnosis of dermatological diseases and has 
many senior dermatologists. In this study, the 
difference between the sensitivity value is 
most probably linked to the definition of the 
gold standard method and the involvement of 
highly skilled dermatologists. Here, FF and 
AO is tissue are more sensitive than ZN 
(p<0.05) and the global sensitivity between FF 
(77%) and AO (77.9%) in tissue are similar. 
The detection rate obtained for AO staining is 
similar to that in previously published studies 
(29) Moreover, sensitivity is identical between 
both methods for HB and LB cases suggesting 
that AO staining on the tissue (Fig. 2) could 
replace FF without any loss of sensitivity. In 
addition, the sensitivity of both FF and AO in 
tissue section is higher (p<0.05) compared to 
SSS for LB cases. This suggests that tissue 
sections should be preferred to SSS for leprosy 
diagnosis.  
 PCR is often acknowledged for its 
great sensitivity among all laboratory 
diagnostic tests (22, 23). A study in Brazil 
reported PCR sensitivity of 40 % for TT, 55.5 
% for BT and 100 % for all BB, BL and LL 
cases, respectively (39). The authors concluded 
that PCR improves the diagnostic efficiency of 
LB cases which mostly have a negative BI 
(39). In our study, the sensitivity was 98.3% 
for LL, BL and BB (HB) cases and 83.6% for 
BT, TT, IND and NEG (LB) cases. The result 
for HB samples was comparable with that of 
the Brazilian study but the sensitivity found for 
the LB samples was relatively higher. Even 
though we were not able to confirm 
independently the histopathologic 
?? ???
classification, we emphasize that the possible 
reason for this higher sensitivity is the use of a 
more effective DNA extraction method. M. 
leprae is an intracellular pathogen with an 
elaborate cell wall which confers resistance to 
alcohol and acid treatment as well as to 
standard pathogen lysis methods. Altogether, 
these characteristics should be taken into 
consideration to ensure proper DNA recovery. 
The importance of the extraction method used 
to obtain M. leprae DNA is often 
underestimated. Indeed, in this study, we 
detected more positive cases when chemical 
lysis was combined with mechanical lysis 
during DNA extraction with an increase of 
sensitivity (p>0.05) from 86.7% to 96.8% 
compared to DNA extraction using chemical 
lysis alone (Table 3).  
 Finally, 10/24 PCR samples among the 
negative cases, classified by the gold standard 
method established here, were positive by PCR 
for which specificity was 100% in our 
investigation. In previous studies, false 
positives have been observed in samples from 
patients with other skin diseases but this was 
probably due to misdiagnosis in the first place 
(39). To avoid false positives, only patients 
with no family history of leprosy were 
included in the non leprosy control group and 
all skin samples were analyzed with standard 
methods such as H&E and FF. Thus, the rate 
of positivity in the negative gold standard 
group is highly encouraging to recommend 
PCR even for routine diagnosis. Overall, these 
results indicate the potential value of a single 
run of PCR to support clinical diagnosis 
rapidly without the requirement of pathologists 
and the other staining tests included in the 
alternatively establish the gold standard 
method in the study. However, drawback of 
conventional endpoint PCR is non-quantitative 
nature. Currently, several quantitative PCR 
tests have been optimized for detection of M. 
leprae but the cost and the absence of a 
standardized protocol is a limitation to its 
implementation at lower level health 
institutions in resource-limited countries (39-
41).  
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Figures and tables 
Table 1: Number and repartition of positive samples according to the gold standard method ?
Histopathology 
(H&E) 
Total 
FF positive – 
ZN negative 
FF negative – 
ZN positive 
FF and ZN 
positive 
FF and ZN 
negative 
Positive 99 19 2 57 21 
Negative 38 6 3 5 24 
 ??
Table 2: Diagnosis performance of the laboratory tests with 95% confidence interval (CI) based 
on the establish gold standard method – PCRm+e: PCR result obtained on DNA extracted with 
mechanical (m) and enzymatic (e) methods; PCRe: : PCR result obtained on DNA extracted with 
enzymatic (e) method only 
Starting 
material   Sensitivity PPV NPV 
 
  % CI (95%) % 
CI 
(95%) % CI (95%) 
SSS 
ZN 59.3 49.668.4 100 94.6-100 34.3 23.346.6 
AO 65.5 56-74.2 100 95.1-100 38.1 26.1-51.2 
Punch biopsy 
H&E 87.6 80.193.1 100 96.3-100 66.7 50.580.4 
FF 77 68.184.4 100 95.8-100 51.8 37.865.7 
AO 77.9 69.1-85.1 
100 95.9 -
100 52.8 38.6-66.7 
PCR 91.1 84.395.7 100 96.5-100 73.7 56.9 77.4 
PCRm+e 96.8 
88.7 – 
99.6  
100 
93.9100  95 
83.1 – 
99.4  
PCRe 84.6  71.993.1  100 92100 80  64.690.9  ?
  
?? ???
Table 3: Sensitivity of tests for different histopathological classified groups with high BI (HB) 
and low BI (LB) – PCRm+e: PCR result obtained on DNA extracted with mechanical (m) and 
enzymatic (e) methods; PCRe: : PCR result obtained on DNA extracted with enzymatic (e) 
method only 
Starting 
material 
  
HB (LL, BL, BB)  
(n=47) 
LB (BT, TT and NEG) 
(n=55) 
 Sensitivity CI (95%) Sensitivity CI (95%) 
SSS ZN 84.5 78.7-90.2 31.0 25.3-36.8 
AO 87.9 82.2-93.7 43.1 37.5-48.9 
Punch 
biopsy 
FF 93.1 87.3-98.8 56.9 51.18-62.6 
AO 93.1 87.3-98.8 58.6 52.9-64.4 
PCR 98.3 92.5-100 79.3 73.5-85.1 
PCRm+e 100.0 92.7-100 92.0 83.2-100 
PCRe 95.5 86.1-100 76.7 68.7-84.7 ???
?
Figure 8:?Histopathological repartition of the gold standard positive and negative samples with 
the number of positive sample and positivity rate (%) for each laboratory tests – HB: high 
bacillary load included samples from the LL, BL and BB groups; LB: low bacillary load 
included samples from the BT, TT, IND and NEG groups – The graphic show the high positivity 
rate for AO-tissue and PCR in all groups compared to other methods. 
?? ???
?
Figure 2. Auramine O stained M.leprae in FFPE tissue section under 40X objective of light-emitting diode 
fluorescence microscope A: Sample with high bacillary load (HB) B. Sample with low bacillary load (LB).?
  
?? ???
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S1 Table: Overview of the socio-demographic and clinical characteristic of leprosy cases 
included in this study with results of the laboratory tests – RR: reversal reaction, ENL: erythema 
Nosodum, N: neuritis, UCP: QIAmp UCP Pathogen kit, Fast DNA: QIAmp Fast DNA preparation kit 
  
?? ???
   
?? ???
 
 
S2 Table: Overview of the socio-demographic and clinical characteristic of non-leprosy cases 
included in this study with results of the laboratory tests and other diseases associated 
?
 
 
 
 
  
?? ???
S3 Table: Histopathological repartition of the gold standard positive and negative samples with 
the number of positives and positivity rate (%) for each laboratory tests – HB: high BI included 
samples from the LL, BL and BB groups; LB: low BI included samples from the BT, TT, IND and 
NEG groups – The table show the high positivity rate for AO in punch biopsies and PCR compared to 
other methods. 
?
 
Number 
of 
sample 
SSS Punch biopsy 
ZN(%) AO (%) FF (%) AO (%) 
PCR 
(%) 
Gold standard 
positive 
  
  
  
  
  
  
  
  
  
LL 24 22(91.7) 23(95.8) 24(100) 24(100) 24(100) 
BL 20 19(95) 19(95) 20(100) 20(100) 20(100) 
BB 14 8(57.1) 9(64.3) 10(71.4) 10(71.4) 13(92.9) 
BT 26 7(26.9) 12(46.1) 14(53.8) 17(65.4) 24(92.3) 
TT 9 0(0) 2(22.2) 4(44.4) 5(55.6 5(55.5) 
INT 6 3(50) 3(50) 4(66.7) 3(50) 5(83.3) 
NEG 14 8(57.1) 8(57.1) 11(78.6) 9(64.3) 12(85.7) 
Total 113 67(59.3) 76(67.3) 87(77) 88(77.9) 103(91.1) 
HBL 58 49(84.5) 51(87.9) 54(93.1) 54(93.1) 57(98.2) 
LBL 55 18(32.7) 25(45.4) 33(60) 34(61.8) 46(83.6) 
Gold standard negative 24 0(0) 0(0) 0(0) 6(25) 10(41.7) ?????? ?
?? ???
?
S4 Table: Statistical value obtained with the binomial tests and the Fisher test for the different 
tests in different condition (all samples, LB samples or HB samples)– p= p-value in red when p> 
0.05 and in green when p<0.05; OR: odds ratio;  
  
All samples LB samples 
    
ZN 
AO in 
SSS 
FF 
AO in 
tissue 
PCRm+c ZN 
AO in 
SSS 
FF 
AO in 
tissue 
PCR PCRm+c 
All 
samples 
AO in SSS p=0.09                     
FF 
p=0.006 
OR= 2.3 
p=0.08 
OR= 1.75                   
AO in 
tissue 
p=0.003 
OR= 2.4 
p=0.05 
OR= 1.85 p=1                 
PCR     
p=0.005 
OR=3 
p=0.009 – 
OR=2.9               
PCRc         
p=0.04 
OR= 5.6             
HB 
ZN           
p=1.7e-8 
OR=10.9           
AO in SSS             
p=3.5e-7 
OR=9.9         
FF               
p=3.3e-5 
OR=8.8       
AO in 
tissue                 
p=7.2e-5 
OR=8.2     
PCR                   
p=0.007O
R=10.9   
LB 
AO in SSS           p=0.2           
FF           p=0.0004 p=0.01         
AO in 
tissue           p=0.01 p=0.01 p=1       
PCR           p=2.2e-16 p=9.8e-9 p=0.01 p=0.01     
PCRm+c                       
PCRc                     
p=0.15, 
OR= 3.7 
 ? ?
?? ???
S1 Fig: Raw data used for the calculation of the sensivity, specificity, PPV and NPV of 
the routine methods, AO and PCREach value represented the number of patients per 
group  
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Chapter 7: Conclusions and perspectives
?
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he rise of genomics has opened an 
unprecedented, accessible and faster 
way to obtain deeper insight into the 
evolution, transmission, pathogenicity and 
resistance mechanisms of infectious disease, 
including leprosy bacilli. At the beginning of 
the 21st century, whole-genome sequencing 
rapidly overcomes standard PCR-sequencing 
techniques to study infectious diseases. 
However, PCR-sequencing is still 
predominately used in the leprosy field. One 
of the main reasons for this is the high cost of 
the whole-genome sequencing technique 
applied to host-derived tissues, in contrast to 
pure bacterial cultures.  
Since the sequencing of the first M. leprae 
genome in 2001 (1), Prof. Cole’s laboratory 
has dedicated part of its research to the 
development of tools to monitor drug 
resistance and to understand leprosy 
transmission using genomics approaches and 
especially whole-genome sequencing. This 
work led to significant breakthroughs in the 
leprosy field and the associated development 
of robust research tools (2–6).  
In this context, my role was to develop 
simpler and more efficient tools to facilitate 
M. leprae genome sequencing. I conducted 
my doctorate programme in a 
multidisciplinary team of researchers 
including molecular bacteriologists, 
biochemists, bioinformaticians, and skilled 
technicians. Moreover, since leprosy is not 
endemic in Switzerland, I collaborated with 
many researchers throughout the world 
(Acknowledgments map p.229), which 
immersed me in the field and helped me to 
understand all the challenges of leprosy 
research. In these collaborative projects, the 
main goal was to develop and apply whole-
genome sequencing tools in order to solve 
specific challenges around leprosy. Thus, in 
this final part of the thesis, I would like to 
summarize the main findings and discuss 
further perspectives and future work. 
 
M. lepromatosis: the new but still 
mysterious agent of leprosy 
 
The whole genome sequencing of M. 
lepromatosis revealed that the new leprosy 
agent and M. leprae are distinct but closely 
related species (Fig.1). They share 92% 
nucleotide identity, far less compared to the 
bovine tuberculosis agent M. bovis and the 
human-associated agent M. tuberculosis 
(99.95%) (9). Interestingly, they both share 
the same level of extensive pseudogenization, 
probably linked with the intracellular 
adaptation of their most recent common 
ancestor. More strikingly, despite their 
divergence, clinical outcomes are similar, and 
it is not possible to distinguish between M. 
leprae and M. lepromatosis infections without 
additional laboratory tests.  
T 
?????????? ????????????????????????????????????????????????? ??????????????????????????????? ?????????????????????? ????? ????????????? ?????? ????? ?????????? ??? ??? ????????? ????????????? ?????????????????? ?????? ????????????????????????????????????????
?? ???
Using genomics, it is now possible to 
target unique genes of M. lepromatosis (such 
as the hemN gene), absent in the M. leprae 
genome, allowing specific differentiation of 
these species. Repetitive regions are other 
sensitive targets to consider for future 
diagnosis purposes. Unfortunately, most of 
these regions are not covered in the current M. 
lepromatosis assembly because it was based 
on short Illumina reads. Prospective efforts to 
sequence these repetitive regions using long 
read sequencing are indispensable for 
developing sensitive and specific diagnostic 
tests as exemplified in M. leprae with the 
specific RLEP sequences (10). 
M. lepromatosis infection is almost 
exclusively reported in Mexico and the 
Caribbean region, with a few sporadic cases in 
Asia and North America (11–14). A survey of 
120 patients in Mexico, with various clinical 
forms of leprosy, revealed that M. 
lepromatosis infection occurs more often than 
M. leprae in DLL cases (63.2%) and that 
some cases (16.1%) might be dual infections 
(15). In our screen of leprosy samples from 
Venezuela, Mali, Brazil, and Mexico, M. 
lepromatosis was identified only in Mexico, 
and was associated with lepromatous leprosy, 
DLL and Lucio’s phenomenon.  
Strikingly, DLL and Lucio's phenomenon 
are also historically principally found in 
Mexico and Central America (16,17) where 
M. lepromatosis is mostly identified. 
However, cases of Lucio’s phenomenon were 
also reported from other regions such as in Sri 
Lanka (18), Perù (19), India (20–24), Brazil 
(25–27), Malaysia (28), USA (11,29), 
Singapore (12), Canada (13), Myanmar (14) 
Tunisia (30) and Iran (31). Unfortunately, the 
molecular characterization of the causative 
agent is rarely performed.  
DLL associated with Lucio’s phenomenon 
is rare but fatal without early treatment. The 
spark that triggers this specific leprosy form is 
unknown. The reason could be an 
environmental factor or the host immune 
response but also the genetics of the infectious 
agent. Systematic sequencing of the leprosy 
bacilli in case of DLL/Lucio’s phenomenon 
and comparative genomics, combined with a 
transcriptomic analysis of the host and 
pathogen in comparison with other forms of 
leprosy, could help to identify the aetiology of 
the DLL form.  
The only non-human M. lepromatosis 
reservoir known to date is the red squirrel in 
the British Isles. When present, symptoms are 
similar to human leprosy, including nerve 
involvement, and tropism for the cooler parts 
of the body such as the muzzle, ears, and 
limbs. Genomic comparison between the 
Mexican and the British strains revealed 
extreme sequence conservation of the strains 
from different areas. However, it is unclear 
whether the British strain could infect humans 
similar to the Mexican one because of the 
differences in the genome. Also, the origin of 
the infection in red squirrels is mysterious 
since, as yet, there is no evidence of human 
infections in the past. Therefore, analysis of 
ancient DNA from human remains might help 
to retrace the origin and the spread of this 
pathogen.  
Taking the data together, one could be 
tempted to make the parallel with the current 
epidemiology and history of M. bovis. As part 
of the M. tuberculosis complex, M. bovis is 
the cause of bovine tuberculosis in cattle and 
in many animals including man and non-
human primates (32). These infections 
occurred in small pockets at different levels 
depending on the animal infected (32,33). 
Moreover, M. bovis tuberculosis is clinically 
indistinguishable from M. tuberculosis 
infection in humans similar to M. leprae and 
M. lepromatosis infections. The main source 
of human infection of M. bovis is cattle 
because humans consume cattle products such 
as meat and milk. Also, in countries where 
tuberculosis in cattle is common, such as 
Mexico, up to 14% of the human cases are 
caused by M. bovis while the WHO estimated 
that M. bovis is responsible for 3,1% of all 
tuberculosis cases in humans worldwide (34). 
However, for other animals such as deer, 
possum, ferret, pigs or llama the animal-to-
human transmission is more limited (35,36). 
For leprosy, one hypothesis would be that M. 
lepromatosis is an animal adapted leprosy 
bacillus that can eventually be transmitted to 
humans in contact with infected animals. This 
could explain why M. lepromatosis is 
identified to a lesser extent compared to M. 
leprae in humans. In parallel, little is known 
about the global burden of M. lepromatosis 
infection nowadays, and new epidemiological 
surveys with the systematic sequencing of the 
strains should be conducted in Mexico, the 
surrounding countries and for each suspected 
?? ???
leprosy case where M. leprae is not found to 
identify the transmission dynamics of the 
bacteria.  
 
Towards an M. leprae complex?  
 
In 2017, the concept of an M. leprae 
complex has emerged following the report of 
two leprosy-like diseases in wild animals 
where the causative agents shared genetic 
similarities with the leprosy bacilli (37). One 
of the new mycobacterial species was 
identified in cows in France as causing bovine 
nodular thelitis (38). Sequencing of six genes 
revealed that this new species is related to M. 
leprae and M. lepromatosis (38). Recently, 
whole genome sequencing of this new species, 
named M. uberis, was achieved in our 
laboratory after DNA extraction from cow 
tissue (data not shown). The genome was 
assembled in 56 contigs amounting to 3.1 Mb. 
Preliminary analysis confirmed the close 
relatedness of M. uberis with the leprosy 
bacilli (Fig. 1). Also, M. uberis underwent 
genome downsizing, often associated with 
extensive reductive evolution. Further analysis 
of the pseudogenization rate is ongoing.  
The second species, named M. lepraefelis, 
causes feline leprosy in domestic cats in 
Australia and New Zealand (39). Preliminary 
sequencing also revealed a close genetic 
relationship with the leprosy bacillus, but the 
whole genome sequence is not available yet. 
The parameters to define a complex are 
not described in the literature, but several 
examples shared the clinical outcome as the 
main feature independently or not of genetics 
(40,41). Both new mycobacterial species have 
a tropism for cool parts of the body and are 
not cultivable in vitro, the same as the leprosy 
bacillus (38,39). Histopathological features 
are similar to leprosy disease; however, bacilli 
are not observed in nerves, a specificity of 
leprosy. Besides, the clinical outcome is 
identical for M. lepraefelis and the leprosy 
bacillus [except for the peripheral neuropathy] 
with disseminated skin lesions whereas M. 
uberis seems to lead to lesions on the cow 
teat. Finally, the two new species are not 
associated with human cases so far. Thus, M. 
leprae and M. lepromatosis could be classified 
in the same complex whereas M. uberis and 
M. lepraefelis would be part of another 
complex based on the clinical outcome.  
Nevertheless, these organisms, regardless 
of the absence of nerve involvement, might 
have some common biological aspects, like 
their cell infection mechanism or interaction 
with the host. Studying them might improve 
our understanding of the biology of the 
leprosy bacilli. 
 
Phylogeny of M. leprae strains 
 
One of the main objectives of my thesis was 
to increase the number of sequenced genomes 
from different parts of the word in order to 
improve the resolution of the M. leprae 
phylogeny and to identify the geographic 
origin of the bacterium. Since 2013, we have 
increased the number of sequenced M. leprae 
genomes by 20-fold, with 283 genomes 
available to date (Fig 2). This dataset gives an 
unprecedented overview of the current 
phylogeny of M. leprae, but also raises new 
questions and hypotheses.  
The current tree conformation fits well 
with the previous SNP typing code established 
by Monot et al. (4). Unfortunately, we did not 
obtain whole genomes for the SNP subtypes 
1C, 3G et 3I to confirm their classification. 
Also, new branches were identified such as 
the 3K1, discussed below. 
Monot et al. suggested that leprosy 
originated in East Africa or the Near East with 
SNP type 2 or SNP type 3 M. leprae and that 
the ancestral strain evolved and propagated 
via past human migrations (4). We confirmed 
that the SNP type 2 is not the ancestral 
lineage, nor is SNP type 3M. In parallel, our 
results corroborated the observation of 
Schuenemann et al. that the SNP subtype 3K0 
(Branch 0) is the ancestral lineage (6). The 
propagation of this lineage was probably 
boosted by the Silk Roads, but the starting 
point remains unclear. India is surrounded by 
both Silk Roads and is today the country with 
the highest number of leprosy cases. India was 
previously hypothesized to be the origin of 
leprosy in Europe when Alexander the Great’s 
troops came back from the Indian campaign 
(42). SNP types 1 and 2 are phylogenetically 
recent lineages and currently predomine in 
India, suggesting that the country was not the 
starting point of leprosy for Europe, which 
contained almost all lineages of M. leprae, 
including the ancestral 3K (43). We 
discovered a new lineage, named 3K1, from a  
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few genomes from Japan and the Marshall 
Islands.  
A PCR screen of additional samples 
performed in our laboratory (data not shown) 
also revealed its presence in the Philippines, 
Korea, and Turkey. Interestingly, the SNP 
type 3K seems to be widely spread in China 
with the presence of the 3K0 in the West part 
of the country (44), but it has never been 
reported in India despite its proximity to 
China (44,45). One of the explanations for the 
absence of the 3K genotype in India could be 
the geographic and cultural barrier between 
the two countries, resulting in limited 
migrations of peoples. Thus, the 3K lineage 
was probably distributed along inland Asia. 
However, since the number of available 
genomes from India is too low to represent the 
entire Indian population, we cannot exclude 
the possibility of the existence of a more 
ancestral unknown lineage. Nevertheless, an 
exhaustive sequencing effort from this part of 
the world would provide more conclusive 
evidence of the past spread of leprosy. 
Similarly, limited information is available for 
other countries along the Silk Road, especially 
Central Asia. Monot et al. reported the SNP 
type 3K in Iran and Turkey (4), but no 
sequencing was performed from these 
countries. Obtaining samples from this part of 
the world is particularly difficult due to 
geopolitical reasons. Moreover, China, the 
biggest country in Asia, and adjacent 
countries associated with the Silk Roads 
(Myanmar, Vietnam, Laos, Mongolia, Nepal, 
Pakistan) should be extensively covered to get 
more resolution and potential insight into 
diversity of the ancestral 3K lineage. 
During my thesis, efforts were also made 
to sequence strains from Brazil, the second 
country, after India, with the highest number 
of leprosy cases worldwide (46). Almost 100 
genomes were sequenced showing great 
genomic diversity, including SNP subtype 3I, 
4N, 4P, and 1D, which probably resulted from 
multiple introductions from different parts of 
the word during the post-Colombian 
colonization of South America. Interestingly, 
some of the SNP subtype 3I strains from 
Brazil belong to the most ancestral medieval 
European lineages (manuscript in 
preparation). Leprosy was, in part, brought to 
the Americas by European settlers, and Brazil 
might still carry the genomic diversity of M. 
leprae from the post-Colombian Europe.  
In the M. tuberculosis complex, the Beijing 
lineage is thought to be the most successful 
lineage, with increased virulence and rapid 
acquisition of drug resistance (47). These 
faculties are explained by a cumulative role of 
environmental factors, immune host pressure 
and strain genetics (47). For M. leprae, several 
SNP types are rare nowadays such as 3M, 3J, 
1B, 1C, 2G and the new 4O/P lineage. On the 
other hand, SNP subtype 3I seems to be 
spreading more successfully, including to 
non-human hosts. SNP type 3K is also 
widespread, despite its age. It is tempting to 
speculate that different M. leprae lineages 
adapted to different host genetics, or became 
more virulent or contagious. Virulence and 
transmission rates are difficult to measure for 
leprosy because of the wide range of 
symptoms, long incubation times and slow 
progress of the disease. However, a study in 
Columbia showed an association of European 
(SNP type 3) and African (SNP type 4) M. 
leprae strains with the ancestral origin of the 
patient (from Europe or Africa) (48). 
Therefore, the rarity of some SNP types might 
be due to strain replacement or the geographic 
isolation of some populations. However, these 
variations in strain distribution could also 
suggest less successful adaptation to the local 
environment or host population. Studying a 
large cohort in a multi-ethnic locale, such as 
Brazil, for example, could be a good approach 
to investigate M. leprae’s adaptation to its 
host or the role of social factors like 
population density or sanitation. Finally, 
another important aspect is the possible link 
between the genetics of the M. leprae strain 
and disease outcome. So far, the aetiology of 
the wide spectrum of leprosy is explained by 
the immune status of the patient at the time of 
infection. However, a link between a 
particular polymorphism (SNP subtype or an 
antigen variation) and a specific clinical 
outcome should not be ruled out. This analysis 
could be achieved in the next few years with 
increased whole genome sequencing of strains 
from well-characterized patients.  
  
Tracking leprosy transmission 
 
Variation of M. leprae strains 
 
M. leprae is a clonal organism with a very low 
substitution rate, leading to extremely limited 
genetic variation between strains from 
?? ???
different areas but also within the same strain 
from different time points.  
This limited variation was first observed in 
two siblings from Guinea-Conakry who both 
developed leprosy within a few years. The 
isolates differed by only two polymorphisms 
(Fig. 2). An isolate from an unrelated patient 
from the same province showed only one 
additional mutation. Similarly, we recently 
sequenced a strain isolated at different 
treatment time points and from different skin 
lesions of the same patient from Madagascar 
and observed zero, or only one polymorphism 
between the isolates (manuscript in 
preparation). A similar low variation was also 
observed in the red squirrel population in 
Brownsea Island. 
The low substitution rate of M. leprae 
poses limitations for short-range transmission 
studies, including characterization of relapse 
cases. For example, among the three recurrent 
Brazilian cases analysed in 2016 (Fig. 2), one 
was undoubtedly reinfected with a different 
strain four years after the first episode, but for 
the two other cases, isolates spanning seven 
and eight years differed only two 
polymorphisms with no mutation in the 
known drug-resistance determining regions. 
Such cases remain inconclusive because they 
could be re-infections with a similar strain 
circulating in the area or true relapses with the 
original strain.  
The mechanism of relapse in the absence 
of drug resistance is unknown in leprosy. 
Apart from treatment failure and non-
adherence to the treatment, the existence of 
more virulent, or persistent strains could 
explain this phenomenon, similar to M. 
tuberculosis (49–53). Systematic and large-
scale studies based on whole genome 
sequencing of isolates from relapse cases will 
help to identify such mechanisms.  
Another interesting question is the 
possibility of a specific strain triggering 
protection after primary infection assuming 
that this protection would only be conferred 
for a specific strain and for a limited period of 
time as is the case for other pathogenic 
bacteria such as Streptococcus pneumoniae 
(54). This is an attractive hypothesis 
suggesting that reinfection could only occur 
with different strains. However, identification 
of such markers will be challenging and will 
require advanced –omics methods of 
investigation such as functional antibody 
repertoire sequencing (55).  
 
The red squirrel reservoir 
 
Until 2016, the nine-banded armadillo was 
the only known animal reservoir of leprosy 
bacilli. The discovery of M. leprae in the red 
squirrel population on Brownsea Island was 
unexpected in a country where leprosy is no 
longer identified in autochthonous human 
cases. The strain is closely related to the one 
circulating in medieval Europe, suggesting 
that the squirrel might have been infected 
during this period when leprosy was at its 
peak in Europe. We were not able to identify 
M. leprae in other parts of the British Isles 
where the population of red squirrels is still 
present. It is possible that the bacteria have 
survived on Brownsea Island because the 
reservoir is isolated and protected, and the 
high density of squirrels on the island 
probably favors the transmission of the 
pathogen. The repercussion of this discovery 
is important because, if an animal reservoir 
can survive long after the disappearance of the 
disease in humans, important reservoirs might 
exist in endemic countries that could 
contribute to the continuous spread of the 
disease. Based on the host preferences of other 
mycobacteria and the known hosts for the 
leprosy bacilli, potential new reservoirs likely 
include other mammals, although other 
animals cannot be excluded, either as hosts or 
vectors. 
 
Drug resistance and compensatory 
mutations 
 
There are six drugs available to treat 
leprosy, three of which have an unknown 
mechanism of action. Clofazimine’s 
mechanism is especially important to 
elucidate because it is also used to treat multi-
drug resistant M. tuberculosis strains (56). In 
addition, as exemplified by the rifampicin-
resistant Airaku-3 strain, which has a wild-
type rpoB, unknown mechanisms of resistance 
still await elucidation. 
Standard susceptibility tests cannot be 
easily performed for M. leprae. Thus, we 
overtook the challenge of genome sequencing 
directly from host tissues and obtained over 
twenty genomes from drug-resistant strains. 
This allowed us to identify probable 
?? ???
compensatory mutations in rpoB, rpoC, and 
rpoA that need to be functionally validated. 
During our analysis, we identified a couple of 
highly mutated genes associated with drug-
resistant strains, such as ribD, fadD9 and nth 
coding for a dihydropteroate synthase analog, 
an acyl-CoA synthetase and the endonuclease 
III respectively. While the impact of the nth 
polymorphism was easily associated with a 
hypermutator phenotype, the challenge 
remains to confirm the role of the other 
mutations. Empirically, the MFP assay is the 
reference method for drug susceptibility test, 
but it is inappropriate for a large screening. 
Current in vitro tests include gene 
replacement in Escherichia coli by specific M. 
leprae genes. This method was successfully 
applied to describe the drug resistance 
mechanism of M. leprae to dapsone (57). 
However, E. coli is a Gram negative 
bacterium and shows different drug 
susceptibility patterns compared to Gram-
positive bacteria (58). Another approach is to 
use close relatives such as the non-pathogenic 
M. smegmatis, or M. tuberculosis. Studies can 
be conducted using gene replacement, or by 
direct mutagenesis of the genome (59–61). 
However, M. smegmatis and M. tuberculosis 
harbor four and six times more coding genes, 
respectively, compared to M. leprae and the 
alternative pathways, or genes with redundant 
functions, might mask the real effect of the 
targeted mutation.  
Phylogenetically, M. haemophilum is the 
closest cultivable species to the leprosy 
bacillus. It grows at a low temperature (30°C 
to 32°C), and it requires iron supplementation, 
such as hemin for in vitro growth, but it was 
shown that it could be engineered to express 
foreign genes. Thus, M. haemophilum could 
be an alternative candidate to elucidate the 
function of M. leprae genetic variants (62).  
 
Adaptation and persistence 
 
In addition to of the known drug-resistance 
associated genes, other hypermutated genes 
were identified in M. leprae without an 
obvious link to drug-resistance, such as some 
PPE and PE proteins, a putative nucleotide 
cyclase, a probable transcriptional regulatory 
protein, a putative ribonuclease J, and some 
genes with unknown function. Some of these 
genes, like ML0411, have no orthologs in 
other mycobacteria, while the function of the 
other genes is not well described in 
mycobacteria, making it difficult to link them 
with particular phenotypes. However, for a 
species with a reduced number of coding 
genes, such a high rate of mutations probably 
led to important biological functions such as 
persistence, dormancy or virulence.  
 
Diagnosis of leprosy 
 
Efficient diagnosis of leprosy during the 
early stages of the disease and identification 
of the different clinical forms is one of the 
biggest challenges of leprosy control, 
especially for the cases with no obvious 
clinical signs. During my thesis, I worked on 
two projects tackling the problem from 
different angles. The first project aimed to 
compare the whole transcriptome of leprosy 
patients with healthy endemic controls in 
order to identify specific signatures of the 
disease in the blood of patients. This work is 
still in progress. The second project was to 
improve the direct detection of the leprosy 
bacilli in the skin using molecular methods, 
which can be more sensitive than standard 
microscopy. However, even molecular 
methods, such as PCR, do not perform well 
for samples with low BI. To overcome the 
problem, I first improved the most critical 
step, DNA extraction from punch biopsies. 
Indeed, efficient lysis of the bacteria is crucial 
to maximise the recovery of DNA. When 
chemical lysis is complemented with 
mechanical lysis, the sensitivity of the method 
improved, especially for samples with a low 
BI. 
The second step where optimization is 
required is the detection. The main drawbacks 
of conventional PCR are the risk of amplicon 
contamination and additional detection steps 
are needed, like gel electrophoresis, compared 
to quantitative PCR where amplified DNA is 
contained, and results obtained are in real 
time. During the last few months of my thesis, 
I optimized a qPCR method combined with 
efficient DNA extraction in order to the 
improve detection rate in low BI samples. The 
validation of the method is in process.  
Overall, our results show that with an 
efficient extraction procedure, enough 
bacterial DNA is recovered to allow sensitive 
detection of the pathogen. This method can be 
applied to even more challenging samples 
?? ???
such as blood, slit skin smears, urine, nasal 
swab or fine needle aspirates.  
 
Conclusion 
 
The results obtained in my thesis work have 
radically changed our understanding of the 
origin and phylogeny of M. leprae and 
established its relationship to other 
mycobacterial pathogen like M. lepromatosis. 
Our results also highlight the need for 
systematic sequencing of all M. leprae 
isolates, especially from drug-resistant or 
recurrent cases, in order to identify new 
biological mechanisms. In parallel, efforts 
should be made to develop tools to automate 
processing and analysis of data, and new 
models should be developed that allow 
functional studies in vitro. Leprosy is a 
challenging disease to study because most of 
the standard microbiological tools cannot be 
used. This is where -omics methods can 
overcome this challenge and help fight this 
devastating disease.  
?  
?? ???
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